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Summary
The studies described were performed on samples obtained from patients 
undergoing high dose therapy and autologous bone marrow transplantation at 
University College and Middlesex Hospital School of Medicine between 1986 and 
1989. Since 1981 a total of 227 patients have undergone autologous bone 
marrow transplantation for the haematological malignancies acute myeloid 
leukaemia (AML), acute lymphoblastic leukaemia (ALL), Hodgkin's disease 
(HD) and Non-Hodgkin's Lymphoma (NHL) and are available for analysis of 
clinical results. The clinical results obtained in each patient group are 
described in the first chapter.
Considerable literature exists on the influence of allogeneic bone marrow 
transplantation on immune recovery. Immune function in these circumstances 
is influenced by the immune suppression which these patients receive and also 
by graft versus host disease. The aim of this thesis is to evaluate the recovery 
of immune function following different forms of myeloablative therapy with 
re-infusion of autologous cryopreserved bone marrow. The major theme of the 
work is to compare in vivo immune responses with in vitro assays of immune 
function using peripheral blood before and after transplantation.
In vivo studies:
The responses to skin testing with recall antigens were used to assess T cell 
responses pre and post ABMT in 69 patients - 20 with with AML, 7 with ALL,
10 with NHL and 32 with Hodgkin's disease. Responses were markedly 
depressed in all patients immediately after ABMT but rapidly returned to 
normal, in most cases by two to three months after ABMT. In patients with 
Hodgkin's disease the response was markedly depressed before ABMT when the 
patients had active disease. Responses recovered to normal only in those 
patients who achieved good responses to the high dose therapy.
B and T cell responses were assessed by measurement of the specific 
immunoglobulin response against influenza virus using a killed influenza 
vaccine administered on the day of return of autologous marrow after high dose 
therapy. A total of 45 patients were vaccinated in the study - 12 patients with 
AML in first complete remission, five patients with ALL in first complete 
remission, eight patients with NHL and 20 patients with Hodgkin's disease. All 
patients with AML, NHL and HD mounted a brisk response, although this 
response was significantly reduced compared to the normal controls. The peak 
response was not delayed compared to the controls despite the recent 
administration of very high dose chemotherapy. In contrast, although the 
numbers are small, in the patients with ALL the responses were barely 
detectable, with no early peak response seen in any of the five patients. It was 
also found that a number of patients given recombinant GM-CSF developed 
antibodies against this recombinant protein and the specificity of this antibody 
response was determined.
In vitro studies:
Peripheral blood mononuclear cells were obtained from 100 patients prior to 
ABMT and at regular intervals following haematological recovery. Fluorescent 
activated cell sorter analysis of the cell surface phenotype of these cells was 
carried out by using available monoclonal antibodies. In 36 of these cases 
double labelling studies were performed with particular emphasis on the 
phenotype of the early recovering cells. There was a rapid recovery of NK and 
B cells after ABMT, but total T lymphocyte numbers did not return to normal 
until nine months after ABMT and there was a reversal of the normal CD4/CD8 
ratio for up to one year after ABMT. The early regenerating CD4 cells were 
found to co-express CD29 and CD45Ro which suggests that these cells are 
derived from previously activated or memory cells.
In vitro T cell proliferative responses were investigated in 91 patients by 
assessment of the mitogenic response to anti T cell monoclonal antibodies and 
the lectins PHA-P and Con A and in 25 patients using a mitogenic combination. 
Abnormal proliferative responses were obtained for 6-9 months post ABMT 
and this abnormality was not corrected by the addition of exogenous 
recombinant IL-2, although each agonist resulted in an increased expression of 
the IL-2R (CD25).
In vitro B cell functions were assessed in 91 patients by measurement of the 
response to polyclonal activators. Specific IgG production against influenza 
virus was assessed using in vitro assay in the 45 patients who had received the
influenza vaccine. In vitro antibody production was absent in samples from 
peripheral blood in the first three months after ABMT. This non 
responsiveness was not altered by the addition of exogenous IL-2 or GM-CSF. 
After the first three months responses remained reduced until one year after 
ABMT and the responses were particularly slow to recover in the patients with 
ALL.
These studies show that after autologous bone marrow transplantation, the 
defect in immune function rapidly corrects in vivo when remission is obtained 
even in heavily pre-treated patients. This is in keeping with the fact that these 
patients have few complications associated with depressed immunity.
The immune defect after ABMT is therfore influenced by the underlying disease, 
the type of therapy given and the response to that therapy. The persisting 
abnormalities detected in the peripheral blood may not be a true reflection of 
the in vivo immunological status and may not have physiological relevance.
Chapter 1.
Clinical Studies on the Use of Autologous Bone Marrow 
Transplantation in the Haematological Malignancies
1.1. Acute Myeloid Leukaemia
Conventional therapy for acute leukaemia has changed over the last fifteen 
years with the aim now being curative and not palliative. It is now generally 
accepted that a proportion of patients with newly diagnosed with acute myeloid 
leukaemia (AML) can achieve long term disease free survival (DFS) by 
intensive induction and consolidation chemotherapy. Complete remission (CR) 
can be achieved in approximately seventy percent of patients. However, more 
than fifty percent of these patients will relapse from CR such that the fraction 
of patients remaining in CR averages 30% in most studies (Rees et al 1986, 
Priesler et al 1987). Following relapse long term DFS in AML is rare (Zander 
et al 1988). Current conventional chemotherapy in adults with AML therefore 
results in a high remission rate with a subsequent high relapse rate. The use 
of maintenance therapy has not been shown to improve DFS (Priesler et al
1987) and this has lead to a search for an effective post remission therapy in 
AML.
Following the first report of successful allogeneic bone marrow transplantation 
for patients with AML in first CR (Thomas et al 1975) allogeneic bone marrow 
transplantation has become an established form of therapy for patients with
AML who have an HLA identical sibling. Transplantation in first CR of AML 
with marrow from an HLA identical sibling donor results in long term DFS in 
approximately 50% of patients. (Appelbaum et al 1988, Clift et al 1987). 
Single centre studies (Clift et al 1987) and data from registries (Gratwohl et 
al 1989) have suggested that long term survival is improved in patients 
treated in first remission by ablative chemo-radiotherapy and allogeneic bone 
marrow transplantation and this has been confirmed recently in prospective 
comparative studies in which actuarial event free survivals of approximately 
50 % have been reported. These prospective studies have been performed to 
establish the role of bone marrow transplantation versus more conventional 
therapy for patients who lack donors and have demonstrated that marrow 
transplantation resulted in increased DFS (Appelbaum et al 1988, Zander et al 
1988). These studies, however, are open to the criticism that patients with 
matched donors are lost from the non-transplant arm of the study and that a 
more informative study would be to randomize patients with donors to receive a 
bone marrow transplant in first CR or at the time of relapse. Such a study 
would require a large number of patients at a single institution and has not been 
performed.
Allogeneic transplantation is generally only applicable to the younger patient 
with an HLA-identical sibling. Reports from the Seattle Marrow Transplant 
Team suggest that the good results with allografting are mainly restricted to 
those patients under the age of 30 years (Clift et al 1987) and yet the majority 
of patients with AML are over the age of 50 years. In the MRC AML 8th trial 
73 % of patients were less than 60 years but only 34 % were less than 40
years and only 21 % were less than 30 years (Rees et al 1986). Furthermore 
since only about 1 in 4 patients in most Western societies have a matched 
sibling, allogeneic trans-plantation, if only offered to those less than 30 years 
old having a matched sibling, will be available to less than 10 % of patients 
with AML.
The majority of patients, therefore, do not have an HLA identical sibling donor 
or are too old to be considered as candidates for allogeneic bone marrow 
transplantation. An alternative approach has been to use high dose 
chemotherapy with rescue using autologous bone marrow harvested and 
cryopreserved while the patient is in remission. Autologous bone marrow 
transplantation (ABMT) is usually associated with a lower frequency of 
transplant associated mortality and morbidity but a higher frequency of relapse 
of leukaemia after transplantation (Linch and Burnett 1986). This may occur 
from the persistence of leukaemia in the patient, in the cryopreserved bone 
marrow or both. ABMT has resulted in long term DFS in up to 60% of patients 
with AML in first CR and several studies report survival comparable to that 
achieved with allogeneic bone marrow transplantation (Gorin et al, 1989, 
Yeager et al 1986). Autografts performed in second or subsequent remissions 
are more easy to evaluate as there is no long term survival in patients 
receiving chemotherapy alone in these groups of patients. Results of 
autografting in AML beyond first remission have been disappointing with 
survival of only 10 - 15% at two years (Yeager et al 1986).
1 .2  Results of ABMT in Acute Myeloid Leukaemia by the 
Bloomsbury Transplant Group at University College and Middlesex 
School of Medicine.
Seventy two adult patients have now been treated using an identical protocol 
(Gribben et al 1989 a). The median follow up of this group is 32 months 
(range 7 - 1 0 3  months). All patients with AML in first complete remission 
were entered into the programme if they gave informed consent, had a good 
performance status (Karnofsky >70 %), had no HLA-matched donor if under 
40 years of age and were aged 16-60 years. It must be noted that because 
some patients were referred to the transplant centres already in remission, an 
element of patient selection by the primary physician on other undefined 
criteria cannot be excluded. There were 34 males and 38 females with a 
median age of 40 years (range 16 to 57 years). Six patients had a preceding 
myelodysplastic syndrome (MDS) which in all cases had progressed to acute 
myeloid leukaemia at the time of commencement of induction therapy. The 
patients were all induced with a combination of daunorubicin, cytosine 
arabinoside and 6-thioguanine (DAT). Some patients who failed initial 
induction therapy received second-line induction therapy with other agents 
such as amsacrine, mitozantrone and etoposide. Patients received two courses 
of consolidation therapy with daunorubicin and cytosine arabinoside after the 
achievement of a complete remission. The treatment plan is shown in figure
Figure 1.1. Treatment plan.
Remission Induction 
Consolidation
if>45 yrs Autologous
and HLA marrow harvest
matched sib
High dose therapy 
ABMT I
High dose therapy 
ABMT II
The median time to achieve remission for the whole group was 53 days (range 
20 to 338 days) and the median time from attainment of remission to ABMT 
was 157 days ( range 23 -365 days).
All patients had a marrow aspirate performed prior to harvesting to confirm 
that they remained in remission by morphological and karyotypic analysis. It 
is of interest that one patient had morphological evidence of early relapse 
(Blast cells 10% of cellularity) at the time of harvest, but progressed to ABMT 
and regenerated normally. He refused to progress to the planned second ABMT,
Allogeneic
BMT
but remained in remission for thirteen months after ABMT (Gribben 1987 a). 
Bone marrow was harvested under general anaesthesia and cryopreserved 
(Linch et al 1982). No in vitro purging was undertaken in an attempt to 
reduce minimal residual disease.
The high dose chemotherapy (UCH1 protocol) given is shown in figure 1.2.
Figure 1.2 
UCH1 protocol
Drug
BCNU
Cyclophosphamide 
Mesna 
Adriamycin 
Cytosine arabinoside 
6 thioguanine 
Marrow return
Dose
300 mg/m2 
1.5 Gm/m2
50 mg/m2 
200 mg/m2 
200 mg/m2
Days
4 - 3 - 2 - 1 0
The autologous marrow was thawed rapidly at the bedside and re-infused on day 
0. Following satisfactory haematological regeneration from the first procedure 
(neutrophils > 0.5 X 109/l and unsupported platelet count of > 50 X 109/l by 
Day 42) patients in whom there was no contra-indication to further intensive 
therapy were advised to proceed as soon as possible to a second ABMT following
re-harvest of bone marrow followed by a second cycle of the same high dose 
chemotherapy. No further therapy was given while patients remained in 
remission. All patients were treated in single rooms with simple reverse 
barrier nursing procedures without laminar flow facilities. Blood products 
were not irradiated (Gribben et al 1987 b) and were not screened for 
cytomegalovirus . Platelets were given prophylactically when the count was 
below 20 x 109/ I. No prophylactic antibiotics were given during the period of 
neutropenia but empirical antibacterial therapy was given for febrile 
neutropenic episodes.
For all 72 patients the median number of days to achieve a total neutrophil 
count of >0.5 x 109/l was 19 days ( range 10-49) and the median number of 
days to achieve an platelet count of > 50 x 109/l, unsupported by platelet 
transfusion, was 34 days (range 13 - 300 days). The median number of days, 
following the second ABMT procedure to achieve a total neutrophil count of >0.5 
x 109/l was 27 days (range 12-48 days) and platelet count of > 50 x 109/l , 
unsupported by platelet transfusion, was 39 ( range of 21-98 days). Paired 
analysis of the times for haematological recovery after the first and second 
procedures in the 26 patients who received two grafts showed a highly 
significant delay (p= 0.0005) for both neutrophil and platelet recovery after 
the second procedure.
There were 4 procedure related deaths from the first ABMT procedure (5.5 %) 
and 9 patients relapsed within 90 days of the first procedure. Of the remaining 
59 patients, 43 (73%) achieved full haematological reconstitution by day 42.
These 43 patients were eligible to proceed to the planned second ABMT however 
only 26 patients actually received the second cycle of chemotherapy and ABMT, 
including two patients who had regenerated between 42 and 49 days after the 
first procedure.
All patients developed fever and required antimicrobial therapy. There were no 
cases of pneumonitis during a first procedure. The causes of the procedure 
related deaths which occurred after a first procedure were cerebral 
haemorrhage (2 cases), hepato-renal failure (1 case) and Aspergillus 
pneumonia (1 case). There were two cases of pneumonitis during a second 
procedure which were both due to cytomegalovirus, neither of which were 
fatal. There was a single death after a second procedure due to a Varicella 
pneumonia. Overall in 98 procedures in 72 patients there have been 5 
procedure related deaths. Therefore the risk of a procedure related death is 5% 
per procedure or 7% overall per patient. There has been a single case of late 
pneumonitis (> 3 months) which occurred in a patient who had received a 
double graft but this resolved completely with a short course of oral steroid 
therapy. The cause of this pneumonitis was ascribed to the cumulative dose of 
BCNU received. There has been no long term morbidity from the procedure, 
except for the one case referred to above and all the survivors have a Karnofsky 
status of 100 %. There has been no case of cataract development in any patient.
The median follow up for the whole group is 31 months and at 5 years the 
projected overall survival is 58 % with a projected leukaemia free survival of 
52 % (figure 1.3).
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Figure 1.3.
Disease free survival after ABMT in 72 patients with AML in first 
remission.
As can be seen in figure 1.4. the outcome in the six patients with a known 
preceding myelodysplastic state has been poor with only 2 out of 6 remaining 
in remission at 6 months and 22 months post ABMT. All of these patients had 
progressed to acute myeloid leukaemia and received induction and consolidation 
therapy to achievement of remission before ABMT
Leukaemia
Free
Survival
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Figure 1.4. Disease free survival after ABMT in patients with 
AML in first remission comparing those patients who had a 
preceding myelodysplastic disorder with those who had de novo 
AML
There have been no relapses later than 26 months after ABMT. In the 25 
patients with an apparently primary disorder who completed the double 
autograft protocol the projected overall survival at 3 years was 76%, with a 
projected DFS of 66% as shown in figure 1.5. This figure compares those 
patients who completed a double graft with only those patients who would have 
been eligible for a second graft, but did not proceed to the second graft.
Leukaemia
Free
Survival
(%).
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40
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Figure 1.5.. Disease free survival comparing those patients who 
received only a single or double autograft.
Prognostic factors for outcome of ABMT which have been analyzed by univariate 
analysis included age, sex, FAB type, interval from diagnosis to remission, 
interval from remission to transplant and the number of consolidation courses 
given. Increasing age was associated with a worse outcome but none of the 
other factors reached statistical significance. In particular when the patients 
are divided into two groups, those grafted within 6 months of remission 
(n=41) and those grafted between 6 and 12 months into remission (n=25) 
there is no significant difference between the two groups in terms of Leukaemia 
free survival (54% versus 51%).
The chemotherapy autografting procedure used in this study has resulted in a 
low early procedure related mortality (7%) compared to the 20% procedure 
related deaths in the first 100 days after allogeneic BMT reported by Seattle 
(Clift et al 1987). In addition, in allograft recipients there is also a 10% 
incidence of late procedure related deaths (Clift et al 1987) compared to no 
late non-leukaemic deaths following ABMT in this study. There has been almost 
no significant long term morbidity from cataracts or pneumonitis observed 
with this regime and this contrasts with the sequelae of conventional 
allografting protocols. The early morbidity with our protocol is however 
considerable compared to conventional therapy as evidenced by the fact that 
only 44% of patients alive in remission after the first procedure proceeded to a 
second autograft as originally planned.
The rationale of the double autograft programme is based on two premises. 
Reharvesting of the bone marrow after completion of the first course of 
chemotherapy when leukaemic contamination is likely to be at a nadir effects an 
"in vivo" purge and the two stage process allows the overall dose of drug which 
is delivered to be increased without a corresponding increase in toxicity.
The advantage of decreased toxicity compared with allogeneic BMT is balanced 
by the increased relapse rate seen after ABMT. However the projected 
leukaemia free survival at 5 years for the two groups is very similar with a 
DFS of 52 % in this study compared with 45 % in a recent report from Seattle 
(Clift et al 1987) and 48 % reported by the IBMTR (Advisory Committee of 
the IBMTR, 1989) for allogeneic BMT in AML in first remission.
The key question in this study is whether survival has been improved compared 
with conventional chemotherapy alone. Unlike the comparison of transplant 
series, the effect of selection of patients for transplantation and the effect of the 
delay between remission and transplantation ("time censoring") needs to be 
considered when these results are compared with those of conventional 
chemotherapy. As this group of patients had been in remission for a median of 
5 months prior to ABMT their outcome has been compared to that of patients in 
the 9 th MRC AML trial who maintained first remission for a minimum of 6 
months. This shows that compared with the projected DFS of 52 % at 5 years 
reported here the projected DFS at 4 years with conventional therapy in the 9 
th MRC AML trial of those in remission for a minimum of 6 months is 40 %. 
(personal communication Dr R Gray). This difference is small but the 
apparent absence of relapse later than 2.5 years from ABMT contrasts with the 
pattern of ongoing relapse seen with the results of long term follow up of 
patients treated with chemotherapy alone . Comparison of patients in different 
studies however cannot justify a definite conclusion and the results of large 
prospective randomized trials are needed.
1.3. Acute Lymphoblastic Leukaemia
The success of chemotherapy in the treatment of acute lymphoblastic leukaemia 
(ALL) in children (Riehm et al 1980) has not been equalled in the treatment of 
adults with this disease who have long term survival of only some 20% 
(Marcus et al 1986, Hoelzer et al 1988). The transition between adult and 
children with this disease appears to be early in adolescence (Crist et al
1988).
In order to improve on these results in adults with ALL many centres 
recommend allogeneic bone marrow transplantation either in first remission 
or at later stages in the disease (Thomas et al 1985). The results of allogeneic 
transplantation in adults with this disease are difficult to ascertain as many 
centres report the results of adults and children together, but the results in 
adults appear to be less satisfactory because of the increased procedure related 
mortality in adults.
As with AML, most patients do not have an HLA matched sibling donor and cannot 
undergo allogeneic bone marrow transplantation. We have therefore offered 
high dose therapy with chemotherapy and subsequent chemo-radiotherapy with 
autologous bone marrow rescue in adults with ALL who do not have an HLA 
matched sibling donor.
1.4. Results of ABMT in Acute Lymphoblastic Leukaemia by the 
Bloomsbury Transplant Group at University College and Middlesex 
School of Medicine.
Thirty one adult patients with ALL have received high dose therapy and ABMT, 
seventeen patients in first remission and fourteen patients beyond first 
remission. There were 13 males and 18 females. The median age was 23 years 
(range 14-47 years). All patients were initially treated with one of the 
Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia 
(UKALL) protocols and received intrathecal methotrexate and cranial 
irradiation unless total body irradiation (TBI) was planned as part of the 
conditioning for ABMT within three months.
Originally the chemotherapy given was identical to that given to patients with 
AML (figure 1.2) and it was planned that all patients would receive two 
consecutive grafts as described for patients with AML. Subsequently twelve 
patients received a TBI containing regimen and in all cases TBI was delivered 
from a Cobalt source as a single fraction to a dose of 9.5 - 10.5 Gray at a slow 
dose rate of <5 cGy/minute. Autologous bone marrow was harvested and 
cryopreserved in the usual manner (Linch et al 1982) and in addition two 
patients with T cell ALL had their marrow treated in vitro with the monoclonal 
antibody CAMPATH-1 during marrow processing. The patients were treated in 
single rooms without the use of filtered air. Sterile food and gut sterilization 
were not used. Patients conditioned with TBI received irradiated blood
products, but these were not used in those patients conditioned with 
chemotherapy only.
There were seven early procedure related deaths due to cardiac arrest (one 
case), intracerebral haemorrhage (one case), bacterial sepsis (one case), 
aspergilius pneumonia (one case) and idiopathic interstitial pneumonitis 
(three cases).
The time taken for haematological recovery did not vary significantly between 
the different regimens used, but as with AML there was a statistically 
significant delay in engraftment following the second ABMT procedure in those 
patients who underwent a second graft. The median survival for those patients 
treated beyond first remission was 178 days and for those patients treated in 
first remission with chemotherapy alone was 272 days. For seven patients 
treated in first remission with Melphelan and TBI three have relapsed and four 
patients remain in remission from 130 to 840 days after ABMT.
The results of intensive therapy and ABMT in ALL patients beyond first 
remission have not been encouraging with long term survival less than twenty 
per cent. The long term survivors are all notable in that they had very long 
duration of first remission before relapse. However, using an identical 
chemotherapy to that used in AML, the results in first remission of disease 
have been disappointing (Gribben et al 1987 c). The EBMTG results have 
suggested an advantage for TBI containing regimens in this disease (Gorin et al
1989) and we have therefore treated seven patients in first remission of
disease with the protocol which produced excellent results in the Newcastle 
study (Proctor et al 1988). This group is too small to be analyzed separately 
but the preliminary results are encouraging.
The procedure related mortality in this group of patients was higher than that 
found in a similar group of patients with AML treated with an identical regimen 
and there have been no procedure deaths in the seven patients treated in first 
remission with Melphelan and TBI. No reason for this higher mortality is 
apparent.
Overall, therefore, the results of ABMT in ALL have been disappointing and the 
role of ABMT in the management of acute lymphoblastic leukaemia in adults 
must remain controversial at the present time.
1.5. Hodgkin's disease
The majority of patients with Hodgkin's disease can now be cured using 
combination chemotherapy or local or extended field radiotherapy (Tura et al 
1986). It is established that chemotherapy is the treatment of choice for 
patients with advanced disease, although there is controversy regarding the 
optimum regimen. Despite these advances there remains a group of patients 
who fail to respond to first-line therapy and who have a very poor prognosis 
(Gribben et al 1987 d). The prognosis of those patients who relapse after first 
line chemotherapy is not necessarily unfavourable because durable remissions 
can be obtained in some patients using alternative salvage chemotherapy 
regimens (Canellos et al 1972, Santora et al 1982). Patients who fail to 
achieve a second CR or who have a further relapse also have a very poor 
prognosis (Gribben et al 1987 d). Patients with primary resistant disease or 
those who fail salvage chemotherapy are therefore candidates for alternative 
forms of therapy. In view of the dose dependent response rate of Hodgkin's 
disease (Frei and Canellos 1980) these patients are eligible for high dose 
therapy necessitating rescue with autologous bone marrow transplantation.
We used the experience obtained by the British National Lymphoma 
Investigation (BNLI) to assess which patients might be candidates for ABMT 
(Gribben et al 1987 d). Since 1970 over 600 patients with advanced 
Hodgkin's disease have been treated with MOPP type regimens and this large 
data base served as a tool for the design of future studies. Various prognostic 
factors can be defined at presentation including age, histological subtype, stage,
haemoglobin, lymphocyte count, ESR and serum albumin (Vaughan Hudson et al 
1983,1987). Age is one of the strongest prognostic indicators with patients 
over the age of 60 years faring most poorly (Vaughan Hudson et al 1983). This 
group will generally not be suitable for autografting and must be excluded form 
further analysis. Using the remaining factors it was not possible to define at 
presentation a sizable group of younger patients who will do sufficiently badly 
to merit ABMT at presentation or in first complete remission . Once a CR has 
been obtained the prognostic influence of the presenting prognostic features is 
considerably reduced. Obviously, determination of what is a sufficiently poor 
survival to merit progression to ABMT is somewhat subjective. We have 
suggested that a projected five year survival of less than 35% is a reasonable 
starting point for the design of a randomized study. Since the earlier morbidity 
and mortality of ABMT is high we also proposed that no patient should receive 
an ABMT if the two year projected survival is more than 65%.
1.6 Results of ABMT in Hodgkin's disease by the Bloomsbury 
Transplant Group at University College and Middlesex School of 
Medicine.
By December 1989 74 patients with Hodgkin's disease had been treated with 
high dose therapy and ABMT at University College and Middlesex Medical School 
and the one year follow up has been reported on 44 of these patients (Gribben 
et al 1989 a). All patients had active disease at the time of ABMT despite 
receiving at least two courses of standard regimen treatments at standard
dosages or following hybrid therapy and were therefore considered to be 
refractory to treatment. The histological diagnosis of each patient was 
reviewed by an independent histopathologist. The median age of these patients 
was 28 years (range 1 8 - 5 2  years). Thirty seven patients had extra nodal 
involvement at some stage during their clinical course but only four patients 
had previous bone marrow involvement. At the time of ABMT no patient had 
bone marrow involvement, but 21 patients had extra nodal disease, 
particularly involving the lung. Four patients had failed to respond to front 
line alternating therapy and progressed immediately to ABMT. All other 
patients had received at least two regimens of chemotherapy and 36 patients 
had received radiotherapy in addition. Forty one patients had never achieved 
CR. The median time from diagnosis to ABMT was 19 months (range 7 - 1 9 5  
months). All patients were treated using the BEAM protocol which consists of 
BCNU 300 mg/m2 day 1, Etoposide 100 or 200 mg/m2 and Ara C 200 or 400 
mg/m2 on days 2-5 and melphelan 140 mg/m2 on day 6. All drugs were given 
by intra venous infusion. The marrow was returned on day 7, 24 hours after 
completion of the melphelan infusion.
36% of patients achieved CR within three months of the procedure. These 
patients received no further therapy as consolidation or maintenance. 51% 
achieved a partial response as defined by a > 50% reduction in tumour mass at 
the time of ABMT. Three patients initially assessed as a PR had slow resolution 
of their residual mass and achieved CR with no further therapy. Six further 
patients had a further decrease in the size of residual mediastinal mass over 14 
- 46 months without having received further therapy and may not have active
disease. The overall survival of patients following ABMT for HD is shown in 
figure 1.6.
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Figure 1.6. Overall survival after ABMT in Hodgkin's disease.
Eleven patients who had a partial response to ABMT as assessed by a residual 
mass on CT scan received subsequent radiotherapy; a full dose mantle was 
planned in eight and an inverted Y in two patients. Full dose was given to seven 
patients, one with major delays because of marrow suppression. 
Myelosuppression limited radiotherapy dosage in three patients. One patient 
receiving a mantle developed moderate pneumonitis. Of the 11 radiotherapy 
recipients four obtained a CR although one later relapsed, three have continued
in stable PR and four had disease progression (McMillan et al 1989). Although 
seven of eleven of these patients appear to have responded favourably, this 
must be viewed with caution as two patients initially assessed as a PR have 
obtained a late CR and a further four patients have had progressive 
improvement in CT scan abnormality over periods of one to three years without 
any subsequent radiotherapy. It is possible that some patients with residual 
mediastinal masses may not have active disease (Radcliffe et al 1988)
Univariate and multivariate analysis were performed to assess the prognostic 
value of age, sex stage at diagnosis and at ABMT, histology, size of largest 
tumour mass at diagnosis and at the time of ABMT, extra-nodal disease, 
previous radiotherapy and whether the patient had ever achieved CR prior to 
transplantation. The size of the tumour mass at ABMT was the only significant 
factor (x2=12.48) identified.
Fourteen of these patients received recombinant derived Granulocyte 
Macrophage Colony Stimulating Factor (GM-CSF) as part of a phase II study to 
determine the effect of this growth actor on haematological regeneration after 
ABMT. This resulted in more rapid engraftment of myeloid precursors, but had 
no effect on platelet regeneration (Devereaux et al 1989). An ongoing study 
involves randomization of patients with Hodgkin's disease to receive either GM- 
CSF or placebo following re-infusion of bone marrow. This study has not yet 
been completed and the randomization code remains intact, so that those 
patients who have recently received GM-CSF cannot definitely be identified.
High dose therapy with the use of additional radiotherapy where applicable has 
achieved a CR rate of 50% in a group of heavily pre-treated patients with 
active Hodgkin's disease. Only three of these patients have subsequently 
relapsed. The prognosis of this group of patients with conventional dose 
therapy is poor with a 5 year survival of <20% and high dose therapy with 
ABMT may represent an advance over conventional salvage therapy. A 
prospective randomized study is now under way to establish whether high dose 
therapy with ABMT is superior to other salvage therapy in these patients with 
Hodgkin's disease.
1.7. Non Hodgkin's Lymphoma
Despite the success of combination chemotherapy in the treatment of diffuse 
intermediate and high grade non Hodgkin's lymphomas, only approximately 
50% of these patients are curable on first line therapy. Those who fail to 
respond to first line treatment or who relapse from first remission have very 
poor prognoses and are only very rarely cured by alternative salvage therapy 
(Gribben et al 1987 d). The rationale for the use of high dose therapy and 
ABMT was from observations made from pilot studies by allogeneic 
transplantation in identical twins in lymphoma (Appelbaum et al 1981) of 
treatment in Burkitt's lymphomas, particularly in the paediatric age group 
(Philip et al 1986).
This led initially to the situation in which transplantation was used as salvage 
therapy for relapsed disease. This was similar to the early pioneering work 
from Seattle in transplantation for acute leukaemias. Once it had been 
established that the procedure could be carried out relatively safely and was 
more efficacious in disease in remission rather than in those who had already 
relapsed, bone marrow transplantation was used more frequently early in the 
course of disease. This has been justifiable because of the overall poor 
prognosis of patients with leukaemia, few of whom are cured by chemotherapy 
alone. Traditionally, patients achieving CR on induction therapy for advanced 
intermediate and high grade therapy have not then received bone marrow 
transplantation, with its attendant related risks, as consolidation therapy
before relapse of disease on the grounds that many of these patients have 
already been cured by first line chemotherapy.
However, many centres are now performing bone marrow transplantation 
procedures as consolidation therapy in first remission of advanced non 
Hodgkin's lymphomas. This area is fraught with many difficulties. Overall, 
about 65% of adult patients who achieve first CR and who are in the age group 
to be eligible for dose escalation and marrow transplantation are cured by their 
first line therapy. The identification of those patients with non Hodgkin’s 
lymphomas who are at risk of relapse has been difficult. Those factors which 
predict for poor prognosis are predictive largely for those patients who will 
fail to achieve remission. After remission has been achieved the value of these 
predictive factor has largely disappeared. (Gribben et al 1987 d). Despite 
these difficulties, however, a considerable number of patients are now being 
transplanted for non Hodgkin's lymphomas in first remission. By analysis of 
the characteristics of these patients we can predict that many of these patients 
had already been cured by chemotherapy and may needlessly have been exposed 
to the risks of the transplant procedure. The setting for the correct use of bone 
marrow transplantation in such patients must be clearly established.
1.8. Treatment of Non Hodgkin's lymphoma.
Although there is general consensus on the first line treatment of patients with 
AML, ALL and HD, this is not the case in NHL. The reasons for this are largely 
the complexities of assessment of responses to therapy because of the
heterogeneity of the histological types of NHL and their impact on response to 
treatment. In terms of the first line treatment of NHL, clinical staging does not 
dictate the treatment strategy in most patients. If pathological staging is 
carried out, the incidence of disseminated disease is nearly 80%. However, 
even in patients with aggressive histologies, excellent results may be achieved 
by localized radiotherapy in patients who have Stage I disease confirmed by 
pathological staging. All patients with aggressive histology beyond pathological 
stage I should receive combination chemotherapy. Prognostic features 
identifying those patients less likely to achieve complete remission include age, 
male sex and presence of B symptoms, low albumin and raised ESR at 
presentation, bulk abdominal disease, low performance status and raised LDH.
1.9. First line treatment regimens for NHL.
In the fourteen years since the publication of De Vita (De Vita et al 1975) that 
the diffuse NHL's were potentially curable, there have been a large number of 
different combinations chemotherapy protocols developed. The major studies 
published during this time are shown in Table 1.1. In the early 1970's the 
powerful anti-lymphoma effect of the anthracyclines was appreciated and CHOP 
became the standard treatment at many centres. The complete remission rates 
reported were between 44% and 70% with approximately 30% of patients 
having long term disease free survival (Gams et al 1985, Armitage et al 
1984). In subsequent studies a number of other agents were added to the basic 
CHOP agents. It was noted in the BACOP study that the incidence of CNS disease 
was high and high dose methotrexate was added to provide CNS prophylaxis
producing the M-BACOD regimen. More recently the dose of methotrexate has 
been considerably reduced without loss of efficacy.(Cannellos et al 1987). 
Further agents were added and the original COP-BLAM regimen was constructed 
to intensify treatment and increase the use of non-myelosuppressive drugs to 
augment tumour kill. Following the apparent improvement of efficacy using 
infusions of vincristine and bleomycin, COP-BLAM 3 was initiated and 
produced excellent responses (remission rate 84%) regardless of stage, 
histology, the presence of bulk disease or B symptoms
Several centres have now reported on the use of sequential different regimens 
such as ProMACE/MOPP (Longo et al, 1987). There have been few studies 
alternating two different non-cross resistant chemotherapy regimens largely 
because there is no obvious alternative which is equally effective as CHOP. In 
an attempt to solve this there has been a development of so-called 'hybrid' 
regimens introducing multiple agents from the beginning of treatment in one 
complex continuous sequence without the use of separate different regimens 
with gaps in between. Examples of these regimens are a hybrid 
ProMACE/MOPP, ProMACE-cytaBOM. A particularly interesting and novel 
strategy is the use of weekly rotating drug schedules such as occurs in MACOP- 
B which has been designed in accordance with the principles of the Goldie- 
Coldman hypothesis. The Vancouver group (Klimo and Connors 1985) have 
produced a preliminary report of excellent results using this sort of hybrid 
regimen although these have not been easily produced in a randomized study 
organized by the South West Oncology (SWOG) group (Fisher et al 1987).
Table 1.1.
Selected combination chemotherapy regimens in advanced diffuse 
non Hodgkin's Lymphoma.
CR DFS Reference 
rate
MACOP-B 84% 69% Klimo & Connors, 1987
ProMACE - CytaBOM 83% 70% Longo et al, 1987
ProMACE - MOPP 77% 58% Longo et al, 1987
M-BACOD 72% 48% Skarin et al, 1983
COP-BLAM I 72% 55% Lawrence et al, 1982
CHOP 47% 35% Gams et al, 1986
MOPP 41 % 35% De Vita et al, 1975
1.10. Salvage chemotherapy for Non Hodgkin's Lymphoma.
This increase in the success rate of modern combination chemotherapy and 
hybrid regimens produces a cure rate in only 50% of patients with 
intermediate and high grade NHL. Patients who relapse from these front line 
regimens are usually refractory to drug treatment at the time of relapse and 
the prognosis is even worse in those patients with primary resistant disease. 
For this reason a number of salvage regimens have been developed, most 
notably at the MD Anderson Hospital in Houston. The first such regimen was 
IMVP16 (Cabinillas et al, 1982). Overall IMVP16 produced a remission rate 
of 37% but with a median remission survival of this group of only 15 months. 
The addition of methyl gag to this regimen (MIME) produced a remission rate of 
33% as salvage in the diffuse large cell lymphomas (Cabinillas et al 1987), 
but a a lower remission rate of 11% in the follicular small cleaved cell types. 
The disease free survival of those who achieved CR was not improved by the 
addition of methyl GAG to the original IMVP16 regimen. In this study 
(Cabinillis et al, 1987) it was noted that the remission rate was highest in 
those patients who had ceased first line therapy more than six months prior to 
relapse and the commencement of MIME. The most recent reported study from 
this same group has been with the DHAP regimen (Velasquez et al, 1988). This 
regimen utilizes the reported synergistic effect of cisplatin and high dose 
cytosine arabinoside with the concurrent use of dexamethasone both as an anti­
tumour agent and as an anti emetic. The DHAP regimen also produced an overall 
remission rate of 31% with a median relapse free survival in these patients of 
15 months. Although the reported follow up in this report is short, there is no
apparent plateau in the survival curves. However, this regimen appears to be 
more effective than MIME in salvage of patients with primary resistant disease 
and in those with lower grade histology.
It also seems likely that the use of more drugs and more intensive regimens for 
first line treatment either as alternating sequential regimens or as "hybrid" 
regimens will mean that the tumour will be even more resistant to salvage 
therapy at the time of relapse. There may therefore be no effective salvage for 
patients who fail these high drug intensity regimens such as proMACE-cytaBOM 
or MACOP-B. If further studies confirm that these regimens truly do not 
produce more effective long term disease free survival than more simple 
regimens, then there may be an argument for saving some drugs to be used as 
potential salvage agents at the time of relapse.
1.11. Autologous bone marrow transplantation in Non Hodgkin's 
Lymphoma.
An alternative form of salvage therapy is the use of dose escalation using high 
dose combination chemotherapy or in combination with total body irradiation 
(TBI) followed by rescue with autologous bone marrow (ABMT). The results 
from selected series of ABMT studies are shown in Table 1.2.
Table 1.2.
Results of selected studies of autologous bone marrow 
transplantation for non Hodgkin's lymphomas.
centre
France, multicentre 
Bloomsbury
Boston
Europe/USA
EBMTG
No CR% C6 Reference
1. Chemosensitive disease
Pr to induction therapy 
1 7 75 75 (2yr) Philip et al, 1988
1 5 6 6 62 (3yr) Gribben et al, 1989 c
Chemosensitive relapse
24 8 5 65 (3yr) Takvorian et al,1987
4 4 8 6 38 (2yr) Philip et al,1987
75 4 0 28 (3yr) Goldstone et al 1989
2. Chemoresistant disease
Bloomsbury
Europe/USA
EBMTG
2 9 1 0 7 (2yr) Gribben et al, 1989 c
5 6 3 4 6 (2yr) Philip et al,1987
194 3 4 15 (3yr) Goldstone et al 1989
1.12. Allogeneic bone marrow transplantation in Non Hodgkin's 
Lymphoma.
It remains extremely difficult to evaluate the usefulness of allogeneic bone 
marrow transplantation in the non Hodgkin's lymphomas. There have been no 
randomized studies between autologous and allogeneic bone marrow 
transplantation and from EBMTG data there are many differences between those 
patients who have received allogeneic as opposed to autologous transplantation 
(Gribben et al 1987 e). The majority of patients who received an allogeneic 
transplant for NHL were poor prognosis patients in complete remission of 
disease at the time of BMT, whereas at that time 87% of patients with NHL who 
received an autologous transplant were treated in relapse. Since multivariate 
analysis of the autograft data had shown that disease status at the time of ABMT 
was the major determinant to predict outcome, one can only attempt to compare 
the two types of BMT procedures in those patients who were in complete 
remission at the time of transplant. There are also major differences between 
these two groups of patients. In those receiving allogeneic transplantation 64% 
had lymphoblastic lymphoma, but only 45% of patients who received ABMT in 
first remission had this histological type. There are other factors which have 
to be considered as to why patients received allogeneic transplantation in NHL 
other than that fact that these patients had a HLA identical sibling donor. 
Whereas only 11% of those patients transplanted in first remission with 
autologous marrow had previous bone marrow involvement, this rises to 55% 
in those patients who received allogeneic BMT. Virtually all patients who 
received allogeneic marrow were conditioned using a TBI containing regimen,
whereas only 27% of patients in first remission who received autologous 
marrow were conditioned with TBI. Despite the differences in patient 
selection, there was no difference in the overall or disease free survival of 
those patients treated in first remission with either autologous or allogeneic 
bone marrow (Gribben et al 1987 e).
The salvage of patients who have bone marrow involvement at relapse is 
difficult. Clearly some such patients may be best treated by allogeneic 
transplantation, but we restrict allogeneic transplantation in NHL to those 
patients under 25 years of age who had bone marrow involvement but little 
other disease. Clearly, the results from the Boston group of purging the bone 
marrow of patients who had obvious disease at the time of ABMT are very 
encouraging (Takvorian et al 1987) and potential methods for purging marrow 
of residual disease are currently under investigation, so that purging of disease 
from involved marrow and use of purged autologous marrow may be feasible in 
many of these patients. Finally, it should also be mentioned that there are a 
small but growing number of patients with NHL with bone marrow involvement 
who have been rescued after high dose therapy with stem cells collected from 
peripheral blood (J Armitage, personal communication).
1.13. Results of ABMT in Non Hodgkin's Lymphoma by the 
Bloomsbury Transplant Group at University College and Middlesex 
School of Medicine.
At our own centre fifty adult patients with diffuse non Hodgkin's lymphoma of 
intermediate and high grade histologies as defined by the International Working 
Formulation have been treated with high dose combination chemotherapy with a 
minimum follow up of one year (Gribben et al 1989 c). All patients had failed 
to achieve CR on conventional first line therapy or had relapsed and had active 
disease at the time of ABMT. The median age of the patients was 38 years 
(range from 18-57 years); 30 were male and 20 female. All patients 
referred were accepted for ABMT if they were less than 60 years of age and had 
failed to achieve CR on conventional dose chemotherapy or had subsequent 
relapsed providing that there was no bone marrow involvement at this time and 
there was no major cardiac, renal or liver impairment. ABMT was performed 
within three weeks of a decision to proceed to this form of therapy. Twenty 
seven patients (54%) had extra nodal disease at some stage in their disease, 
but only two patients had previous bone marrow involvement and two further 
patients had previous central nervous system (CNS) involvement. All patients 
had received a regimen containing adriamycin at some stage and twenty 
patients (40% ) had also received localized radiotherapy. Thirty four patients 
(68%) had never achieved CR. Nineteen of these patients had primary 
refractory disease, defined as no response (NR) to first line regimens or 
initial partial response (PR) but subsequent progressive disease while still 
receiving treatment. A further fifteen patients had only a partial response,
defined as achieving a reduction in tumour mass greater than 50% (but not CR) 
and still responding to conventional dose chemotherapy. Nine of the patients 
who achieved PR went on immediately to ABMT after failing first line therapy 
(although three patients received prophylactic cranial radiotherapy) and 
another six received alternative conventional therapy (systemic chemotherapy 
or local radiotherapy excluding prophylactic cranial radiotherapy) and failed 
to attain a CR but continued to show response to therapy, before going on to 
ABMT. Sixteen patients achieved CR from initial therapy and subsequently 
relapsed. Five patients achieved a partial response (greater than 50% 
reduction in tumour mass) to the first three to four courses of salvage therapy 
and then went on to ABMT. These patients were defined as "responding relapse" 
(RR). Ten patients who had achieved a CR but did not respond to salvage 
therapy were defined as "non responding relapse" (NRR). One patient could 
not be classified for response as he did not receive any further therapy after 
relapse but proceeded immediately to ABMT.
Overall therefore, twenty patients had disease which was still responsive to 
chemotherapy at conventional dosage, twenty nine patients had disease which 
was resistant to chemotherapy at conventional dosage and one patient could not 
be classified by this criteria.
There was no evidence of bone marrow involvement in any of the patients at the 
time of ABMT by histological examination only of iliac crest trephine biopsies. 
No immunological assessment of potential marrow involvement was carried out. 
Bone marrow was harvested under general anaesthetic and cryopreserved as
previously described (Linch et al, 1982). Bone marrow was not "purged" by 
any method in an attempt to remove residual lymphoma. Unless there was 
already such a line in place, all patients had a Hickman central venous catheter 
inserted at the time of bone marrow harvest.
The first eight patients were treated with the UCH-1 regimen, consisting of 
BCNU 300 mg/m2 on day 1, Cyclophosphamide 1.5 Gm/m2 on days 1-4 and Ara 
C 200 mg/m2 on days 2-5 and it was initially planned that all patients would 
electively undergo a double ABMT procedure. Three patients received a second 
procedure on this protocol using the UCH II regimen, in which the high dose 
cyclophosphamode is replaced by methotrexate 1 Gm/m2 on day 1, the second 
time. This approach was felt to result in excessive toxicity which would limit 
applicability to older patients and was therefore replaced by the BEAC regimen 
which differed from UCH-1 regimen by the addition of etoposide 75 mg/m2 on 
days 1-4, and the BEAM regimen which was identical to that given to the 
patients with Hodgkin's disease. Two patients who had no response to BEAM 
underwent a second ABMT with one patient subsequently receiving a second 
procedure conditioned with cyclophosphamide and total body irradiation and the 
other patient receiving a second BEAM regimen.
All patients were treated in single rooms with simple reverse barrier nursing 
procedures and without laminar flow facilities. Blood products were not 
irradiated and were not screened for Cytomegalovirus. No prophylactic 
antibiotics were given during the period of neutropenia.
All patients were assessed for response by computerized axial tomography (CT) 
scan at three months after ABMT in addition to clinical and radiological review.
Twelve patients (24%) achieved CR within three months of ABMT. These 
patients received no further therapy as consolidation or maintenance until 
relapse of disease. Five of these patients remain in continuous complete 
remission at 19 - 43+ months post ABMT. Seven patients relapsed from CR, 
all within two years of the procedure. Six of these patients have died of 
progressive disease. The seventh patient remains in stable non-progressive 
disease at 37 months after relapse and is maintained on therapy consisting of 
a-lnterferon, chlorambucil and prednisolone.
Seventeen patients had a partial response to high dose therapy. Three of these 
patients received radiotherapy to sites of residual disease and two patients 
entered CR. One patient who had no response to the first procedure using BEAM 
and was assessed as a partial response to her second ABMT with BEAM, died at 
27 months post ABMT of pulmonary toxicity and was found to have no evidence 
of lymphoma at an extensive post mortem examination. The overall complete 
remission rate of the whole group is therefore 30% i.e. 15 patients. Five 
patients assessed as PR on the basis of an abnormal CT scan have shown no 
progression of their disease despite receiving no further therapy for periods of 
16 - 68+ months post ABMT and a total of 20 patients (40%) have thus had a 
good response (CR or lack of progression of residual radiological abnormality 
for more than one year) to the procedure.
Twelve patients had no response to ABMT and eleven have died of progressive 
disease within one year of the procedure. One patient remains alive with 
relapse of disease at sixteen months after ABMT. One of these patients initially 
received BEAM and received a second procedure after conditioning with 
cyclophosphamide/TBI but died during the second aplastic period of progressive 
disease and sepsis.
The overall survival of all patients is shown in figure 1.7.
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Figure 1.7. Overall survival after high dose therapy and ABMT in 
50 patients with non Hodgkin's lymphoma
Using statistical analysis, the influence of sex, age at diagnosis and at ABMT, 
histology, stage at the time of diagnosis and at ABMT, presence of extra nodal 
disease previously or at ABMT, size of greatest tumour mass at diagnosis and at 
ABMT, response status (as defined by response to conventional dose therapy), 
administration of previous radiotherapy, time to recovery of granulocytes or 
platelets and the high dose regimen used were assessed to determine their 
significance as prognostic factors with regard to response to high dose therapy 
and overall survival after ABMT. The response status of patients at the time of 
ABMT (%2= 20.8, p < 0.001) was the only factor which had statistical 
significance, on univariate and multivariate analysis, as a predictive factor for 
survival after ABMT and in particular size of mass at ABMT (p = 0.39), 
presence of extra nodal disease (p = 0.47) and use of previous radiotherapy (p 
= 0.84) were not significant factors on analysis. The overall survival of 
patients dependent on response status at the time of ABMT is shown in figure 
1.8.
The major procedure-related toxicities were significant marrow suppression 
in all patients and febrile episodes which occurred in 92% of patients. Nine 
patients (18% ) died of sepsis during the aplastic phase and one further patient 
who died at 27 months after the procedure, while in CR, must also be 
considered a toxic death producing an overall toxic related death rate 20%. 
There is a marked difference in the procedure related death rate in those 
patients who still had disease responsive to conventional dose therapy (PR and 
RR) compared with those who had disease resistant to conventional dose 
therapy. All nine deaths occurring within three months of the procedure
occurred in those patients who had chemotherapy resistant disease and the 
procedure related death rate in this group is therefore 31%. Only one 
treatment related death occurred in those patients who still had chemotherapy 
responsive disease and this occurred at 27 months in the one patient who had a 
double procedure with BEAM. The treatment related mortality in the patients 
with chemotherapy responsive disease is therefore 5%. No other patients had 
failure of marrow engraftment. The median period after re-infusion of 
autologous marrow to achieve a neutrophil count of 0.5 x 109/l was 21 (range 
13 - 40 )  days and to achieve a platelet count greater than 50 x 109/l without 
transfusion was 24 (range 1 4 - 5 4 )  days. No patient remains transfusion 
dependent following the procedure. Mucositis was troublesome in all of the 
patients, particularly in those treated with the BEAM regimen, but resolved in 
all cases within a few days of neutrophil recovery. Herpes simplex infections 
were documented or suspected on clinical grounds in 78% of patients and in all 
cases responded to intravenous acyclovir.
In the 15 patients who had a partial response to initial therapy, 10 patients 
(67%) achieved CR and a further three patients have non progressive disease 
on CT scan as the only abnormality. One patient who had no response to the 
procedure received a second procedure after a second BEAM and died in CR at 27 
months of presumed chemotherapy induced pulmonary toxicity. This patient 
represents the only procedure related mortality which occurred in this group 
of patients. It must be acknowledged that many of the patients with persistent 
residual masses after initial chemotherapy were not re-biopsied. Active 
disease at the time of the ABMT was not therefore unequivocally proven.
However their prompt response to intensive therapy (reduction in mass) is, 
we beiieve,indicative of disease and not fibrosis. Even in the three patients in 
this group who did not achieve CR but have shown no progression of residual 
masses, all had a greater than 50% reduction in the tumour mass following 
ABMT.
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Figure 1.8. Overall survival after ABMT of patients with non 
Hodgkin's lymphoma depending on status at ABMT. Twenty 
patients had disease responsive to conventional therapy and 29 
patients had disease unresponsive to conventional therapy
Of the 20 patients who still had chemotherapy responsive disease the procedure 
had low toxicity and a high response rate in agreement with the excellent 
results reported from the Boston group (Takvorian et al 1987) who electively 
treated only small bulk disease, which was still responsive to chemotherapy, 
with cyclophosphamide and total body irradiation (TBI) and rescue using bone 
marrow purged of residual disease using the monoclonal antibody B1. Although 
a number of their patients had obvious bone marrow involvement with 
lymphoma at the time of ABMT and these may have benefited from the purging 
procedure, the patients who had chemotherapy responsive disease and reported 
here had comparable results, despite a greater tumour burden at the time of 
ABMT and did not receive purged marrow. This suggests that the role of patient 
selection is as important as purging of bone marrow in such patients.
Ten of our patients had resistant relapse at the time of ABMT. Only two patients 
achieved CR and in both cases this was of short duration. Two patients in this 
group died of bacterial septicaemia during the aplastic period. All ten patients 
in this group died within 18 months of the procedure.
Nineteen patients had primary refractory disease. Only one patient achieved CR 
and relapsed after seven months and died of progressive lymphoma. Five 
patients achieved a partial response, two of whom have non-progressive 
changes present on CT scan at 24 and 32 months after ABMT and represent the 
only long term survivors in this group of patients. Seven of these patients died 
of sepsis during the aplastic period resulting in a treatment related mortality 
rate in this group of 37%.
In none of the cases was the bone marrow purged with either monoclonal 
antibodies or chemotherapy to attempt removal of residual disease in the bone 
marrow. Only two patients relapsed after ABMT at sites not previously 
involved; one patient relapsed in the bone marrow and one in the CNS. This 
suggests that re-infusion of residual lymphoma from the bone marrow is not a 
major problem in those patients who have no histological evidence of marrow 
involvement at the time of marrow harvest. Until there are more effective 
methods of elimination of residual tumour from the patient the precise role of 
bone marrow purging will be difficult to elucidate.
There is no significant difference in survival between those patients who were 
deemed to have achieved a CR and those who achieved a PR after ABMT despite 
the fact that 42% of these complete remissions have been maintained. This 
illustrates some of the difficulties in defining response in patients with 
malignant lymphoma. Firstly, the definition of CR is dependent on the 
sensitivity of the investigations used to detect residual tumour. Those patients 
who relapse shortly after the procedure may not have achieved CR post ABMT. 
All patients in this study were assessed by CT scan but Nuclear Magnetic 
resonance (NMR) and surgical restaging were not performed. Secondly, it is 
often difficult to assess the significance of residual masses remaining after 
therapy, particularly in those patients presenting with large mediastinal or 
retroperitoneal masses. Five patients in this study who were defined as PR on 
the basis of residual masses detected on CT scan have had resolution or non 
progression of these masses at periods from 16 - 68+ months after high dose 
therapy. Such masses may not represent active disease (Surbonne et al 1988.)
Two further patients initially assessed as achieving PR received localized 
radiotherapy to sites of residual disease and subsequently achieved CR, so that 
all the long term survivors in the PR group may have no active disease.
These findings, from a single centre, confirmed previous reports from multi­
centre studies (Philip et al 1987, Goldstone et al 1989) that those patients 
who have no response to chemotherapy at conventional doses have little further 
response to dose escalation which may also be associated with high and perhaps 
unacceptable levels of morbidity and procedure related mortality. This differs 
from the results obtained in resistant Hodgkin's disease, where the response to 
BEAM followed by ABMT was not affected by the response status to conventional 
dose therapy. (Gribben et al 1989 a)
In those patients with NHL who have disease still responsive to conventional 
dose chemotherapy however, dose escalation is associated with good responses 
and low levels of morbidity and mortality. This is in agreement with the 
findings reported from the Boston group (Takvorian et al 1987) for those 
patients with chemotherapy responsive, low bulk disease and from the multi­
centre French study (Philip et al 1988) of patients who achieved a partial 
response to first line therapy. Although as described above, poor responses 
have been reported to conventional dose salvage regimens, a number of the 
patients in these studies were in the category of patients who have fared equally 
badly with high dose therapy and ABMT. For this reason a prospective 
randomized study of high dose therapy versus best conventional salvage therapy 
in these chemotherapy responsive patients should now be carried out.
However, the use of recombinant haemopoietic growth factors may allow 
improved salvage therapies to be developed without the use of autologous 
marrow transplantation. Until this trial has been carried out it remains 
unclear if the potentially lethal procedure with high dose therapy requiring 
ABMT has a role in the management of patients with non-Hodgkin's lymphoma. 
No randomized studies have been undertaken of allogeneic transplantation 
versus either autologous transplantation or chemotherapy in the non Hodgkin's 
lymphomas. Although many necessary studies may now never be performed, it 
is essential that dose escalation requiring marrow rescue be compared in 
prospective randomized studies against conventional dose salvage therapy to 
determine the use of this approach.
1.14. Late complications of Autologous Bone Marrow  
Transplantation.
ABMT is therefore used increasingly in the management of the haematological 
malignancies and also in a variety Of other solid tumours. The morbidity and 
mortality of ABMT is largely due to infectious complications, treatment related 
toxicities and relapse of disease. Although most of these infections occur during 
the neutropenic period these patients remain at increased risk of infection 
particularly during the first year after transplantation. Herpes zoster 
infections are particularly common in patients with malignancies and in those 
receiving chemotherapy, including ABMT. Herpes zoster infection occur after 
allogeneic bone marrow transplantation in one third to one half of patients,
making it one of the most common late complications of allogeneic BMT. In a 
recent study of one hundred and fifty patients undergoing ABMT 28% developed 
zoster infections after ABMT at a median of five months after ABMT with 91% 
occurring in the first year. Although there were only a small number of 
patients with lymphoma, the incidence of VZ was higher in patients with 
Hodgkin's disease and Non-Hodgkin's lymphoma (46%) than in those with acute 
leukaemia (23%) (Schuchter et al 1989). The overall incidence of zoster 
after ABMT is therefore similar to that reported after allogeneic BMT and the 
incidence, median time of onset and the morbidity appear to be similar in the 
two groups. The rate of dissemination to varicella and the mortality of VZ 
infections is higher in those patients receiving allogeneic bone marrow 
transplantation as opposed to those receiving ABMT.
1.15. Late complications after ABMT at University College and 
Middlesex School of Medicine.
The results described in each of the patient groups have focussed on patient 
selection, the early toxicities of the procedure, response to high dose therapy 
and subsequent disease free survival following ABMT. An important 
consideration is the quality of life and the longer term complications of high 
dose therapy and ABMT.
Only two cases of Cytomegalovirus pneumonitis have been seen in the entire 
population of patients autografted at this centre and both patients responded to 
Gancyclovir and intravenous gammaglobulin therapy. No cases of Pneumocystis
carinii have been seen. One patient developed pneumonitis with lung biopsy 
changes of fibrosis at one year after double ABMT for AML in first CR, but this 
responded well to a short course of steroids. Varicella pneumonia was fatal in 
one case, but this occurred during the neutropenic period. Herpes zoster 
infections have been seen in the first year after ABMT in forty two patients, 
but the 28 of these patients had Hodgkin's disease which had not responded to 
high dose therapy. It is noteworthy that the incidence of herpes zoster infection 
in this population of patients is lower than that reported from Johns Hopkins 
(Schuchter et al 1989) despite the fact that our own patient group comprises 
more patients with NHL and Hodgkin's disease, who were reported to be at 
particularly high risk.
Overall therefore these patients are not subject to the opportunistic infections 
which are seen in bone marrow allograft recipients. It therefore seemed 
important to evaluate the immune function of these patients following ABMT
Chapter 2.
Effects of Bone Marrow Transplantation on Immune Function.
Intensive chemotherapy required for the treatment of refractory malignancies 
is ablative to the lymphoid as well as the myeloid component and is therefore 
associated with severe immune depression. In allogeneic transplantation this 
immune suppression is secondary not only to the preparative chemotherapy and 
radiotherapy used but also to the host - graft relationship and the 
immunosuppressive therapy given to prevent graft versus host disease 
(GVHD). Syngeneic bone marrow transplantation is also associated with delay 
in immune reconstitution and this provided evidence that the preparative 
regimen itself is in some way responsible for the immune dysfunction which 
follows bone marrow transplantation. The use of high dose therapy with 
autologous bone marrow transplantation as rescue allows evaluation of the 
immune suppressive effects of high dose therapy uncomplicated by the presence 
of GVHD or immune suppressive therapy to prevent GVHD
2.1. Immune function after a llogeneic  bone m arrow  
transplantation.
The high dose chemo/radiotherapy required for the treatment of refractory 
malignancies and the immune suppression required to prevent allogeneic graft 
rejection is associated with immunosuppression and an altered immune
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reconstitution such that after bone marrow transplantation the recipient is 
affected by a functional cellular and humoral immune deficiency which lasts for 
up to one year (Witherspoon et al 1984 a). This immune deficiency is 
worsened and prolonged by the presence of GVHD (Witherspoon et al 1984 b). 
Immunological impairment is one of the major causes of morbidity and 
mortality after allogeneic bone marrow transplantation as the associated 
immune deficiency is associated with opportunistic infections which may be 
life threatening. Although the period of greatest risk is during the first 100 
days the patients with GVHD remain at risk for periods beyond one year.
Studies in patients receiving allogeneic grafts have shown that the re­
population of the immune system is dependent on the proliferation, maturation 
and differentiation of donor cells, exactly analogous to re-population of the 
haemopoietic system. Immunological reconstitution depends on the emergence 
of different components of the immune system such that the patients progress 
from an immunological state of relatively primitive systems with the early 
emergence of natural killer (NK) activity (Ault et al 1985, Reittie et al 
1989) and phagocytic functions followed by a more orderly re-establishment 
of lymphoid cells having firstly a excess of suppressor and specific cytotoxic 
function and subsequently T cells responsible for regulatory control functions 
(Keever et al,1989).
/
2.2. B cell function after A llogeneic Bone Marrow
Transplantation.
Following allogeneic bone marrow transplantation serum levels of IgG and IgM 
return to normal 3 to 4 months after grafting but IgA levels remain low for 
years (Gale et al 1978). Marrow recipients have severely depressed 
responses to immunization with new antigens (Witherspoon et al 1981), but 
may have normal responses to recall antigens within the first three months 
(Lum LG, 1987). It is likely that the source of these antibodies are B cells of 
donor origin and not surviving host B cells since host ABO isohaemagglutinins 
are absent by three months after BMT (Witherspoon et al 1981). The adoptive 
transfer of antibody responses from donor to recipient has been performed for 
recall antigens has been performed after BMT with both whole marrow and 
marrow depleted of T cells. (Wimperis et al 1986) and the requirements for 
the primary transfer of antibody responses have been established (Wimperis 
et al, 1990).
B cell phenotyping data is scanty after BMT. CD20 cells return rapidly but 
CD5+ B cells have been reported during the early post transplant period (Ault 
et al 1985) suggesting that more immature forms of B cells are present in the 
circulation in the early post transplant period. In vitro assays of Ig production 
from enriched B ceii popuiaiions are consistently markedly reduced even in the 
presence of normal T cells (Witherspoon et al 1982) and similarly in vitro 
assays of B cell activation with Staphylococcal aureus Cowan I remain abnormal 
in the early post transplant period despite the addition of normal T cells
(Matsue et al 1987). These B cell defects return to normal by one year in 
healthy bone marrow recipients, but remain abnormal beyond this period in 
those patients who have chronic GVHD (Lum et al 1986).
2.3. T cell function after A llogeneic Bone Marrow  
Transplantation.
Consistent phenotypic and functional abnormalities have been described after 
allogeneic bone marrow transplantation. A number of studies have shown that 
the CD8+ cells quickly return to normal or even above normal levels but the 
CD4+ cells remain low for periods beyond six months after BMT, so that there 
is a reversal of the normal CD4/CD8 ratio (Reviewed by Lum LG, 1987). 
These changes are most pronounced in the early recovery period and in patients 
with acute and chronic GVHD (Friedrich et al 1982). It has also been noted 
that the CD3+ cells have decreased CD5 expression. The majority of these 
CD3+, CD5- cells co-express CD8 (Bierer et al 1989). These changes have 
largely reverted to normal by one year after BMT, but again those patients with 
GVHD have prolongation of the reversed CD4/CD8 ratio (Witherspoon et al 
1984).
in vivo delayed type hypersensitivity reactions are impaired during the first 
three months after BMT and similarly, in vitro assays of T cell proliferative 
function show persistent defects to a range of mitogens during this early post 
transplant period (Witherspoon et al 1984).
Consistent phenotypic and functional abnormalities of T cells have therefore 
been described after BMT. These abnormalities are most pronounced in the 
early recovery period and in allogeneic patients with acute or chronic GVHD and 
may be increased by concomitant viral infections particularly with 
cytomegalovirus.
2.4 Immune function after Autologous Bone Marrow
Transplantation
The immune deficit following allogeneic transplantation has been extensively 
investigated. The recovery of immune function after ABMT provides a model 
for the assessment of the effect of high dose therapy alone on immune 
reconstitution without the concomitant effects of GVHD, but as yet few studies 
have been published on immune function after ABMT
2.5. B cell function after autologous bone marrow
transplantation.
Following ABMT serum levels of IgM and IgG either remain at the lower limits 
of normal (Arrnitage et al 1986) or rapiaiy reiurn to normai ieveis by three 
months after ABMT (Baumgartner et al 1988, Pedrazzini et al 1989).
Very few studies have been reported on B cell function after ABMT. Kiesel et al 
assayed the proliferative responses to anti p, SAC and low molecular weight B 
cell derived growth factor (BCGF) and found absent responses in 9 out of 22 
patients and defective responses in a further 8 patients. 19 of these 22 
patients had normal in vitro IgG secretion. The authors postulated that the in 
vivo serum IgG may be produced from the stimulation of a small number of re­
infused pre-committed memory B cells while in parallel immature B cells may 
develop from autografted haemopoietic progenitor cells (Kiesel et al 1988).
Following ABMT with bone marrow purged with the monoclonal antibody B1, 
Pedrazzini et al reported in vitro impairment of proliferative responses to anti 
Ig, Epstein Barr virus (EBV), Interleukin 2 (IL-2) or low molecular weight 
BCGF for up to two years post ABMT. It is noteworthy that in this study serum 
Immunoglobulin levels were below the normal range for IgM for 3 months, IgG 
for 6 months and IgA for 2 years (Pedrazzini et al 1989). This may be 
explained by the fact that in these studies there has clearly been re-infusion of 
only a very small number of pre-committed memory cells because of the 
purging with B1.
B cell phenotyping data after ABMT is also scanty. In this same study 
Pedrazzini reported that CD20+ cells were detected immediately at the first 
evidence of engrafiment and that 50% of patients had reached normai numbers 
by 3 months post ABMT (Pedrazzini et al 1989).
2.6. T cell function after Autologous Bone marrow
transplantation.
There have been a number of reports confirming that a similar pattern of 
phenotypic abnormalities of T cells is seen after ABMT as is seen after 
allogeneic bone marrow transplantation. There is a rapid regeneration of CD8+ 
cells with a more slow recovery of CD4+ cells, resulting in a reversal of the 
normal CD4/CD8 ratio. (Armitage et al 1986, Olsen et al 1988, Bengtsson et 
al 1988, Pedrazzini et al 1989,).
Functionally, there is defective IL-2 production by T cells (Bosly et al 1987). 
This has been attributed to the low numbers of CD4+ cells, but perhaps may 
also be due to a decreased responsiveness of these cells to endogenous IL-2 
(Lopez-Botet et al 1987, Cayeux et al 1989). The precise nature of the T cell 
defect remains unknown.
These studies suggest that similar defects occur in vitro after autologous and 
allogeneic bone marrow transplantation, but that these changes tend to be of 
shorter duration. These studies have failed to explain why the autografted 
patients are not prone to the same opportunistic infections that are seen after 
allogeneic BMT.
Chapter 3.
Lymphocyte ontogeny and function
Lymphocytes can be functionally subdivided into distinct populations by their 
expression of unique cell surface and molecular markers. Human T cells were 
classically defined by their expression of sheep red blood cell (sRBC) 
receptors and their ability to modulate immune responses. B cells were 
identified by their expression of cell surface or cytoplasmic immunoglobulin 
(Ig). During the past decade, the development of monoclonal antibodies (mAbs) 
directed against T cell molecules expressed on the surface of human 
lymphocytes has led to great advances in defining the phenotypic and functional 
characteristics of these cells. mAbs have been also been useful in the 
determination of cellular lineages and in identifying normal stages of lymphoid 
generation.
3.1. Normal B Cell Ontogeny.
Normal B cell ontogeny can be conveniently divided into stages including pre-B 
cells, resting B cells, activated/proliferating B cells, differentiating B cells 
and plasma cells whciich are secreting immunoglobulin (figure 3.1.). These 
stages can be defined by the expression of unique cytoplasmic and cell surface 
antigens. In this regard, human B cell antigens can be subgrouped into broad 
categories including: pan B cell; resting B cell; activation antigens; and plasma 
cell antigens.
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Figure 3.1.
B cell development.
Pre-B cell differentiation takes place in the foetal liver and bone marrow 
prenatally and in the bone marrow in adults. The earliest pre-B cells have 
been defined by their expression of cell surface antigens including MHC class II 
(HLA-DR) and CD19, and rearrangements of immunoglobulin p heavy chain 
genes (Brouet et a! 1979, Korsmeyer et a! 1981, Korsmeyer et al 1983, 
Nadler et al 1983, Nadler et al 1984). CD19 is the most reliable cell surface 
marker of B lineage at the pre-B cell level. In addition to these cell surface 
proteins, a B cell restricted antigen, CD22 is present in the cytoplasm
(cCD22) at the earliest stages of pre-B cell differentiation then exported to the 
cell surface at the mature resting B cell stage when slgD is first expressed 
(Dorken et al 1986, 1987). Following the expression of CD19 and cCD22 
cells express CD10 (cALLa). Pre-B cells next express the pan-B cell 
restricted antigen CD20 (Nadler 1981, Stashenko et al 1980). The last stage 
of pre-B cell ontogeny appears with the expression of cytoplasmic Ig heavy 
chain without the expression of light chains. Several other antigens are 
expressed during pre-B cell development including CD9, CD24, CD45R 
(leukocyte common antigen), CD74 and CDw78 (Funderdud et al 1989, Kersey 
et al 1981, Hercend et al 1981)
As pre-B cells mature, they are exported to the peripheral blood and lymphoid 
tissues where they reside until activated by antigen (mature B cells). Mature 
resting B cells express slgM/D and HLA-DR, CD19, CD20, CD24, CD22 but no 
longer express CD9, CD10, and CD34. Coincident with the maturation to the 
slg+ stage, cells express the CD11a/CD18 LFA-1 complex (Campana et al
1986). Resting B cells also express CD44 which has been shown to be involved 
in lymphocyte recirculation and homing. In addition, resting B cells express 
CD21 which is the receptor for the C3d cleavage fragment of complement and 
for Epstein Barr virus (EBV) and CD35 which is the C3b complement receptor 
(lida et al 1983, Fingeroth et al 1984).
A subset of mature B cells have recently been described which express the T 
cell associated antigen CD1. CD1 is a member of the immunoglobulin supergene 
family and shares homology to both MHC class I and class II. CD1 exists as 3
molecules, CD1a (49 kD), CD1b (45 kD), and CD1c (43 kD) which are non- 
covalently associated with beta2 -microglobulin. Approximately 50% of
normal adult splenic B cells and a proportion of peripheral blood B cells are 
CD1c+, and following activation CD1c is up-regulated (Small et al 1989). B 
cells acquire several other antigens which are present until the plasma cell 
stage (CD37, CD39, CDw75, CD76) (Ling et al 1987, Dorken et al 1989, 
Erikstein et al 1989).
Following triggering with antigen or various polyclonal mitogens, resting B 
cells are activated and subsequently proliferate. This activation of resting B 
cells is accompanied by a sequence of cell surface antigenic changes. Within 
24 hours of activation, resting B cells begin to lose slgD, CD21, and CD22, and 
this process is complete by 72 to 96 hours (Boyd et al 1985a). As these 
antigens are lost, a number of B cell restricted and associated antigens 
sequentially appear (Kehrl et al 1984, Boyd et al 1985 b). These activation 
antigens are excellent candidates for growth factor receptors, molecules which 
regulate proliferation and differentiation, structures involved in cell-cell 
interaction and molecules which play a role in the localization and binding of 
activated B cells within a micro-enviroment. The majority of these activation 
antigens demonstrate peak expression by 72 hours and are no longer expressed 
on the cell surface at 120 hours.
With terminal differentiation there is the gradual loss of the B cell activation 
antigens as well as pan-B cell antigens including la, CD19, CD20, and CD24 
(differentiating B cell). This terminal differentiation stage is also
characterized by the appearance of several other antigens including CD38 and 
PCA-1 which are expressed on plasma cells (Terhorst et al 1981, Stamenkovic 
et al 1989, Anderson et al 1983)
Immunoglobulin gene rearrangements.
A vast variety of possible immunoglobulin molecules exist each corresponding 
to a unique antigenic epitope. This divergency is though to be produced by 
genetic recombination within the DNA of B lymphocytes. The germline DNA 
contains segments coding for different subunits of the immunoglobulin 
molecule. For the immunoglobulin heavy chain, these consist of a very large 
number of many different variable (V) segments, a smaller number of 
different diversity (D) segments, a few joining (J) segments, and a constant 
region for each subclass of immunoglobulin.
The usual mechanism for achieving recombination of the immunoglobulin gene 
DNA includes bringing together a single V, D, and J segments with the 
appropriate constant region segment and excising the unused segments. 
Therefore, the numbers of potential recombinants of V, D, and J segments are 
enormous. Light chain genes have a similar mechanism but lack D segments. A 
functional rearrangement of a heavy or light chain gene prevents 
rearrangements of anoiher gene of ine same chain type (aiieiic exciusion), 
whereas an abnormal heavy or light chain rearrangement which cannot be 
transcribed will allow the other heavy chain allele, or one of the other light 
chain alleles, respectively, to attempt rearrangement. This functional allelic
exclusion ensures that only one immunoglobulin specificity is allowed for any 
one B cell. The heavy chain gene undergoes rearrangement first, followed by 
the kappa, and then the lambda light chain genes.
3.2. Normal T Cell Ontogeny.
A large number of mAbs have been developed which define cell structures which 
are expressed on the surface of human T cells. These mAbs have been used to 
characterize the stages of T cell ontogeny and differentiation, identify subsets of 
functionally distinct T cells, and elucidate the function of some of these cell 
surface antigens (Haynes et al 1989).
During embryonic and early post-natal life, bone marrow precursor cells 
migrate to the thymus. The thymic micro-enviroment provides a setting for 
the processing and eventual development of functionally competent T cells. 
These cells are subsequently exported into peripheral lymphoid tissues and the 
circulation. A sequence of changes in cell surface antigens identified by mAbs 
are observed to accompany intrathymic differentiation (Reinherz and 
Schlossman 1980) The cells in the earliest stage (stage I) of intrathymic 
differentiation, which constitute 10% of the thymic lymphocytes, express CD2 
(E rosette receptor), CD71 (the transferrin receptor), CD38, and CD7 
(Terhorsi ei al 1981).
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Figure 3.2.
Normal T cell development.
At the next stage of differentiation (stage II) thymocytes are characterized by 
the loss of CD71, and the acquisition of CD1 (Terhorst et al 1981, Amiot et al
1987) and co-expression of CD4 and CD8 (McMichael et al 1987). The
population, co-expressing CD1, CD2, CD4, CD7, CD8 and CD38, constitute 
70% of thymocytes.
With further maturation (Stage III) cells lose CD1 and acquire mature T cell 
antigens CD3, CD5, and CD6 (Campana et al 1987). In parallel with the 
expression of CD3, cells express the T cell antigen receptor (TCR). CD3 is a 
complex of 5 chains - y, 8, e, £ and tj, which are non-covalently associated with 
the T cell antigen receptor(Acuto and Reinherz 1985) . The TCR can exist as 
an ap heterodimer and unlike the antigen receptor for B cells, slg, the 
CD3/TCR complex recognizes antigen in the context of MHC. A second T cell 
receptor, is also associated with CD3 termed y8 (Brenner et al 1986). Cells 
which express the yS TCR appear earlier in ontogeny than ap TCR cells, are 
CD4 and CD8 negative, and are associated with natural killer cell activity 
(non-MHC restricted cytotoxicity).
When cells leave the thymus, they no longer express CD38 and are segregated 
into cells expressing CD4 or CD8, constituting 60-70% and 30-40% of 
peripheral blood T cells, respectively. More recently, a series of mAbs have 
been developed which further subdivide CD4 helper cells into inducers of help 
(CD45R) and the inducers of suppression (CD29) (Morimoto et al 1985a , 
1985 b). Peripheral T cells, when activated by antigen, mitogen, anti-CD2, 
anii-CD3, or anii-TCR mAbs, undergo additional changes in ceii surface 
antigens. During the first 2 days after activation, T cells express CD25 - the 
IL-2 receptor (Uchiyama et al 1981) and CD26. The transferrin receptor
(CD71), CD70, CD9 (Hercend et al 1981), as well as CD38 reappear by 4 
days of in vitro culture and HLA-DR antigens are present by 6 to 8 days.
T Cell Receptor Gene Rearrangements.
As described above the T cell receptor (TCR) is composed of several subunits 
including a heterodimer composed of the a and p chains or y and 8 chains in 
associated with the CD3 complex. The a, p and y chains genes undergo 
rearrangements in the same way as immunoglobulin genes. V, D, and J DNA 
segments have been identified for the p chain gene, and so far, V and J segments 
for the others. There is also a temporal progression of rearrangement and gene 
expression, starting with y chain gene rearrangement, followed by p chain gene 
rearrangement, and ychain gene mRNA expression, followed by p chain mRNA 
expression, and finally a chain gene rearrangement, and a chain mRNA 
expression. It may be possible to utilize this progression to assign a stage 
within early T cell differentiation to a particular T cell lymphoma.
3.3. T
Lymphocyte cell surface antigens - structure and function
Monoclonal antibodies reactive with a number of lymphocyte surface proteins 
have recognised a varieiy of cell surface proteins which exhibit some homoiogy 
with the immunoglobulins and are known as the immunoglobulin supergene 
family. This group include the T cell receptor, MHC class I and class II 
molecules, CD2, CD3, CD4 and CD8 each of which is critical to T cell activation.
In general the function of these molecules seems to be to mediate adhesion 
between cells
The T cell receptor and CD3
T cell receptors (TCR) are heterodimer glycoproteins expressed on the 
membrane of T cells in association with the CD3 complex. The TCR-CD3 
complex contains at least seven polypeptide chains; two TCR chains and the y, 5, 
e, n and C CD3 chains
The classical TCR ap (TCR2) is involved in specific recognition by T cells of 
antigens on the surface of other cells. Initiation of an immune response against 
antigen requires recognition by the TCR of both antigen and MHC class II 
determinants on the surface of the antigen presenting cell, a phenomenon known 
as MHC restriction.
Recently a second TCR was described, namely the TCR yS (MB Brenner et al 
1986) which is also expressed in association with the CD3 complex. The TCR 
y5 (TCR 1) is mainly expressed on CD4-, CD8- double negative T cells, which 
can be found in low numbers in the adult thymus, spleen, lymph node and 
peripheral blood. However, in the early stages of thymic ontogeny y8 bearing 
cells account for the majority of T ceiis. There is evidence that there is a 
limited variability in the expressed TCR y8, but the function of the TCR y8  
bearing cells in unknown. The genomic organization and basic structure of the 
TCR a, p, y and 8 genes is now well characterized .
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CD2
Originally described as the sheep red blood cell receptor, an alternative name 
was LFA-2. It exists on the cell surface as a 50 kD monomer, primarily on T 
cells, though it is also found on NK cells. Its natural ligand is LFA-3 (CD58), 
which is another member of the immunoglobulin supergene family (Selvaraj et 
al 1987). The virtual restriction of CD2 to T cells, with an almost ubiquitous 
expression of LFA-3 suggests that this may allow adhesion of T cells to any cell 
type requiring immune surveillance. The molecule is known to undergo 
conformational change on binding with the mAb 9.6 exposing a new epitope 
recognised by the mAb 9.1(CD2R). Stimulation of T cells with both antibodies 
induces antigen presenting cell independent T cell activation (Meuer et al 
1984), but it is as yet unclear what the physiological significance of this 
pathway may be.
CD4 and CD8.
CD4 and CD8 are expressed on mutually exclusive populations of peripheral T 
cells, although as described above, during T cell ontogeny cells co-express CD4 
and CD8. T cells do not recognize antigens in isolation but only in the context of 
an MHC molecule. Most antigens must be processed in order to bind to MHC 
molecules to be presented io T ceiis. Several pathways of processing have been 
identified and processing of antigen could potentially play a role in the 
triggering of a particular functional subset of T cells by targeting the processed 
peptide to a particular MHC class. T cells expressing CD4 almost invariably
recognise foreign antigens as peptides presented by self MHC class II molecules 
to which they bind (Doyle and Strominger 1987) whilst CD8+ T cells 
recognise foreign antigen presented as peptides by self MHC class I molecules 
and there is direct evidence for binding of CD8 to MHC class I (Rosenstein et al 
1989) .
CD4
CD4 is a monomeric 55 kD cell surface glycoprotein. There are four 
extracellular domains each homologous to the immunoglobulin V regions. There 
is homology between human and murine CD4 which is most marked in the 
intracytoplasmic domain, suggesting a functional role for this part of the 
molecule. The cytoplasmic tails of CD4 contain serine residues that are 
phosphorylated via protein kinase C (PKC) as a consequence of antigen or 
mitogen stimulation. PKC activation results in the down modulation and 
internalisation of CD4.
The molecule was originally described as a marker for T cells with helper 
function and CD4 expression is predominantly associated with helper T cell 
function. However, expression of CD4 is most strictly associated with 
recognition of antigen in association with self MHC class II molecules. The 
stringent association of CD4 expression with MHC ciass ii recognition of target 
cells has led to the suggestion that CD4 increases the avidity of cell - cell 
interaction by direct binding of CD4 to determinants of the MHC class II 
structure. This binding function of CD4 may not be its only function. Recent
evidence suggests that CD4 may associate with TCR/CD3 (Anderson et al 1988) 
and be involved in signal transduction (Janeway 1989). CD4 regulatory 
function may be through its association with a T cell specific protein tyrosine 
kinase (p58Lck) (Rudd et al 1988).
Whilst most helper T cells are CD4+, it is clear that not all CD4+ T cells are 
capable of providing help to B cells to produce antibodies. CD4+ cells may be 
cytotoxic, suppressor or T cells that activate macrophages and share the ability 
to mediate their effects by secreting IL-2 (Janeway 1989). Similarly most 
cytotoxic T cells express CD8 but CD8+ T cells can provide T helper function 
and some can secrete IL-2.
Recognition of other surface proteins has helped to delineate functional subsets 
of CD4 cells. Helper T cells have the phenotype CD4+, CD45R-, CD29+. 
(Morimoto 1985a) Suppressor inducer cells are CD4+, CD45R+, CD29- 
(Morimoto 1985 b). Suppressor effector cells are CD4+ and are induced after 
activation with anti CD3 with IL-2 playing a major role in their 
differentiation.
T cell dependent B cell activation requires direct interaction between B cells 
and activated T cells, presumably involving specific cell surface receptors 
which have not yet been recognized, it is possible that CD45R- CD4+ ceiis may 
express interaction molecules at a higher density. There is evidence that CD4 
cells may function directly also as suppressor effector cells and that CD45R+ 
CD4+ cells can directly suppress B cell responses in poke weed mitogen
cultures. This suppressor activity can be abrogated by irradiation of the CD4 
cells. CD45R+ CD4+ cells induce suppressor CD8 cells more effectively than 
CD45R- CD4+.
CD4 also serves as the receptor of Human Immunodeficiency Virus I.
CD8
CD8 has been characterised as a 32-43 kD protein which is present on the cell 
surface as an ap heterodimer or aa homodimer.
The molecule originally described a subset of T cells delineated as 
cytotoxic/suppressor, but this is now known to be an over-simplification. 
Experimental evidence suggests that the CD8 molecule may have several roles 
to play on the surface of T lymphocytes. In conjunction with other accessory 
molecules it may enhance TCR/antigen interaction by facilitating adhesion 
between the T cell and antigen presenting cell. As with CD4, CD8 has been 
implicated in functioning also as a signal transduction molecule.(Emmrich et al
1986). Like CD4, the CD8 antigen is coupled to a protein tyrosine kinase 
(p58Lck) (Barber et al 1989).
CD19 is a 95 kD glycoprotein which is a member of the Ig supergene family, 
with three extracellular Ig-like domains (Tedder et al 1989). In vitro studies
with normal mature B cells and pre-B cells demonstrate that anti-CD19 mAbs 
inhibit pre-B and mature B cell proliferation (Pezzutto et al 1987).
CD20
CD20 is a 35 kD nonglycosylated phosphoprotein. In vitro B cell functional 
studies suggest that CD20 is involved in the regulation of B cell activation. 
Different mAbs directed against CD20 can both inhibit B cell 
activation/proliferation or induce B cells to go from the G0 phase of the cell 
cycle to the G-j phase, depending on the source and state of activation of B cells 
(Clark et al 1985, Tedder et al 1985). From the cDNA, it is hypothesized that 
CD20 has a very small extracellular domain, several hydrophobic regions 
which traverse the cell membrane multiple times and a large cytoplasmic 
domain (Tedder et al 1988, Einfeld et al 1988, Stamenkovic et al 1988).
CD25
CD25 is the 55 kD Tac antigen which is the low affinity IL-2 receptor. It is 
encoded by a single gene with at least two forms of mRNA present. Originally it 
was believed that the CD25 antigen was present only on activated T cells, but it 
is now clear that it is also present on activated B cells and monocytes.
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CD 29
This is the common p chain of the very late antigen (VLA) and is a member of 
the integrin supergene family. The putative function of CD29 is to act as an 
adhesion molecule and perhaps also to modulate signal transduction.
CD56
This pan NK antigen is also expressed on a subset of T cells and IL-2 activated T 
cells that mediate MHC unrestricted cytotoxicity (Lanier et al 1986) It is 
present on the cell surface as a 175 kD isoform of the adhesion molecule N- 
CAM.(Lanier et al 1989)
CD45 - The Common Leucocyte Antigen
CD 45 is a family of major membrane glycoproteins that range from 180 - 
240 kD and are found on all haemopoietic cells except the erythroid series. 
Eight isoforms of CD45 have been described in mammals which are expressed 
differentially on leukocyte sub-populations (Thomas & Lefrancois 1988). 
These isoforms differ both in their pattern of glycosylation and in their 
primary structure as a result of alternative splicing of mRNA (Streuli et al
1987). The CD45 molecule has three distinct segments; a heavily glycosylated 
cysteine rich extracellular segment, a 22 residue transmembrane segment and 
a large carboxy terminal cytoplasmic residue which is the same in each 
isoform.
There are several potential phosphorylation sites for PKC within the 
cytoplasmic domain and it is proposed that phosphorylation of CD45 on key 
tyrosine residues may regulate its activity (Clark and Ledbetter 1989). The 
fact that CD45 is a phosphatase suggests that it may function by interacting 
with other membrane associated proteins (Charbonneau et al 1988). CD45 is 
potent regulator of lymphocyte signal transduction and affects signalling in a 
number of ways. When CD3, CD2 or CD28 receptors on resting human T cells 
are cross linked with mAbs, there is an increase in cytoplasmic free Ca+ + 
(iCa++) which is abolished if these same receptors are cross-linked to CD45 
(Ledbetter et al 1988). Similar results are obtained when CD45 is brought 
into close proximity with receptors which can transmit a signal resulting in 
increased iCa++ in resting B cells such as surface Immunoglobulin and CD19. 
(Ledbetter et al,1988.). CD45 functions most effectively when in close 
proximity to other membrane associated proteins. It is possible that CD45 
modifies signal transduction in T cells directly by dephosphorylating 
membrane associated cytoplasmic proteins required for T cell activation. When 
CD45 is brought into close proximity with CD4 it enhances rather than 
inhibits CD4 mediated signal transduction.(Ledbetter et al 1988). Together 
these data suggest that CD45 can regulate pathways dependent on 
phosphoinositol hydrolysis. CD45 can also inhibit signalling associated with 
with CD40 which activates cells independently of a rise in iCa++. CD45 can 
therefore regulate signal transduction through receptors that either do or do 
not depend on Ca++ mobilisation (Ledbetter et al 1988). These multiple 
functions may be facilitated by the differential expression of the different 
isoforms of CD45 on resting, memory and activated T and B lymphocytes.
3.4. Cell surface changes on activation
During cell differentiation there are changes in the expression of surface 
membrane proteins which may modify the cell's ability to interact with other 
cells or its environment. Cellular adhesion plays a crucial role in the 
induction, expression and regulation of the immune response. The LFA-1 
molecule has been shown to be of particular importance. Monocyte and T cell 
LFA-1 contribute to the adhesive interaction between these cell types. LFA-1 
is a cell surface glycoprotein which has been implicated in adhesion of 
lymphocytes, macrophages and granulocytes. LFA-2 is also known as CD2 and 
is restricted to T lymphocytes. LFA-3 is a widely expressed glycoprotein 
which has been shown to be the ligand for CD2 .(Selvaraj et al 1987). LFA-3, 
CD2 and LFA-1 may also function in cell activation. T cells can be activated by 
binding of mAbs to CD2 (Meuer et al 1984) and LFA-3 can participate in this 
activation (Bierer et al 1987) Binding of mAb to LFA-3 can induce IL-1 
secretion by monocytes and thymic epithelium. The role of other adhesion 
molecules and their interaction with their natural ligands is an area of great 
interset at the present time.
There have been a number of studies which have shown that there are 
alterations in the cell surface expression of a number of surface proteins on T 
cells which have undergone primary antigenic stimulation. These memory T 
cells are capable of mounting a rapid anamnestic response. CD29, CD45R and 
CD45Ro (UCHL1) have each been reported to be altered in expression on the 
subset of cells which mount secondary in vitro responses to recall
antigens.(Morimoto et al 1985, Smith et al 1986). The CD45 molecule 
undergoes important changes with cell activation, so that CD45R is down- 
regulated while CD45Ro is up-regulated (Sanders ME et al 1988.). The 
enhanced expression of adhesion molecules on previously activated memory 
cells could then be critical to their ability to respond rapidly to subsequent 
stimulation. The activation of T cells induces a wide variety of cell surface 
molecules. Some, such as CD25 or HLA class II molecules are induced only 
transiently and are useful markers of recently activated cells. Others have 
stable expression after activation and therefore serve as markers of previously 
activated (memory) cells. LFA-3, CD45Ro and CD29 are particularly useful 
markers of prior activation.
3.5. In vitro activation of T cells
The development of mAbs to T cell surface proteins has provided useful tools for 
can be used to understand the activation pathways within T cells. The CD3/TCR 
complex is thought to represent the initial pathway which in the presence of a 
second signal from an alternative pathway will result in T cell activation and 
proliferation. The monoclonal antibody UCHT1 is an lgG2a antibody directed 
against the CD3 complex. It induces an accessory cell dependent T cell 
proliferation. The function of the accessory cell involves production of IL-1 
and interaction of the Fc receptor with the Fc part of the monoclonal antibody 
promoting cross linkage of the TCR/CD3 complex. Activation of resting T 
lymphocytes to proliferation and terminal differentiation is a multi-step 
process involving synthesis of IL-2 and expression of the IL-2 receptor. IL-1
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is necessary for the the synthesis of IL-2. Early studies of T cell triggering 
relied exclusively on the mitogens PHA and Con A. These also activate cells 
through the CD3/TCR complex, but since the introduction of monoclonal 
antibodies, the signalling can be studied more directly. As described above 
stimulation of T cells with the antibodies 9.6 in combination with 9.1 induces 
antigen presenting cell independent T cell activation via the CD2 receptor. 
(Meuer et al 1984). Because this pathway does not involve CD3 it is known as 
the alternative pathway of T cell activation and proliferation. Although 
CD3/TCR and CD2 are not physically associated they do interact (Bockenstedt et 
al 1988).
Chapter 4
General materials and methods
4.1. Media
RPMI 1640 with L glutamine and 20 mM Hepes buffer, Gibco (Paisley). 
Penicillin (50 U/ml) and streptomycin (50 mg/ml) were added to the medium 
before use. Foetal calf serum (FCS) was obtained from Gibco (Paisley). 
Batches were screened for their ability to stimulate optimal cell growth in in 
vitro liquid culture systems. FCS was heat inactivated before use by heating to 
56°C for 30 minutes, aliquoted and stored at -70°C before use.
Ficoll Hypaque.
Ficoll Hypaque obtained from Lymphoprep (Upsala, Sweden) was used 
throughout.
Buffers.
The following buffers were used:
Bicarbonate buffer pH 9.6 was made by mixing 1.59 g Na2C0 3 , 2.9 g NaHCC>3 
and 0.2 g NaN3 with 1 litre of distiled water.
Phosphate/citrate buffer pH 5 was made by adding 25.7 mis of 0.2 M Na2HP04 
and 24.3 mis of 0.1 M citric acid to 50 mis of distiled water.
Phosphate buffer pH8 was made by titrating 0.2 M NaH2P04 with 0.2M 
Na2HP04 and diluting to 0.1 M with distiled water.
Monoclonal antibodies used
Antigen Antibody Iso type Source
CD2 9.6 Mouse lgG1 Gift from Dr Linda Terry, New York.
9.1 Mouse lgG1 Gift from Dr Linda Terry, New York.
CD3 UCHT1. Mouse lgG1. Gift from Prof PCL Beverley
CD4 T4 . Mouse lgG1. CoulterClone(Coulter,Hialeah,FL, USA)
CD8 T8 Mouse lgG1 Coulter Clone (Coulter, Hialeah, FL, USA)
UCHT4. Mouse lgG1. Gift from Prof PCL Beverley
CD14 UCHM1. Mouse lgG1 Gift from Prof PCL Beverley
CD20 B1 Mouse lgG2a Gift from Dr LM Nadler, Boston.
CD25 2AS Mouse lgG1 Gift from Prof PCL Beverley
CD29 4B4. Mouse lgG1. Coulter Clone (Coulter, Hialeah, FL, USA)
CD45R 2H4 Mouse IgG1. Coulter Clone (Coulter, Hialeah, FL, USA)
CD45R0 UCHL1. Mouse lgG2a Gift from Prof PCL Beverley
CD56 NKH1 Mouse lgG1. Coulter Clone (Coulter, Hialeah, FL, USA)
TCRy8 Identi-
TTCR51
Mouse lgG1 T cell sciences (Cambridge, MA, USA)
4.3. Lectins
The following lectins were used
Phytohaemagglutin PHA-P (Sigma) salt free, lyophilised powder.
Conconavalin A - Con A (Sigma) purified salt free, lyophilised powder. 
Phytolacca americana - Pokeweed Mitogen (Sigma) partially purified TCA 
precipitate, salt free, lyophilised powder.
All mitogens were dissolved in PBS and sterilized by membrane filtration 
before use.
4.4. Isolation of peripheral blood mononuclear cells (PBM).
Peripheral blood samples were taken into preservative free heparin at 2 U/ml. 
The blood was diluted approximately one in two with RPMI and layered on to an 
approximately equal volume of lymphoprep. The tubes were centrifuged at 100 
g for 20 minutes at room temperature with no braking force applied. Low 
density cells were harvested from the interface between the medium and the 
lymphoprep using a plastic pasteur pipette. The cells were washed twice and 
resuspended in RPMI.
4.5. Cell counting and Viability.
10pJ of cell suspension was mixed with 10jil of 0.25% Trypan Blue solution 
(Flow Laboratories) and counted microscopically in a new, improved Neubeaur 
cell counting chamber. Viable cells remain unstained whereas the dead cells 
took up the blue dye.
4.6. Preparation of AET treated sheep red blood cells.
402 mg of 2-aminoethylisothioronium bromide hydrochloride (AET) (Sigma) 
was added to 10ml double distiled water, the pH adjusted to pH 9.0 and the 
solution sterilized by membrane filtration. Sheep red blood cells (SRBC) 
(Tissue Culture Services Limited) were washed three times in RPMI and one 
volume of washed cells incubated with four volumes of AET at 37°C for 30 
minutes.. The cells were washed four times in RPMI and resuspended at a final 
haematocrit of 4%.
4.7. Rosetting procedures.
T cells were prepared from PBM's by rosetting with sheep red blood cells 
(SRBC). Cell suspensions at 107/ml were mixed with an equal volume of 4% 
AET treated SRBC and 20% final volume FCS. The cells were then pelleted by 
centrifugation at 400 g for five minutes and kept on ice for 60 minutes. The 
pellet was then gently resuspended and re-layered onto lymphoprep as 
previously described for whole blood separation. The E- cells were collected
from the interface. The E+ cells were separated from the rosetted SRBC by 
lysis with red blood cell lysis reagent (Ortho Diagnostic Systems Ltd, High 
Wycombe, Bucks). The E+ and E- cells were washed three times in RPMI and 
counted and assessed for viability before use.
4.8. Removal of adherent cells
5 mis of PBMC suspended at 3 x 106/ml in RPMI (20% FCS) was incubated at 
37°C  in a plastic petri dish for one hour . The non adherent cells were 
removed by gentle washing with RPMI. Non adherent cells were washed three 
times with RPMI before use. This process results in partial depletion of 
monocytes.
4.9. Immune rosetting with magnetic beads.
Cells were incubated with 50pl of mouse monoclonal antibodies (at optimal 
concentration) in tubes and left on ice for 20 minutes. The cells were then 
washed three times with RPMI kept on ice. 10 pi per 106 cells of magnetic 
microbeads coated with rabbit anti mouse IgG (Dynabeads, Dynal, Oslo, 
Norway) was added and incubated at 4°C for 30 minutes with occasional gentle 
mixing. The tubes were placed in a Dynamagnet (Dynal) overnight and cells 
stained with monoclonal antibody adhered via the magnetic beads to the 
Dynamagnet The unbound cells remained in the supernatant medium. The 
supernatant medium was collected, the cells washed and counted.
4.10. Freezing and Thawing of Cells.
For freezing, cells at 10® cells/ml were resuspended in freezing medium 
consisting of RPMI with 20% v/v FCS and 10% v/v dimethyl sulphoxide 
(DMSO) (BDH) and aliquotted at 1 ml/vial into freezing vials. These were left 
overnight in a -70°C freezer in a sealed polystyrene box before transfer to a 
liquid nitrogen storage tank.
Cells were thawed rapidly in a 37®C water bath, transferred to a 20 ml 
universal tube and slowly diluted with RPMI with 20% v/v FCS. The cells 
were washed once in RPMI and the cell viabilities determined as described 
above.
4.11. Direct and Indirect Immunofluorescence and Flow 
Cytometric Analysis.
For direct fluorescence aliquots of 2 x 10® cells were stained with 50 pi of 
monoclonal antibodies directly conjugated to fluorescein (green fluorescence) 
or phycoerythrin (red fluorescence). The cells were incubated with antibody 
at the appropriate concentration on ice for 30 minutes and washed three times 
with RPMI kept on ice. Care was taken to centrifuge the plates containing the 
cells at 4°C to prevent capping of the antigen on the cell surface.
For indirect fluorescence, aliquots of 2 x 10® cells were stained with 50 pi of 
monoclonal antibodies (at the appropriate concentration) in V bottomed flexible
microtitre plates and left on Ice for 20 minutes. The cells were then washed 
three times with RPMI kept on ice. 50 pi of fluoresceinated goat anti mouse Ig 
was added to each well. The cells were further incubated for 20 minutes and 
washed a further three times with RPMI.
Flow cytometric analysis was performed initially using a FACS IV (Becton 
Dickinson, Oxnard, California) and subsequently using an EPICS (Coulter, 
Hialeah, FL, USA)
4.12. Proliferation Assays.
Radiolabelled precursors of DNA were used to assess cell proliferation. Cells at 
the required concentration were plated out in quadruplicate in round bottomed 
microtitre plates in RPMI supplemented with 10% v/v FCS and the compound 
under assessment for growth stimulation. Cells were cultured for 72 hours in 
a fully humidified atmosphere of 5% CO2 at 37°C. 1 pCi of tritiated thymidine 
was added to each well for the last eight hours of culture. The cells were 
harvested onto Whatman fibreglass filters using an Automash (Dynatech). 
Counts were assessed using a scintillation counter for ®H and results are 
expressed as median counts per minute.
4.13. ELISA Method for the Measurement of non specific 
Immunoglobulin.
Non specific Ig was measured by an enzyme linked immunoabsorbent assay 
(ELISA) using the sandwich technique. Rabbit anti human IgG Fc fragment (1 
in 500) and sheep anti human p chain (1 in 200) were diluted in bicarbonate 
buffer pH 9.6. 100pl of each was added per well to flat bottomed microtitre 
plates and incubated for 1 hour at 37°C. The plates were washed 4 times in 
PBS using an automatic plate washer (Automash 2000, Dynatech).
Unknown samples were added in 100 pi volumes to the wells. A standard Ig 
solution was also added at duplicate serial doubling dilutions starting at 500 
ng/ml of IgG or 5 pg/ml of IgM. The plates were incubated for one hour at 
37°C and washed as before. The plates were then incubated with 60 pi of 
alkaline phosphatase conjugated anti human IgG (Sigma a-3150) or IgM 
(Sigma a-3151) for a further 90 minutes. The plates were washed twice with 
PBS and once with de-ionised water. 100 ml of the substrate p -  nitrophenyl 
phosphate (Sigma) at 1 mg/ml diluted in bicarbonate buffer pH 9.4 and 
incubated at 37®C for 90 minutes. Absorbence at 405 nm was measured using 
a Dynatech automatic plate reader and the optical densities related to the 
concentration Ig by reference to the standard preparation.
4.14. ELISA Method for the Measurement of Specific Antibodies
a) Detection of Specific Antibodies against Influenza Virus
Flat well EIA microtitre plates (Linbro, Flow laboratories) were coated with 
100 pi of purified Influenza Virus at a concentration of 100 pg/ml in 
phosphate buffered saline (PBS) at pH 8.6. A standard solution of human IgG 
was also set up on each plate in serial doubling dilutions starting at a 
concentration of 500 ng/ml. The plates were incubated at 37® C for six hours 
and washed three times PBS containing 1% bovine serum albumin (BSA). The 
plates were further incubated for one hour with 200 ml/well of PBS - 1% 
bovine serum albumin (BSA) to block non specific binding sites. After 
washing, 50 pi of cell culture supernatant or patients' serum diluted one in 
four in PBS was added to each well in quadruplicate and incubated for a further 
90 minutes. The wells were then washed as before and allowed to dry. The 
plates were then incubated with 60 pi of alkaline phosphatase conjugated anti 
human IgG (Sigma a-3150) for a further 90 minutes. The plates were again 
washed and 100 pi of the substrate p -nitrophenyl phosphate (Sigma) at 1 
mg/ml added to each well and the plate was incubated at 37°C for 90 minutes. 
To ensure that rh GM-CSF binding had occurred in each plate a positive control 
was set up using supernatant from the cell culture of cells which were known 
to respond to that virus (JG) or serum from the same individual. Absorbence 
at 405 nm was measured using a Dynatech automatic plate reader and the 
optical densities related to the concentration log IgG by reference to the 
standard preparation with one unit defined as the absorbence corresponding to 
1 ng/ml of the IgG standard.
b) Detection of Specific Antibodies against Granulocyte 
Macrophage Colony Stimulating Factor
Flat well EIA microtitre plates (Linbro, Flow laboratories) were coated with 
60 pi of rh GM-CSF at 2 mg/ml in phosphate buffered saline (PBS) at pH 9.0. 
A standard solution of human IgG was also set up on each plate in serial doubling 
dilutions starting at a concentration of 500 ng/ml. The plates were incubated 
at 37° C for six hours and washed three times PBS containing 1% bovine 
serum albumin (BSA). The plates were further incubated for one hour with 
200 ml/well of PBS - 1% bovine serum albumin (BSA) to block non specific 
binding sites. After washing, 50 ml of patients' serum, diluted one in four in 
PBS, was added to each well in quadruplicate and incubated for a further 90 
minutes. The wells were then washed as before and allowed to dry. The plates 
were then incubated with 60 ml of alkaline phosphatase conjugated anti human 
IgG (Sigma a-3150) for a further 90 minutes. The plates were again washed 
and 100 ml of the substrate p-nitrophenyl phosphate (Sigma) at 1 mg/ml 
added to each well and the plate was incubated at 37°C for 90 minutes. To 
ensure that rh GM-CSF binding had occurred in each plate a positive control 
was set up using a monoclonal anti GM-CSF antibody (provided by Dr D 
Warren) which was detected as before but with the use of an alkaline 
phosphatase conjugated anti mouse IgG. Absorbence at 405 nm was measured 
using a Dynatech automatic plate reader and the optical densities related to the 
concentration log IgG by reference to the standard preparation with one unit 
defined as the absorbence corresponding to 1 ng/ml of the IgG standard.
Chapter 5.
Skin Response to Recall Antigens.
T cell in vivo responses can be assessed by the measurement of cutaneous 
testing to antigen. This can be assessed by using new antigens such as 
Dinitrochlorobenzene which measures the body's capacity for immunization. 
However, by introducing an antigen to which the body has already been exposed, 
the capacity of the T lymphocytes to respond to an antigen already in the T cell 
memory repertoire can be assessed. These 'recall antigens' are assessed by 
measuring the delayed cutaneous hypersensitivity at 48 hours by measuring 
the diameter of induration after subcutaneous injection of the appropriate 
antigen. Cutaneous tests therefore represent a simple and quick technique, 
with rapid interpretation.
5.1. Method.
The Multitest CMI (Merieux, France) is an applicator consisting of eight heads 
with nine tines on each head loaded with seven different recall antigens and a 
glycerin control. The antigens were applied to the patients' back. The skin was 
first cleaned with disinfectant solution, the skin stretched and the Multitest 
applied maintaining firm pressure for five seconds to ensure equal intradermal 
penetration of each of the eight heads.
The antigens consist of
1. Tetanus antigen 550000 U/ml,
2. Diphtheria antigen 1.1 MU/ml,
3. Streptococus antigen (group C) 2000 U/ml,
4. Tuberculin antigen 300,000 U/ml,
5. Glycerine control 70% w/v,
6. Candida albicans antigen 2000 U/mi,
7. Trichophytonantigen 150 U/ml,
8. Proteus mirabilis antigen 150 U/ml.
Reading of the tests was performed after 48 hours. Positivity was defined only 
as induration and not erythema. The glycerin control serves as a means of 
comparison to assess the positivity of weak reactions. Using calipers provided 
with the Multitest the score for each antigen was assessed by measurement of 
the induration of two perpendicular diameters. The CMI score is the sum of all 
positive reactions read at 48 hours.
Results
A normal response range was established by assessing the CMI scores in six 
normal individuals on a total of 20 occasions over a one year period. There was 
no significant increase in score in any of the normal individuals with repeated 
testing. The normal range established for the CMI score was 36-48. (Mean 42 
±  2 SD of results obtained). Responses were assessed in a total of 69 patients
before and at intervals after ABMT - 20 patients with AML, 7 with ALL, 10 
with NHL and 32 with Hodgkin's disease.
5.2. Acute Myeloid Leukaemia.
The skin responses to recall antigens were assessed in twenty patients with 
acute myeloid remission in first CR before commencement of high dose therapy 
and at intervals after ABMT.
The responses elicited in six patients immediately before and at intervals after 
single ABMT are shown in figure 5.1. The responses before and at intervals 
after double ABMT in a further 14 patients are shown in figure 5.2.
Even though these patients had all received recent chemotherapy, the responses 
were normal before ABMT. There was no significant difference in response 
after the second procedure in those patients who had a double procedure 
compared to the responses elicited in those patients who only had a single 
procedure (p = 0.42).
The response to the recall antigens was markedly impaired in all of the patients 
following high dose therapy and ABMT. However, three of eight patients had 
responses in the normal range by three months after ABMT and a further three 
patients had normal responses by three months after the second procedure. The 
responses were normal in virtually all patients by six months after the second 
procedure.
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Figure 5.1.
Response to recall antigens assessed by CMI score in patients 
undergoing single ABMT in first CR of AML
ABMT 2 time after ABMT (months)
Figure 5.2.
Response to recall antigens assessed by CMI score in 14 patients 
undergoing double ABMT in first CR of AML
5.3. Acute Lymphoblastic Leukaemia.
The skin response to recall antigens was tested in seven patients with ALL 
before and for twelve months after ABMT. The first two patients received 
chemotherapy alone and received two consecutive autografts. In these two 
patients the time after ABMT relates to the time after the second graft. The 
subsequent six patients received ABMT following melphelan and TBI, although 
follow up skin testing was possible in only five of these patients. Figure 5.3 
shows the responses in these patients.
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Figure 5.3.
Response to recall antigens assessed by CMI score in patients 
undergoing ABMT in first CR of ALL. Two patients received 
chemotherapy alone and five patients received TBI.
Before ABMT the responses in the patients with ALL were significantly reduced 
compared to the normal controls (p<0.05) and to the patients with AML 
(p<0.05). Although conclusions cannot be drawn because of the small numbers 
of patients, both patients who received chemotherapy alone had a return to 
their pre-transplant response by three months after the second procedure. In 
contrast, the patients who received TBI continued to have depressed responses 
compared to pre ABMT for one year after ABMT.
5.4. Non Hodgkin's Lymphoma
The skin response to recall antigens was tested in ten patients with NHL prior 
to ABMT. The response was heterogeneous in this group of patients. Those 
patients who had no response to first line therapy and who had bulky disease at 
the time of ABMT had the lowest score in skin testing - these patients also had 
the poorest response to the high dose therapy. Because of the very poor 
response to ABMT and subsequent high mortality of this group of patients only 
four patients were available for longer term assessment of response.
As can be seen in figure 5.4., the response was markedly depressed following 
ABMT, but in the four patients who had a good response to the ABMT, there was 
a return to normal response by three months after ABMT.
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Figure 5.4.
Response to recall antigens assessed by CMI score in patients 
undergoing ABMT for NHL. Because of the poor outcome in this 
group of patients, only four patients were available for long term 
follow up.
Figure 5.5 shows the responses in AML, ALL and NHL patients expressed as 
mean ±  standard deviation. There is no difference in responses in the AML and 
the small number of NHL patients. The response in the patients with ALL is 
significantly reduced compared to AML and NHL patients until one year after 
ABMT.
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Figure 5.5.
CMI score skin responses to recall antigens expressed as mean ±  
standard deviation in AML, ALL and NHL patients after ABMT.
5.5. Responses in patients with Hodgkin's disease.
Responses to recall antigens were assessed in 32 patients with Hodgkin's 
disease. The most striking feature in Hodgkin's disease is that all patients had a 
marked abnormally reduced response prior to ABMT (mean 27% of normal). 
All patients had active disease at the time of ABMT and this illustrates the 
immune suppressive effect of Hodgkin's disease.
Figure 5.6 shows the responses before and after ABMT in this group of patients. 
Although responses rapidly return to the pre-tranplant level, often when the 
patient has few circulating lymphocytes, many patients continued to have 
markedly reduced responses beyond one year after ABMT. In this group of 
patients there was a marked variation in response to the recall antigens at each 
time period.
Figure 5.7. shows the response to the recall antigens assessed by the response 
the patient was subsequently found to achieve after ABMT. Fifteen patients 
achieved CR and seventeen patients did not achieve CR after ABMT. Those 
patients who achieved CR after ABMT had significantly higher scores than those 
who did not achieve CR (p<0.005) and this difference was apparent by as early 
as two months after ABMT. In those patients who did achieve CR only half had 
responses within the normal range at six months after ABMT. One patient in 
this group had markedly reduced responses at six months after ABMT but had a 
normal response at one year after ABMT. In those patients who did not achieve 
CR the response to recall antigens never returned to normal.
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Figure 5.6.
Response to recall antigens assessed by CMI score in patients 
undergoing ABMT for Hodgkin's disease.
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Figure 5.7.
Response to recall antigens assessed by CMI score in patients 
undergoing ABMT for Hodgkin's disease. The open circles show the 
response in those patients who were subsequently found to have 
achieved CR after ABMT (n=15) and the solid circles show the 
responses of those who did not achieve CR after ABMT (n=17).
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Figure 5.8.
Response to recall antigens assessed by CMI score in patients 
undergoing ABMT for Hodgkin's disease. The responses are 
significantly reduced in those patients who did not achieve CR 
after ABMT compared to those who achieved CR after ABMT 
(p>0.005). The normal range is shown on the right.
5.6. Conclusions.
Following ABMT the skin response to recall antigens was markedly depressed in 
all cases studied. This decreased responsiveness rapidly reversed with the 
majority of patients having a normal response by three to six months after 
ABMT. Patients with ALL, who received total body irradiation had significantly 
reduced response compared to those who had received chemotherapy alone for 
up to one year after ABMT. The responses were markedly reduced in patients 
with Hodgkin's disease at the time of presentation for ABMT, reflecting the 
immune suppressive effect of active Hodgkin's disease. The responses returned 
to normal rapidly in those patients who achieved a good response to the high 
dose therapyn given.
The duration of this depressed response after ABMT may be therefore be 
affected by the patient's disease type, the bulk of disease present, the form of 
high dose therapy given, whether chemotherapy alone or chemotherapy in 
combination with TBI, or the response of the disease has to the high dose 
therapy.
Chapter 6.
B cell responses in vivo after Autologous Bone Marrow 
Transplantation. Specific Anti Influenza Immunoglobulin  
Production In Vivo
Introduction
6.1. Influenza Viruses
Influenza A viruses are classified into subtypes on the basis of two antigens; 
haemagglutinin (H) and neuraminidase (N). Three subtypes of haemagglutinin 
are recognized (H i, H2, H3) and two subtypes of neuraminidase (N1 and N2) 
are recognized among influenza A viruses that have caused widespread human 
disease. Immunity to these antigens, especially the haemagglutinin antigen, 
reduces the likelihood of infection and the severity of disease if infection 
occurs. However, over time there may be enough antigenic variation (antigenic 
drift) within the same subtype that infection or vaccination with one strain 
may not induce immunity to distantly related strains of the same subtype. 
Although influenza B viruses have shown more antigenic stability than A 
viruses, antigenic variation does occur. For these reasons, epidemics of 
respiratory disease caused by new variants of influenza viruses continue to 
occur.
6.2. Influenza Vaccines.
The antigenic characteristics of current strains provide the basis for the 
selection of strains in each years vaccine. The Influenza vaccine is made from 
highly purified, egg grown viruses that have been rendered noninfectious by 
inactivation. Most vaccines available have been chemically treated to reduce 
the incidence of febrile reactions in children and contain highly purified 
haemagglutinin and neuraminidase antigens prepared from strains of influenza 
virus currently recommended by the World Health Organization. Vaccination 
causes minimal systemic upset or febrile reactions. 90% of vaccinated young 
adults develop haemagglutinin-inhibition antibody titres. Titres are maximal 
1 0 - 2 1  days after vaccination and persist for up to nine months. Elderly 
patients and certain individuals with chronic diseases may develop lower levels 
of antibody after vaccination. Because the vaccine contains only non-infectious 
viruses, it cannot cause influenza. There are occasional reports of respiratory 
disease after vaccination which most probably represent coincidental illness 
unrelated to the vaccine. The most frequent side effect, occurring in one third 
of patients, is soreness around the vaccination site which may last for one to 
two days. Fever, myalgia and other systemic symptoms occur infrequently and 
occur six to twelve hours after vaccination. Immediate, presumably allergic 
reactions occur extremely rarely after influenza vaccination and probably 
result from hypersensitivity to some component of the vaccine, especially the 
egg protein. Although the current vaccines contain only a small amount of egg 
protein, the vaccine is contra-indicated in those who have anaphylactic 
hypersensitiviy to egg. Unlike the 1976 swine influenza vaccine, subsequent
vaccines prepared from other viral strains have not been associated with an 
increased frequency of Guillain Barre syndrome. There are no reported 
adverse effects reported with the virus and any other drugs.
6.3. In vivo antibody production against influenza vaccination.
Patients undergoing autologous bone marrow transplantation were vaccinated 
using the killed Influenza vaccine on the day of marrow return. Serum samples 
were obtained at twice weekly intervals. Specific serum anti-influenza IgG 
levels were measured by ELISA as described in the methods section.
6.4 Results
Patients undergoing ABMT were vaccinated with Influenza vaccine (Merieux, 
France) on the day of bone marrow return as shown in figure 6.1. A total of 
45 patients were vaccinated in the study. - 12 patients with AML in first CR, 
five patients with ALL in first CR, eight patients with NHL and 20 patients with 
Hodgkin's disease. All the patients with AML, NHL and NHL received high dose 
therapy consisting of chemotherapy only, as previously described. In the AML 
patients the Influenza vaccine was given on the day of the marrow return with 
the second graft. All five patients with ALL received high dose therapy 
combination of high dose melphelan and total body irradiation (TBI).
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Figure 6.1.
Responses were assessed before high dose therapy and immediately 
prior to ABMT. Immunization was performed on the day after 
bone marrow return. IgG responses to Influenza were assessed 
before and at intervals after ABMT
A normal response range was established by measuring the response after 
vaccination of 12 normal individuals who were in the same age range as the the 
patients. All 12 of the normal volunteers mounted a brisk response following 
vaccination with a peak level of IgG detected at 20 to 30 days post vaccination. 
In all cases with the controls and the patients the maximal response was 
mounted against the Influenza A H3N2 component of the vaccine and the results 
shown are for specific IgG against the X87 (A H3N2) component of the vaccine 
only. Ten patients with acute leukaemia - five with AML and five with ALL who 
did not progress to ABMT were vaccinated with influenza vaccine to assess the 
response in patients who had previously received chemotherapy. There was no
significant difference in peak response or day to peak response in these patients 
compared to normal controls (Table 6.1).
No. Day ng/ml ± SD p value
Controls 12 28 137 25.8
AML 5 2 4 122 42.4 0.766
ALL 5 28 1 1 8 30.6 1.467
Table 6.1.
Peak response and day to peak response in normal controls and 
patients with acute leukaemia who did not undergo ABMT
Responses in patients with acute leukaemia.
Seventeen patients with acute leukaemia were given the Influenza vaccine on 
the day after marrow recovery. Twelve patients with AML were immunized on 
the day of return of the second marrow after the second course of high dose 
therapy. Five patients with ALL were immunized on the day after marrow 
return after high dose chemotherapy and total body irradiation. The responses 
elicited in patients with acute leukaemia are shown in Figure 6.2.
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Figure 6.2.
In vivo IgG response after vaccination with Influenza vaccine in 
12 normal adult control individuals, 12 adult patients with AML 
in first remission undergoing second ABMT and five adult patients 
with ALL in first remission undergoing ABMT after TBI. The 
results are shown as mean + SD.
All patients with AML mounted a brisk response although the peak response was 
significantly reduced compared to the normal controls. The time course of the 
response was not delayed compared to the controls despite the recent 
administration of very high dose chemotherapy.
In contrast, although the numbers are small, in the patients with ALL the 
responses were barely detectable, with no early peak response seen in any of
the five patients vaccinated. The subsequent small rise in titre occurring after 
three months may be due to subsequent exposure to the virus in the community.
Responses in patients with Hodgkin's disease.
Twenty patients with Hodgkin's disease received the Influenza vaccine on the 
day after marrow return. The response in patients with Hodgkin's disease is 
shown in figure 6.3.
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Figure 6.3.
In vivo IgG response after Influenza vaccination in 12 normal 
adult control individuals and in 20 patients with Hodgkin's 
disease undergoing ABMT.
The specific anti Influenza IgG response in patients with Hodgkin's disease was 
brisk, although the peak response was also suboptimal compared to normal 
controls. Compared to the normal controls and the patients with AML there was 
a delay in the peak response after vaccination in the HD patients, the peak 
response occurring 60 days after vaccination. This may be correlated with the 
more rapid regeneration of lymphocytes seen in the AML patients after ABMT 
compared to those patients with HD. After the first six weeks after ABMT there 
was no significant difference in response in the AML and HD patients.
Responses in patients with Non Hodgkin's Lymphoma.
Eight patients with NHL were vaccinated on the day of return of their autologous 
bone marrow. The responses elicited in these patients with NHL are shown in 
figure 6.4. The responses show a similar pattern to that seen in patients with 
AML with a brisk if suboptimal response compared to the normal controls and 
no delay in peak IgG response compared to normal controls.
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Figure 6.4.
In vivo IgG response after Influenza vaccination in 12 normal 
adult control individuals and in 8 patients with Non Hodgkin's 
Lymphoma undergoing ABMT.
6.5. Conclusions.
Despite the very recent administration of very high dose chemotherapy, all the 
patients with AML, NHL and Hodgkin's disease mounted a brisk humoral 
response against the Influenza vaccine with significant no delay in the time to 
peak response after vaccination. There was no evidence that patients with 
refractory Hodgkin's disease had reduced responses compared to those patients 
who subsequently achieved CR with high dose therapy. In contrast, all the
patients with ALL had very poor IgG responses after vaccination. This may be 
due to differences in the patient populations, but since responses were not 
significantly reduced in the ALL patients who did not progress to ABMT, this 
more likely reflects the different effects of the conditioning with TBI compared 
to chemotherapy alone.
Chapter 7.
Development of Antibodies to recombinant derived Granulocyte 
Macrophage Colony Stimulating Factor
7.1. Introduction
Granulocyte-macrophage colony stimulating factor (GM-CSF) is an important 
molecule in the regulation of growth and differentiation of haemopoietic 
progenitor cells. The naturally occurring protein has been isolated and 
partially sequenced and the gene coding for GM-CSF has been cloned (Wong et al 
1985, Cantrell et al 1985). The availability of recombinant human (rh) GM- 
CSF has made it possible to explore a number of potential therapeutic 
indications for this protein and encouraging preliminary results showing that 
rh GM-CSF accelerates neutrophil recovery in neutropenia have been reported. 
(Groopman et al. 1987, Brandt et al.1988, Antin et al 1988, Antman et al 
1988, Devereaux et al. 1989. )
rh GM-CSF is available for use in man in several forms, rh GM-CSF with the 
identical amino acid sequence to the naturally occurring protein has been 
produced in mammalian cells (Chinese Hamster Ovary (CHO) cells) and is 
variably glycolysated on both O-linked and N-linked sites giving rise to a 
heterogeneous population of proteins with molecular weights of 18-30 kD 
(Wong GC et al 1985 ) and in E. coli resulting in a non glycosylated product 
with a molecular weight of 14.1 kD. A further form of rh GM-CSF has been 
produced in yeast with a single amino acid difference from the naturally
occurring protein with the substitution of a leucine for a proline at position 23 
of the amino acid sequence to remove a Kex protease site (Gillis et al. 1987) . 
This product is N-linked glycosylated resulting in three molecular species of 
molecular weight 15.5, 16.8 and 19.5 kD (Cantrell et al 1985). The non 
glycosylated rh GM-CSF (produced in E. coli) and partially glycosylated rh 
GM-CSF (produced in yeast) appear as efficacious as the fully glycosylated 
product which is produced in mammalian cells (Mayer et al.1987). All three 
forms of rh GM-CSF have been used in phase I and II clinical trials.
7.2. Patients
Four patients with solid tumours which were resistant to chemotherapy 
received yeast derived rh GM-CSF for ten days in phase 1 studies at a time 
when they were receiving no chemotherapy or radiotherapy. Twelve patients 
receiving high dose combination chemotherapy and ABMT for resistant 
Hodgkin's disease received either yeast (13 patients) or E. coli ( 3 patients) 
derived rh GM-CSF (Devereaux et al 1989). In the ABMT recipients only a 
test dose of rh GM-CSF of 15 pg/ m2/hour for one hour was given prior to the 
ablative chemotherapy and treatment by continuous infusion was started after 
the ablative therapy and 24 hours following infusion of autologous bone 
marrow. rh GM-CSF was given at a dose of 100 - 400 ng/ m2/day. It was 
planned that all patients should receive at least ten days therapy although the 
treatment schedule was curtailed in two patients.
Since it had been shown that these patients could mount a humoral immune 
response against influenza vaccine, the sera of these patients was screened for 
the development of antibodies against recombinant GM-CSF.
The majority of the results in this chapter have recently been published 
(Gribben et al 1990). I acknowledge the help of Mr HM Jones for help with the 
marrow cultures and Dr NSB Thomas for help with the Western blotting.
Serum was obtained three times weekly until patients were discharged from 
hospital. Sera from twenty patients other with Hodgkin's disease undergoing 
autologous bone marrow transplantation but not receiving rh GM-CSF were 
examined as controls.
7.3. rh GM-CSF
rh GM-CSF containing a single amino acid substitution from the naturally 
occurring protein were obtained from Immunex Seattle,USA (yeast derived), 
rh GM-CSF, with no amino acid substitutions, expressed in mammalian cells 
was obtained from Sandoz, Basel, Switzerland and in E coli from 
Hoechst/Behringwerke,Marburg, W Germany.
7.4. Assays for the detection of antibodies to GM-CSF.
ELISA.
Antibody to rh GM-CSF was detected by a solid phase immunoassay using a 
modification of the method of Voller (Voller et al 1976) as described in the 
general methods section.
Western Blotting.
For western blotting, rh GM-CSF proteins were diluted 1 in 2 in SDS gel 
sample buffer at 30 pg/ml,50 pg/ml and 100 |ig/ml for the E.coli, yeast and 
mammalian derived products respectively and electrophoresed on 15% 
acrylamide gels (Laemmli U K. 1970) . Proteins were then transferred onto 
nitrocellulose (HybondC Extra, Amersham Intl.) by semi-dry blotting (Atto, 
Japan) at 0.5A for 45 min in 25 mM Tris, 197 mM Glycine, 20% methanol. 
After blotting, the filter was immersed in blocking solution (10% BSA, 
phosphate buffered saline (PBS)) and agitated for >1 hr at room temperature. 
The filter was then incubated overnight at 4°C with the serum samples at 1 in 
10 dilution in 10% BSA in PBS, 0.05% Tween-20 (Sigma)). After three 
washes the filter was incubated for 1 hr at room temperature with [125l] 
mouse anti human antibody (20mCi/mg; Amersham Intl.) at 1mCi/ml in 10% 
BSA in PBS, 0.05% Tween-20). The filter was again washed with three 
changes of PBS, 0.05% Tween-20, dried and exposed to X-Ray film 
(Amersham Intl.). As a positive control, the filter was incubated with anti
GM-CSF monoclonal antibody, washed and incubated with [125l] sheep anti 
mouse antibody (20mCi/mg; Amersham Intl.) at 1mCi/ml in 10% BSA in 
PBS, 0.05% Tween-20).
7.5. Marrow cultures
10 mis of marrow was aspirated at the time of bone marrow harvest from a 
normal donor. The mononuclear cell fraction was obtained by centrifugation 
over Ficoll gradient and washed in RPMI (Gibco). The cells were incubated with 
AET treated sheep red blood cells and the E '  fraction obtained and washed. The 
resulting cell fraction was then depleted of adherent cells by incubating in 
plastic plates at 37°C for one hour. The non adherent cells obtained were 
cultured in 0.9% agar containing 25% foetal calf serum and 10% human 
serum with rh GM-CSF at 12.5 ng/ml (optimal concentration) and 1.25 ng/ml 
(suboptimal concentration) or rh G-CSF at 2.5 x 103 U/ml with or without 
sera obtained from patients pre and post infusion of rh GM-CSF to assay for the 
presence of neutralizing antibodies. The cells were cultured at a final 
concentration of 2 x 104/ml for twelve days.
7.6. GM-CSF assays.
GM-CSF concentration in patients' sera were assayed using a commercially 
available ELISA ( Medical Resources Ltd, Surrey Hills, NSW, Australia) 
(Cebon et al. 1988) and are expressed with reference to a standard curve 
obtained using E. coli derived rh GM-CSF.
7.7. Production of Deglycosylated rh GM-CSF.
The deglycosylated forms of the mammalian derived rh GM-CSF were produced 
as follows. N linked sugars were cleaved by digesting 20 mg rh GM-CSF with 
1U glycopeptide-N-glycosidase (PNGaseF) (ex F lavobacterium  
meningosepticum, Boehringer Mannhein, West Germany) in 100 mM NaPC>4 , 
25 mM EDTA, 0.5% (v/v) Triton X 100, 0.1% (w/v) SDS, 1 mM DTT pH 7.0 
(Buffer A) at 37^C for 18 hours. O-linked sugars were removed by the 
following procedure: 50 mg GM-CSF was digested with 0.05 U Neuraminidase 
(ex Vibrio cholerae, Boehringer Mannhein, West Germany) and 5 m il N- 
acetyl-b-D-glucosaminidase (EC 3.2.130; ex Diplococcus pneumoniae; 
Boehringer Mannhein, West Germany) in 50 mM Na3C6H507  pH 5.0, 2 mM 
CaCl2 at 37°C for 18 hours. Following dialysis against 100 mM NaP04 pH 7.0, 
the sample was boiled for 5 minutes in buffer A and then 20 mg was digested 
with 4 mU endo-a-N-acetylgalactoaminidase (EC3.2.1.97; ex Diplococcus 
pneumoniae; Boehringer Mannhein, West Germany) at 37°C for 18 hours.
7.8. Results
Detection of antibodies to rh GM-CSF.
Of sixteen patients who received rh GM-CSF in Phase I/ll clinical studies in 
our institution four patients who had received yeast derived rh GM-CSF 
developed serum antibodies reactive to this protein (Table 7.1. ).
Table 7.1.
Peak Level of Anti rh GM-CSF IgG (U/ml) detected 
and day of peak level
Patient Source of GM-CSF
Yeast E. coli CHO cell
1 26.9 24.7 0
day 17 day 17
2 36.3 29.8 0
day 10 day 10
3 29.4 22.7 0
day 16 day 16
4 16.1 21.1 0
day 13 day 13
Anti rh GM-CSF antibody was found in four patients. The peak level of antibody 
and the day on which this occurred following initiation of rh GM-CSF 
administration is shown. There was full cross reactivity against the E coli 
derived rh GM-CSF not no cross reaction against the mammalian derived 
product. The units used approximate to ng/ml as defined by the absorbence 
obtained from the standard curve.
None of the three autograft recipients who received E. coli derived rh GM-CSF 
developed detectable antibodies. No antibodies were detected in any of twenty 
autologous bone marrow transplant recipients who did not receive rh GM-CSF. 
The development of these antibodies was rapid and, as shown in figure 7.1, 
could be detected in each case by seven days after the commencement of the rh 
GM-CSF treatment.
The ABMT recipients had all received a test dose of rh GM-CSF one week before 
commencing therapy, but no test dose had been given to the patients in the phase 
I study. In the recipients of very high dose therapy and ABMT it is noteworthy 
that the antibodies were produced at detectable levels at a time when there were 
no circulating leucocytes.
7.9. Specificity of anti GM-CSF antibodies.
These antibodies were initially detected by specific solid phase ELISA using 
yeast derived rh GM-CSF as the coating antigen. The serum from these patients 
showed no reactivity against plates coated with irrelevant protein (influenza 
virus). The antibodies from all four patients showed full cross reactivity 
against the E. coli derived GM-CSF but no reactivity with the mammalian 
derived rh GM-CSF (Table 7.2).
An attempt was made to detect the presence of IgM antibodies as it was felt that 
this may represent a primary immune response. However this was not 
possible since in each instance it proved impossible to block non specific 
binding of IgM to the ELISA plates under the assay conditions used.
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Figure 7.1.
The time course for the production of specific IgG against the 
yeast derived rh GM-CSF after commencement of continuous 
infusion in the four patients who developed antibodies against 
GM-CSF. The rh GM-CSF infusion was for ten days in three 
patients and for seven days in the fourth patient .
IgG response to rh GM-CSF in different giycosylation states.
Source of rh GM-CSF 
E coli
Anti rh GM-CSF (U/ml)
all patients patient 1 patient 3 ELISA optical 
pre post post density readings
rh GM-CSF on the same plate
using a murine 
monoclonal anti 
GM-CSF
30.6 22.7 0.678
Yeast 29.7 24.9 0.702
Mammalian 0.639
Mammalian 
N cleaved
Mammalian 
O cleaved
Mammalian 
O and N cleaved
NoGMCSF
0 25.9
0 29.4
0.624
21.3 0.648
25.1 0.671
0.075
Table 7.2.
The reactivity of Sera from patients 1 and 3 against different 
forms of rh GM-CSF
In the same experiments a mouse monoclonal anti GM-CSF reacted equally well 
with all three forms of rh GM-CSF. The serum from these patients showed no 
reactivity against uncoated plates and plates coated with irrelevant protein
(influenza virus) and the reactivity was inhibited by the addition of excess 
yeast derived rh GM-CSF to the serum (figure 7.2)
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Figure 7.2.
The addition of free yeast derived rh GM-CSF inhibits binding of 
the specific IgG (U/ml) in the solid phase ELISA with yeast 
derived material as the coating antigen. The results shown were 
obtained from the post rh GM-CSF serum of patient 2. Inhibition 
of binding was similarly produced by the addition of E. coli and O- 
deglycosylated and fully deglycosylated CHO derived rh GM-CSF 
but not with glycosylated CHO derived rh GM-CSF or N- 
deglycosylated rh GM-CSF.
1 3 4
The specificity of the antibodies was confirmed by Western blotting of samples 
from two patients (patient nos. 1 and 2) from whom sufficient sera were 
available. The electrophoretic patterns of the different forms of rh GM-CSF 
are shown as are the autoradiographs of the Western blots using patient's sera 
and a monoclonal anti GM-CSF antibody (figure 7.3)
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Figure 7.3.
The electrophoretic pattern of the recombinant forms of GM-CSF, 
unglycosylated E. coli, glycosylated CHO cell and g lycosyla ted 
yeast derived recombinant GM-CSF is shown on the left (A) with 
m olecu lar w e igh t m arkers (Amersham, pre sta ined ra inbow  
markers) of 14.1 and 30 kD. The autoradiographs obtained after 
incubation of the Western blots obtained w ith B) serum from  
patient 2 followed by [1251] mouse anti human antibody and with 
C) a mouse monoclonal anti GM-CSF and [125l] sheep anti mouse 
antibody are shown on the right.
The antibodies in all four patients did not react with the yeast N glycosidically 
linked carbohydrate side chains as there was full cross reactivity with the non 
glycosylated E coli product. The yeast material contains an amino acid 
substitution at position 23 (proline -> leucine) but again the reactivity with 
the E coli product which does not contain this substitution excludes this amino 
acid substitution as the antigenic site. It thus seemed probable that the 
antibodies were produced to a portion of the amino acid backbone protected by 
glycosylation in the native and Chinese hamster ovary (CHO) cell produced 
material. Whereas mammalian derived rh GM-CSF has two O-linked and two N- 
linked glycosylation sites, E coli derived material is not glycosylated and yeast 
derived material is only N-linked glycosylated. To test this hypothesis, N and 0  
glycosidically linked sugars were removed from the mammalian derived rh 
GM-CSF. Removal of the O-linked sugars exposed antigenicity of the GM-CSF 
molecule to sera from the two patients studied (patients 1 and 4). (Table 2). 
Binding of antibody to the O-linked deglycosylated mammalian derived rh GM- 
CSF was inhibited by greater than 95% by addition of excess free E coli and 
yeast derived rh GM-CSF and binding of antibody to E coli derived rh GM-CSF 
was similarly inhibited by excess free O-linked deglycosylated mammalian rh 
GM-CSF (data not shown).
7.10. Biological activity of anti GM-CSF antibodies.
No evidence was found in the marrow culture assays to suggest that the 
antibodies detected had neutralizing activity. (Figure 7.4 ) but this may not be 
a sensitive assay of the neutralizing effects of the anti GM-CSF antibodies as 
described in detail below.
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Figure 7.4.
This shows the number of colonies counted at day 12 from the non 
adherent ceils cultured at a final concentration of 2 x 104/ml in 
0.9% agar containing 25% foetai calf serum and 10% human 
serum with
1)rh GM-CSF at 12.5 ng/ml (optimal concentration)
2)1.25 ng/ml (suboptimal concentration)
3) rh G-CSF at 2.5 x 103 U/ ml
with or without sera obtained from patients 1 and 2 pre and post 
infusion of rh GM-CSF to assay for the presence of neutralizing 
antibodies and as a control from pre and post infusion of a 
combination of six patients who received rhGM-CSF but did not 
develop antibodies.
However, in the one patient who developed antibodies during the phase I study 
and who had not received prior chemotherapy there was a loss of the rise in 
neutrophil count which is normally seen during GM-CSF infusions and the 
plasma GM-CSF concentration fell to undetectable levels despite continuation of 
the rh GM-CSF infusion at the same dosage (Figure 7.5.). In two other patients 
in the Phase I study, who did not not develop anti GM-CSF antibodies, the levels 
of GM-CSF remained constant throughout the infusion. In the three ABMT 
recipients of rh GM-CSF who developed anti GM-CSF antibodies the levels of 
GM-CSF on day 7 or 8 of the infusions were 43%, 43% and 46% of the levels 
measured in the steady state on the first day of the infusion. In seven other 
ABMT recipients who did not develop detectable antibodies, there was a marked 
fall of the GM-CSF levels in one patient (26% on day 9) but in all other 
patients the level at days 7-9 were similar to those on the initial day of the 
infusion.
Evaluation of the clinical effects of antibody formation is difficult. The anti 
GM-CSF antibodies were detected retrospectively and were not suspected at the 
time of administration of growth factor. In the one patient who developed 
antibodies during the phase I study and who had not received prior 
chemotherapy there was a loss of the rise in neutrophil count normally seen 
during GM-CSF infusions and the plasma GM-CSF concentration fell to 
undetectable levels despite continuation of the rh GM-CSF infusion at the same 
dosage (figure 7.5). This may suggest that in this patient development of the 
antibodies resulted in more rapid plasma clearance of the rh GM-CSF. In the 
three recipients of ABMT it is not possible to tell whether the appearance of
anti GM-CSF antibodies influenced neutrophil regeneration as the time after 
ABMT to reach 0.5 x 109/l neutrophils was highly variable. One patient died 
of progressive disease before neutrophil recovery at 17 days after ABMT and 
the time to achieve a neutrophil count of 0.5 x 109/l in the other two patients 
was 14 days and 27 days respectively.
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Figure 7.5.
Neutrophil count, the level of anti GM-CSF IgG (U/ml) detected 
and serum GM-CSF concentration (pg/ml) in patient 1 during and 
after continuous infusion of rh GM-CSF (100 mg/m2/day).
Although it is not possible to assess the biological response to GM-CSF in the 
ABMT patients in terms of their regeneration of neutrophils, by monitoring the 
serum level of GM-CSF it can be seen in figure 7.6 that despite continuing the 
infusion at a constant rate, GM-CSF levels fell in all patients who developed 
antibodies. In contrast, in those patients who did not develop antibodies, the 
serum level of GM-CSF fell in only one patient.
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Figure 7.6.
Serum level of GM-CSF expressed as a percentage of the day 1 
level in patients in whom antibodies were detected.
GM-CSF levels as % day 1 in patients who 
did not develop anti GM-CSF antibodies
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Figure 7.6.
Serum level of GM-CSF expressed as a percentage of the day 1 
level in patients in whom antibodies were not detected.
7.11. Conclusions.
A high proportion of patients (four out of thirteen) who have received yeast 
derived rh GM-CSF have developed antibodies to this product . Although the 
yeast sugars do not contribute to the antigenicity it is possible that these sugars 
serve as haptens to augment the antigenicity of the unprotected O-linked 
glycosylation site(s). Only three patients received E coli derived material and 
although none developed antibodies, conclusions cannot be made about its
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antigenicity. A large number of patients have received E. coli derived G-CSF 
and the development of antibodies to this protein has not been reported.
The antibody response against the rh GM-CSF was rapid, appearing in all cases 
by seven days after commencement of the infusion, despite the recent 
administration of myeloablative and immunosuppressive cytotoxic drugs in 
three of the patients. In these three cases the patients had previously received 
a test dose of rh GM-CSF immediately prior to the ablative chemotherapy and 
this may have initiated the antibody response. In all cases IgG antibody was 
produced suggesting that this is a secondary immune response, although in 
patient 1 the IgG response was equally rapid and no test dose was given. IgM 
responses were not ascertained as it proved impossible to eliminate non 
specific IgM binding under the ELISA conditions used. It is possible that the 
primary response had occurred previously to trace quantities of native non 
glycosylated protein, however, providing GM-CSF is produced in intra uterine 
life, exposure to native non glycosylated protein would be expected to induce 
tolerance It has previously been reported that GM-CSF may augment antibody 
responses by enhancing the function of antigen presenting cells (Morrisey et 
al. 1987). This itself may lead to an increase in the production of antibody 
against the antigenic sites on the recombinant derived protein.
Evaluation of the clinical effects of antibody formation is difficult. The anti 
GM-CSF antibodies were detected retrospectively and were not suspected at the 
time of administration of growth factor. No evidence was found to suggest that 
the antibodies detected had neutralizing activity. The marrow culture assays
were performed with 10% patients' sera and even with the highest titre of anti 
GM-CSF antibodies the specific antibody concentration would be only 3.6 
ng/ml. With a GM-CSF concentration of 1.25 ng/ml there is still a molar 
excess of GM-CSF and this assay must therefore be considered an insensitive 
test of neutralizing activity. It is not possible to tell whether the appearance of 
anti GM-CSF antibodies influenced neutrophil regeneration as the time after 
ABMT to reach 0.5 x 109/l neutrophils was highly variable. One patient died 
of progressive disease before neutrophil recovery at 17 days after ABMT and 
the time to achieve a neutrophil count of 0.5 x 109/l in the other two patients 
was 14 days and 27 days respectively. The finding that the presence of anti 
GM-CSF antibodies was associated, in the one patient who had not received 
chemotherapy, with a decline in biological effect and a marked decrease in 
serum levels of GM-CSF despite continued infusion, suggests that development 
of this antibody resulted in more rapid plasma clearance of the rh GM-CSF. 
This is supported by the finding of a fall in circulating GM-CSF levels in the 
three ABMT recipients who developed antibodies compared to one out of seven 
who did not. This may indicate that when such antibodies are detected either the 
dose of administration should be increased or that there should be a change to an 
alternative source of recombinant product. Our findings may be particularly 
important where repeated administration of a growth factor is employed. 
Furthermore, it is clearly important that the sera of all patients receiving 
investigational cytokines and growth factors are analyzed for antibody 
formation using highly sensitive assays.
Chapter 8
Lymphocyte regeneration after ABMT
8.1. Introduction.
Consistent phenotypic abnormalities have been reported following both 
allogeneic and autologous BMT as discussed in chapter 2. Using available 
monoclonal antibodies the phenotype of the regenerating lymphocytes were 
assessed following ABMT. Lymphocyte phenotype characterization was 
performed in patients following ABMT by single antibody labelling in 93 cases 
In 34 of these cases dual antibody analyses were performed using commercially 
available antibodies directly labelled with fluorescein or phycoerythrin.
Blood was obtained from patients before the commencement of high dose therapy 
and at regular intervals following marrow regeneration in each of the patient 
groups studied. The mononuclear cell fraction was collected by separation over 
Ficoll as described in the method section. The cells were washed and incubated 
with monoclonal antibodies as described in the methods section. The cells were 
either stained fresh or after thawing of previously frozen cells. 2 x 105 cells 
were added to microtitre plates and predetermined optimal quantities of the 
appropriate antibodies were added to the cells and incubated on ice as described 
in the methods section.
Regeneration was studied in a total of 93 patients - 23 with AML (15 after 
double and 8 after single grafts), 8 with ALL, 45 with HD and 17 with NHL.
Results
The tabulated results obtained in individual patients with the mean and standrad 
deviation for each antigen for each patient group are shown in appendix 1. 
Before high dose therapy the total lymphocyte count, T cell count T cell subsets, 
B cells and CD56 cells were normal in patients with acute leukaemia and NHL 
Compared to the patients with AML, patients with Hodgkin's disease had a 
significantly lower total lymphocyte count (p<0.05) and CD4/CD8 ratio 
(p<0.005). This reduced CD4/CD8 ratio was due to a decreased number of CD4 
cells with a normal CD8 count.
8.2. T cell regeneration after ABMT.
The total peripheral blood lymphocyte count rapidly fell to near zero after high 
dose therapy and lymphocytes account for the earliest regenerating cells seen 
in the peripheral blood. The early cells have a distinct morphological 
appearance with increased size and a granular cytoplasm compared to the 
normal resting lymphocyte and are known as large granular lymphocytes. 
Figure 8.1 shows the cell numbers of regenerating lymphocytes, T lymphocytes 
(CD3+) and NK cells (CD56+) in all the patients after ABMT.
There was a significantly reduced total lymphocyte count after ABMT in the 
patients with ALL compared to the other patient groups for up to six months 
after ABMT (p<0.05).
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Figure 8.1. Regeneration of lymphocytes, T lymphocytes and NK 
cells after ABMT.
The percentage of cells staining positively with monoclonal antibodies against 
CD3 and CD56 are shown in figure 8.2.
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Figure 8.2. Regeneration of T cells and NK cells expressed as % 
positive cells expressing CD3 and CD56 after ABMT
As can be seen in figure 8.1. the total number of peripheral blood T 
lymphocytes (CD3+ cells) is markedly reduced for nine months after ABMT. 
There are differences, however, in the regeneration pattern of T cell subsets 
after ABMT. There is a rapid recovery of CD8+ cells which have reached 
normal numbers by two months after ABMT in most cases . The CD8+ cell 
count may be significantly elevated above the pre-transplant number until six 
to nine months after ABMT. In contrast the CD4+ cells are markedly reduced in
the early post transplant period and do not return to pre-transplant levels 
until one year after ABMT. The patients therefore have a reversal of the 
normal CD4+/CD8+ ratio. At 3-6 weeks after ABMT the mean CD4/CD8 ratio 
was 0.36 (±.0.14), at six months 0.78 (±. 0.25) and at one year 1.47 
(±0.37). All results are expressed as mean ±  standard deviation.
NK cells, as defined by positivity with the CD56 antibody NKH1, rapidly return 
to normal levels by six weeks after ABMT. Although these cells regenerated 
rapidly, there was no evidence of an actual increase in NK cells numbers during 
the early regenerative period. The CD8+/CD3- cells probably represent NK 
cells, but double labelling studies were not performed to confirm that these 
cells are the same population as those expressing CD56.
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Figure 8.3.
Regeneration of T lymphocytes, T cell subsets and Natural Killer cells in 
patients after ABMT
Figure 8.4 shows the % CD3+ cells after ABMT in each of the patient groups. 
There is no statistical difference in regeneration of T cells at any time point 
after ABMT in any of the patient groups. The total T lymphocyte numbers 
remain below 50% of the pretransplant level for six months after ABMT and do 
not return to normal levels until nine months to one year after ABMT.
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Figure 8.4.
Regeneration of CD3+ lymphocytes after ABMT in AML, ALL, HD and 
NHL patients. There is no statistical difference in T cell regeneration 
among any of the patient groups.
Regeneration of CD4+ cells after ABMT.
As can be seen in figure 8.5. CD4+ cells are markedly reduced in both % of 
lymphocytes and total number of cells nine months to one year after ABMT.
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Figure 8.5.
Regeneration of CD4+ lymphocytes after ABMT . The results are 
expressed in terms of % CD4+ ceils and also as total CD4+ cell count.
Regeneration of CD8+ cells after ABMT.
As can be seen in figure 8.6 there is a rapid regeneration of CD8+ cells after 
ABMT. These cells account for greater than 60% of the early regenerating cells 
after ABMT. Normal or above normal numbers of CD8+ cells are seen by two to
three months after ABMT. Clearly CD8+ cells exceed CD3+ cells and these 
cells do not therefore represent true T cells. CD3+/CD8+ cells classically 
represent suppressor function/cytotoxic T cells. CD3-/CD8+ cells most 
probably have NK function although double staining studies with CD56 were not 
performed to confirm this.
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Figure 8.6.
Regeneration of CD8+ cells after ABMT. The results are expressed in 
terms of % CD8+ cells and also as total CD8+ cell count.
CD4/CD8 ratio after ABMT
Normally the CD4:CD8 ratio is approximately 2. Immediately prior to ABMT 
the ratio of the whole group was 1.68:1. The CD4:CD8 ratio was particularly 
depressed in the patients with HD (1.5 ±  0.46) before ABMT compared to the 
other patient groups.
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Figure 8.7.
CD4+ and CD8+ cells after ABMT expressed as % positive cells.
Figure 8.8 shows the absolute numbers of CD4+ and CD8+ cells after ABMT and 
clearly shows that this abnormal ratio is caused by the slower regeneration of 
CD4+ cells compared to the rapid regeneration of CD8+cells.
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Figure 8.8.
CD4+ and CD8+ cells after ABMT expressed as absolute cell count.
As can be seen from figure 8.9 the normal CD4/CD8 ratio is markedly reversed 
during the early regenerative period. There is no significant difference in the 
CD4/CD8 ratio in any of the patient groups at any time after ABMT. At 3-6 
weeks after ABMT the mean CD4/CD8 ratio was 0.36 (±0.14), at six months
0.78 (+ 0.25), at nine months 1.01 (+0.21) and at one year 1.47 (±0.37). 
All results are expressed as mean ±  standard deviation.
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Figure 8.9. CD4/CD8 ratio after ABMT in patients with AML, 
ALL, NHL and HD.
There is no statistical difference in the CD4/CD8 ratio among the different 
patient groups for nine months after ABMT. At one year after ABMT the 
patients with Hodgkin's disease have a significantly reduced CD4/CD8 ratio 
compared to the other patients (p < 0.05). There is a reduced CD4/CD8 ratio 
in those patients with Hodgkin's disease who do not achieve CR after ABMT 
compared to those who do achieve CR (p < 0.01). There is no significant 
difference in CD4/CD8 ratio in those patients with Hodgkin's disease who 
achieve CR and patients with AML, ALL or NHL
8.3. B cell regeneration after ABMT.
There is a rapid regeneration of CD20+ cells after ABMT with a normal per 
centage of cells expressing CD20 cells by two months after ABMT in AML, HD 
and NHL patients. In no cases were there any cells which were CD10+. There 
is a significant delay in CD20 regeneration in ALL patients compared to the 
other patient groups (p<0.05). Figure 8.10 shows the regeneration of CD20+ 
B cells after ABMT.
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Figure 8.10.
Regeneration of B cells after ABMT expressed as a percentage of cells 
expressing CD20.
Figure 8.11 shows the regeneration of CD20+ cells expressed as total number 
of cells. Normal numbers of B cells are seen in AML, NHL and HD patients by 
three months after ABMT with no difference seen in regeneration of B cells 
among these groups. In contrast patients with ALL do not regenerate pre 
transplant numbers of B cells until six to nine months after ABMT.
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Figure 8.11.
Regeneration of CD20+ cells after ABMT expressed as absolute cell 
count.
8.4. T 5 expression after ABMT
During the early regenerative period 13 of 31 patients examined had increased 
percentage of circulating T cells expressing the T 5 chain suggesting that these 
cells expressed the Ty8 receptor. No patient had more than 5% of lymphocytes
expressing TCR 8 before transplant but these cells accounted for up to 30% of 
peripheral blood lymphocytes in some cases in the first two months after 
ABMT. This increased expression was transient in all but one patient with 
Hodgkin's disease in whom the expression of T 8 remained at 20 - 30% for one 
year after ABMT. Double labelling studies revealed that these cells do not co­
express CD4, CD8 or CD56. The results obtained in individual patients are 
shown in figure 8.12.
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Figure 8.12.
% of cells expressing TCR 8 before and after ABMT. There is an 
increased expression early after ABMT in 13 of 31 patients 
examined. This increase was transient in all but one patient.
Double labelling studies
Double labelling studies were performed using commercially available directly 
conjugated antibodies. These antibodies are extremely expensive and the 
studies were therefore directed at the determination of the cell phenotype in the 
earliest regenerating cells after ABMT. Obviously, the potential number of 
studies that can be performed with dual antibodies is large and the studies were 
further directed at the recovery of memory cells after ABMT. These studies 
were performed on 148 samples obtained during the recovery period in a total 
of 34 patients.
Although the CD4+ cells account for only a small percentage of the earliest 
regenerating ceils, these CD4+ cells co-express CD45Ro (84% + 11%) and 
CD29 (89% + 7%) but not CD45R (11% ±  5%). As discussed in chapter 3, 
this suggests that these cells are derived from the mature, memory T cell 
population. The CD8+ cells are largely CD45Ro negative (12% + 7%). No 
cells were found to co-express CD4 and CD8 during the very early regenerative 
stage.
CD56+ cells do not co-express CD4 or CD8. As discussed above, TCR 78 
expressing ceils also do not co-express CD4, CD8 or CD56, although these cells 
may have NK function.
These results suggest that there is little evidence that during the early 
regenerative phase that the peripheral blood lymphocytes have an immature
phenotype. Although there is an increase in TCR 8 expression, there are no 
cells which co-express CD4 and CD8. Although the CD4 cells are reduced in 
number they have almost entirely a memory cell phenotype. This suggests that 
the CD4 cells may be derived from either mature lymphocytes present in the 
re-infused bone marrow or from cells which survived the high dose 
chemotherapy and do not represent cells derived from the re-infused lymphoid 
progenitor cells.
Chapter 9.
In vitro T cell responses after ABMT.
9.1. Introduction.
As described in chapter 3, the CD3, the antigen specificity of individual T cells 
is determined by the TCR which recognises antigen complexed with self MHC. 
TCR ap are expressed on the cell surface in close association with CD3 which 
together form the TCR/CD3 complex. The CD3 complex is involved in signal 
transduction that occurs on antigen receptor binding. This antigen specific 
activation via the TCR/CD3 complex can be mimicked in a polyclonal fashion by 
antibodies with specificity on the TCR or on the closely associated CD3 
structures. This leads to a hydrolysis of phosphoinositol bis phosphate to 
diacylglycerol (DAG) and inositol tris phosphate (IP3). DAG induces activation 
of protein kinase C and IP3 increases intracellular free Ca++.
Human T cells produce a proliferative response when stimulated by antigen . 
This stimulation may be induced also by monoclonal antibodies against the CD3 
complex which results in polyclonal activation of T cells. The lectins 
phytohaemagglutinin A (PHA) and conconavalin A (Con A) also mediate 
mitogenesis via CD3.
The CD2 antigen has also been implicated in T cell activation. Combinations of 
antibodies reactive with CD2 and CD2R, reactive with different epitopes on the
CD2 molecule are also mitogenic to mature T cells (Meuer et al 1984). This 
activation apparently involves the same intracellular second messengers 
(Alcover et al 1988). Peripheral blood T cells activated through either 
TCR/CD3 or CD2 pathways produce IL-2 and respond to it by proliferation 
(Weiss et al 1984).
PHA-P, but not anti CD3 activation of T cells can be blocked by anti CD2 
antibodies, indicating that CD2 is involved in PHA-P induced stimulation 
(O'Flynn et al 1985). The exact mechanism of PHA-P activation of T cell 
remains unclear. However, since the mitogenic combination of anti CD2 
antibodies was available in only very limited amounts, the lectin PHA-P was 
used to assess activation via this alternative pathway. It had been reported that 
this pathway was accessory cell independent, but it has recently been shown 
that this pathway is accessory cell dependent for maximal stimulation and that 
this dependence may be mediated by CD44 (Denning et al 1989).
9.2. Methods
Cell proliferation was assessed using the measurement of incorporation of 
radiolabelled thymidine as described in the methods section. Assays were plated 
out in quadruplicate at 2 x 105 cells in round bottomed microtitre plates in a 
final volume of 200 pi in RPMI supplemented with 10% FCS and the compound 
under assessment for growth stimulation. The lectins PHA-P and Con A and the 
monoclonal antibodies UCHT1 and 9.6/9.1 combinations were used at pretested
optimal concentrations. Assays were set up ±  recombinant IL-2 (Boehringer 
Mannheim FRG). IL-2 was added at a final concentration of 10 U/ml.
The stimulation index (S.I.) represents the ratio of cpm of the test sample 
divided by the cpm obtained in the same patient sample set up in identical 
culture but with no added mitogen. The stimulation index was assessed in ten 
normal individuals to define a normal control value. Normal cells were set up 
in culture at the same time as the patient samples to confirm that optimal 
concentrations of mitogen were added.
T cell proliferative responses were investigated in 91 patients using PHA, Con 
A and lgG2a anti CD3 - 25 with AML, 7 with ALL, 12 with NHL and 47 with 
Hodgkin's disease. In 25 of these patients with Hodgkin's disease responses 
were also assessed using a combination of anti CD2 antibodies. The responses 
to the mitogens in individual patients with the mean and standard deviation for 
each group are shown in appendix 2.
9.3. Responses in patients with AML.
Samples from 25 patients with AML were studied before and at intervals after 
ABMT. The response to UCHT1 in 17 patients who received double grafts is 
shown in figure 9.1 and the responses of a further 8 patients who received only 
a single graft are shown in figure 9.2. Before ABMT all patients with AML in 
first CR had normal mitogenic responses. In all cases studied the response was 
markedly reduced for six months after ABMT, but returned to normal by one
year after the procedure. There was no difference in the pattern of response 
after a single procedure in those patients who did not have a second graft with 
the responses after the second graft..
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Figure 9.1
Mitogenic response to UCHT1 in AML patients who had double 
grafts. The stimulation index to UCHT1 in 10 normal individuals 
is shown as a control on the left. Time 0 is the day of re-infusion 
of marrow after the second ABMT.
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Figure 9.2.
Mitogenic response to UCHT1 in AML patients who had single 
grafts. The stimulation index to UCHT1 in 10 normal individuals 
is shown as a control on the right.
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9.4. Responses in patients with ALL.
In the ALL patients tested the mitogenic responses to UCHT1 were significantly 
reduced prior to ABMT compared to normal controls (p<0.05). Responses were 
markedly decreased after ABMT in all cases until one year after ABMT.
ALL: Mitogenic response to UCHT1
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Figure 9.3
Mitogenic response to UCHT1 in ALL patients. The stimulation 
index to UCHT1 in 10 normal individuals is shown as a control on 
the left.
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9.5. Responses in patients with NHL.
Before ABMT the response in patients with NHL was heterogeneous, with the 
majority of patients having responses below the normal limit of normal. The 
stimulation index after stimulation with UCHT1 in patients with NHL is shown 
in figure 9.4. Responses were markedly decreased for three months after 
ABMT but had returned to the pre transplant levels by six months after ABMT. 
By one year after ABMT the majority of patients had normal responses. Those 
patients who had not achieved normal responses by one year after ABMT were 
those patients who had not achieved CR with the transplant procedure, although 
it must be noted that a number of patients who still had active disease had 
normal responses by one year after ABMT.
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Figure 9.4
Mitogenic response to UCHT1 in NHL patients. The stimulation 
index to UCHT1 in 10 normal individuals is shown as a control on 
the left.
Similar patterns of responses were seen to each of the mitogens PHA-P and 
Con-A in each of the patient groups. The responses in ail of the patients with 
AML, ALL and NHL to the mitogens UCHT1, PHA-P and Con A are shown as the 
mean response ±  standard deviation in figure 9.5.
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Figure 9.5.
Response to the mitogens UCHT1, Con A and PHA-P in patients 
with AML, ALL and NHL. The results are expressed as the mean + 
standard deviation.
To each of the mitogens used there was a markedly decreased response seen 
after ABMT and this abnormal response was particularly marked in the early 
regenerative period. There was no evidence that the pattern of response after 
ABMT was different with the mitogens activating through the CD3 pathway, that 
is UCHT1 and Con A from the response with PHA-P acting through the CD2 
pathway.
As discussed in chapter 2, there have been reports that there is defective 
production of IL-2 after bone marrow transplantation. The same assays were 
therefore set up with the addition of exogenous IL-2. The effect of the addition 
of this exogenous IL-2 at 10 U/ml final concentration is shown in figure 9.6. 
This illustrates the mean and standard deviation of the stimulation index to the 
mitogen UCHT1 in patients with AML, ALL and NHL ±  IL-2.
There was no significant difference at any time point in the responses obtained 
to UCHT1 with exogenous IL-2 compared to those with no IL-2. The same 
results were obtained in responses to PHA-P and Con A. (data not shown).
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Figure 9.6.
The effect of the addition of exogenous IL-2 on the response to 
anti CD3 monoclonal antibodies
Although the total number of cells added to the cultures was constant, the 
percentage of cells expressing CD3 and therefore the total number of T cells 
was reduced in the cultures set up from the samples obtained from patients 
after ABMT. The mitogenic response to UCHT1 was therefore assessed in assays 
corrected to contain the same number CD3+ cells that were present in the 
controls. The results obtained are shown in figure 9.7.
Although this results in a more rapid return of the responses to the normal 
range, by six months after ABMT, there is no significant effect on the responses 
obtained during the first three months after ABMT when the responses are the 
most depressed.
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Figure 9.7.
Mitogenic responses to UCHT1 in cell cultures with numbers 
corrected for decreased numbers of CD3 cells present.
9.6. Responses in patients with Hodgkin's disease.
Samples from a total of 47 patients with Hodgkin's disease were available for 
analysis. In Hodgkin's disease patients the responses were markedly depressed 
in almost all cases immediately before ABMT. Figure 9.8 shows the mitogenic 
response response to UCHT1 in all patients with Hodgkin's disease. A similar 
pattern was obtained on testing with Con A (figure 9.9) and PHA-P (figure 
9.10). In samples from 25 patients cells were set up in culture with the 
mitogenic combination of anti CD2 monoclonal antibodies. The results obtained 
are shown in figure 9.11.
Decreased responses were seen in all cases after ABMT. By six months after 
ABMT six patients had responses which were at the lower limits of normal, but 
many patients still had markedly abnormal responses by one year after ABMT.
In view of the known immune suppressive effect of Hodgkin's disease the 
mitogenic responses were assessed by the subsequent response the patient 
achieved after ABMT. The responses generated by each mitogen depended upon 
the response the patient achieved after ABMT. These responses are shown for 
the UCHT1 (figure 9.12), Con A (figure 9.13), PHA-P (figure 9.14) and the 
mitogenic anti CD2 combination 9.6/9.1 (figure 9.15)
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Figure 9.8. Mitogenic response to UCHT1 in patients with 
Hodgkin's disease after ABMT
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Figure 9.9. Mitogenic response to Con A in patients with 
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Figure 9.10. Mitogenic response to PHA-P in patients with 
Hodgkin's disease after ABMT.
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Figure 9.11. Mitogenic response to anti CD2 in 25 patients with 
Hodgkin's disease after ABMT.
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Figure 9.12.
Mitogenic response to UCHT1 in patients with Hodgkin's disease by 
the response the patient subsequently achieved after ABMT.
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Figure 9.13.
Mitogenic response to Con A in patients with Hodgkin's disease by 
the response the patient subsequently achieved after ABMT.
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Figure 9.14.
Mitogenic response to PHA-P in patients with Hodgkin's disease 
by the response the patient subsequently achieved after ABMT.
1 7 8
15 n o rem
CMo
o
control
c
CO
X0)■u
c
c
o
a
3
E
CO
12960 3
months after ABMT
Figure 9.15.
Response to a mitogenic combination of anti CD2 monoclonal 
antibodies in 25 patients with Hodgkin's disease by the subsequent 
response those patients achieved to the ABMT. The responses in 
normal controls are shown on the right.
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Figure 9.16.
The response to the mitogen UCHT1 expressed as mean + standard 
deviation in those patients who achieved CR compared to those 
patients who did not achieve CR.
9.7. IL-2 Receptor expression after T cell activation.
IL-2 receptor (CD25) expression was assessed prior to culture by incubating 
cells with anti CD25 monoclonal antibody and subsequently goat anti mouse 
antibody couples with fluorescein as described in the methods section In no 
case did CD25 expression exceed 5% before culture. After three days of 
culture with each of the mitogens studied the CD25 expression was markedly 
increased, even in those samples obtained immediately after ABMT in which 
there was suboptimal response to the mitogens studied. Figure 9.17 shows the
mean responses in samples from patients at six weeks after ABMT after three 
days culture with UCHT1 and is typical of the pattern after culture with the 
other mitogens.
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Figure 9.17.
CD25 expression before and after culture with UCHT1 in samples 
from 86 patients at six weeks after ABMT.
9.7. Conclusions.
T cell proliferative responses were investigated in 91 patients after ABMT. 
Before ABMT the responses achieved were normal in patients in AML, slightly 
reduced in patients with ALL and were heterogeneous in patients with NHL. 
Patients with active Hodgkin's disease had uniformly depressed responses 
before the administration of high dose therapy.
Abnormal proliferative responses were obtained after ABMT in all of the 
patients studied. This depressed response was most marked in the first three 
months after ABMT. The decreased response during this period was not due to 
the reduced numbers of T cells present, since the defect was not corrected by 
compensating for the decreased percentage of T cells present following ABMT. 
The abnormality was not corrected by the addition of exogenous recombinant 
IL-2, although each agonist resulted in an increased expression of the IL-2R 
(CD25).
These findings suggest that the defect present after ABMT may be caused by a 
decreased responsiveness of the cells to IL-2 or by a suppressive effect on cell 
proliferation by cells with suppressor phenotype which are increased in 
number during this period. Further studies will be necessary to address this 
question.
Chapter 10.
In vitro antibody responses by human B lymphocytes
10.1. Introduction.
The induction of an antibody response is a complex process involving the 
activation of resting B cells with subsequent proliferation and differentiation of 
some of these cells into mature immunoglobulin secreting cells. A number of 
model systems have been designed to examine the sequence of events involved in 
triggering this B cell activation, proliferation and differentiation.
Anti Immunoglobulin is a polyclonal B cell activator which stimulates resting B 
cells to enter the early G1 stage of cell cycle where they acquire 
responsiveness to the T cell derived factor B cell growth factor (BCGF). BCGF 
is necessary to drive the cells into late G1 where they now require the 
monocyte derived factor IL-1 to enter S phase (Muraguchi et al 1984)
In vitro antibody responses by human B lymphocytes can be studied by the use 
of these polyclonal activators of B cells. The response of B cells to the 
polyclonal activators pokeweed mitogen and anti Ig with BCGF were studied 
before and at intervals after ABMT in each of the patient groups. Specific 
antibody responses were studied using an in vitro assay for the production of 
anti influenza antibodies. I am grateful to Dr Robin Callard of the Institute of
Child Health in London for allowing me to spend time in his laboratory to learn 
these techniques.
10.2. Polyclonal activation of B cells
B cell actiavation responses were investigated in 91 patients - 20 with AML, 5 
with ALL, 52 with Hodgkin's disease and 14 with NHL, before and after ABMT 
using the measurement of immunoglobulin secretion in vitro following 
activation with anti immunoglobulin or pokeweed mitogen.
Method.
Peripheral blood mononulclear cells were twice depleted of T cells by 
incubation with anti CD3 followed by incubation with goat anti mouse Ig coated 
magnetic beads as described in the methods section. The remaining fraction was 
further partially depleted of monocytes by plastic adherence for 45 minutes at 
37°C as described in the methods section. This B cell enriched fraction was 
washed three times with RPMI, 5% FCS and the cells set up in culture for ten 
days at 37°C in round bottomed microtitre plates in quadruplicate at 2 x 10 5 
cells/ml in a final volume of 200 pi with
1) anti Ig plus B cell derived growth factor (BCGF) - Gift from Dr. L Nadler, 
Dana Farber Cancer Institute, Boston.
2).Poke weed mitogen 10pl/ml final concentration plus BCGF.
BCGF was added at the concentration found to produce maximal immunoglobulin 
secretion in normal controls. There was considerable variation with different 
vials used.
The supernatants were assayed for IgG production by ELISA as described in the 
methods section. The Ig production was calculated by subtracting the levels 
detected in the control plates containing the cells from the same patient with 
the addition of no stimulatory factor from that produced in the test plate.
Results.
As can be seen from figure 10.1 there was a marked decrease in the in vitro IgG 
production with anti Ig and BCGF in the samples obtained after ABMT. The 
levels remained significantly decreased for six to nine months after ABMT in 
patients with AML, NHL and HD. The patients with ALL had decreased responses 
for a longer duration and responses were still not within the normal range at 
one year after ABMT.
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IgG production (ng/ml) in vitro with anti Ig and BCGF in 20 
patients with AML, 5 patients with ALL, 47 patients with HD and 
14 patients with NHL before and following ABMT. The mean of 
normal control samples + 2 SD are shown for comparison.
Figure 10.2 shows the response to the polyclonal activator pokeweed mitogen. 
Similar results were obtained, with decreased responses in all patients after 
ABMT. This was particularly marked in patients with ALL in whom responses 
reached the lower limits of normal only by one year after ABMT.
Unlike the T cell mitogen responses after ABMT, there was no difference in 
response in those Hodgkin's disease patients who achieved complete remission
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Figure 10.1.
after ABMT compared to those who did achieve complete remission (data not 
shown).
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Figure 10.2.
IgG production (ng/ml) in vitro with Pokeweed mitogen (PWM) 
and BCGF in patients 20 patients with AML, 5 patients with ALL, 
47 patients with HD and 14 patients with NHL before and 
following ABMT. The mean of normal control samples + 2 SD are 
shown for comparison.
10.3. in vitro antibody production against influenza virus.
In this study patients undergoing ABMT for haematological malignancies were 
vaccinated with killed influenza vaccine on the day of marrow re-infusion and 
in vivo and in vitro assessments of Ig responses made at various times after 
ABMT. The in vivo responses were discussed in chapter 6.
Method.
(Modified from Zander et al 1981)
The strains of Influenza virus appropriate to that found in the vaccine were 
provided by Dr J Skehel (NIMR, Mill Hill). Peripheral blood lymphocytes 
were prepared blood samples obtained from normal volunteers and from 
patients pre and recovering from autologous bone marrow transplantation as 
described in the methods section. Separation of E- and E+ cell fractions were 
performed using AET treated sheep red blood cells as described in the methods 
section. Partial depletion of the monocyte/macrophage population was 
performed by adherence to plastic as described in the method section.
Cells were suspended at 2 x 106/ml in PRMI 1640 with 25 mM Hepes , 10% 
Horse serum and 10'5 M hydrocortisone and cultured in round bottom 
microtitre plates (Linbro) in quadruplicate in 200 pi aliquots. Influenza 
virus was added at 1 pg/ml final concentration. Optimal IgG production 
occurred when all three strains of virus were added together in the culture 
system.
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Figure 10.3.
Scheme for detection of specific antibody production in vitro.
Cells were incubated with antigen for seven days in an atmosphere of 10% CO2 
at 37°C. After seven days the medium was removed by suction using a 21 guage 
sterile needle and the cells were washed twice in RPMI. The cells were re­
suspended in 100 pi of RPMI containing 20 mM Hepes and 5% foetal calf serum 
for a further 48 hours. Supernatants were harvested and stored at - 20°C in 
microtitre plates before assay.
Antibodies to influenza virus were assayed by ELISA as described in the methods 
section.
R esu lts.
None of the normal controls or patients had detectable amounts of antibody 
against any of the viruses before vaccination. In the normal controls there was 
a rapid induction of in vitro response after vaccination which was detectable 
from peripheral blood samples obtained ass early as ten days after vaccination. 
Optimal responses in each case were obtained against the X/87 component of the 
vaccine. Response were increased after partial monocyte depletion, but the 
response is monocyte dependent as the responses were absent when the 
monocytes were totally depleted by immune rosetting with anti CD14 coated 
magnetic beads. As can be seen in figure 10.4, in the normal controls there 
was an early peak in response vaccination and that the response was maintained 
for more than one year after vaccination. The peak response was obtained from 
peripheral blood samples obtained from normal controls 1 0 - 2 0  days after 
vaccination.
In none of the patients studied after ABMT was there a detectable in vitro 
specific antibody response in samples obtained up to 100 days after ABMT. The 
response after vaccination in samples from normal controls and from patients 
in the first one hundred days after ABMT is shown in Table 10.1.
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Figure 10.4.
In vitro specific anti-influenza IgG production against X/87 with 
partially monocyte depleted cell fraction.
In view of the fact that there are reports of decreased production of IL-2 after 
ABMT, exogenous IL-2 was added to the system at a final concentration of 10 
U/ml. In an attempt to augment antigen presentation in the in vitro system, 
recombinant GM-CSF was also added to the culture system at a final 
concentration of 12.5 ng/ml.
Table 10.1.
+ I L - 2  +GM-CSF
before vaccination 
1 0 0 0
2 5 + 4  7 + 3  5 + 4
after vaccination 
Normal controls
1 400 ±  163 460 ±.123 375 + 108
2 755 + 120 780 + 148 708 + 95
Patients after ABMT
three months after ABMT.
1. 0 0 0
2 . 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
Six months after ABMT
6. 55 + 14 6 2 + 1 9  44 + 22
Response in vitro in normal controls and patients ABMT.
1) Whole cell fraction
2) Partially monocyte depleted.
3) E+/E- 3:1 from sample post ABMT
4) E+ pre ABMT/E- post ABMT
5) E+ post ABMT/E- pre ABMT
6) Partially monocyte depleted.
The addition of IL-2 or GM-CSF had no effect on the peak response in normal 
controls. Presumably there is already optimal lymphokine production in the 
culture system in normal individuals. The addition of neither IL-2 nor GM- 
CSF had any effect on specific immunoglobulin production in vitro. Altering the 
ratio of E- to E+ fractions of cells present in the assay system similarly had no 
effect on immunoglobulin production during the first three months after ABMT.
10.4. Conclusions.
There was a marked decrease in B cell activation by polyclonal activators as 
measured by antibody production in vitro for periods up to one year after 
ABMT. These changes were particularly marked in patients with ALL who had 
received total body irradiation. Specific antibody production following 
vaccination with influenza virus occurred immediately in vivo but was absent 
in vitro for six months after ABMT and markedly reduced responses continued 
to be seen after this time.
The addition of IL-2 or GM-CSF had no effect on the failure by peripheral blood 
lymphocytes from patients after ABMT to respond to influenza virus in vitro. 
This non responsiveness was not due to a reduction in the number of B cells 
since the B cell numbers rapidly returned to normal in most of these patients 
while the responses were still absent. Optimal responses were reported to be 
optimal with mixing E+ and E- cell fractions in a ratio of 3:1. Experiments 
were performed altering the ratio of E+ and E- cells. This had no influence on 
non responsiveness after ABMT. Similarly, there was no effect by the addition
non responsiveness after ABMT. Similarly, there was no effect by the addition 
of T cells (E+) or B cells (E-) from cell samples frozen before ABMT, 
although it must be noted that these samples were obtained before vaccination 
and since none of the patients responded to the virus pre transplant, these 
presumably do not contain specific memory cells which are necesary for 
response.
In vitro Ig production with polyclonal activation and of specific anti influenza 
responses were detectable in most patients by 100 -120 days after ABMT, but 
these responses remained suboptimal and were not influenced by the addition of 
IL-2 or GM-CSF to the culture system. There was a particular delay in 
responses from patients with ALL in whom responses were absent in four out of 
five patients at six months after ABMT.
Chapter 11.
Discussion
Following allogeneic bone marrow transplantation there is a well documented 
period of immune suppression which is influenced by the presence of graft 
versus host disease. Following allogeneic bone marrow transplantation the 
regenerating immune system is derived from the donor and is thought to 
regenerate from the re-infused stem cell population. It has been postulated 
that the same pattern of regeneration would occur after autologous bone 
marrow transplantation, so that this setting would allow investigation of the 
re-capitulation of lymphocyte ontogeny without the effects of concomitent graft 
versus host disease.
Following autologous bone marrow transplantation, there are a number of 
analogous features to those found after allogeneic bone marrow transplantation. 
There was a rapid regeneration of NK cells, the earliest regenerating T cells 
expressed CD8 and there was slower regeneration of CD4, with a subsequent 
inversion of the normal CD4/CD8 ratio, all features which are seen after 
allogeneic bone marrow transplantation.
Although there is evidence of an increased TCR y8 expression in some patients 
in the early regenerative period, there is little other evidence that the 
peripheral blood lymphocytes have an immature phenotype. The CD4 cells 
almost entirely co-express CD45Ro and CD29 which are markers of cells
which have been previously activated and represent memory cells. No cells 
were found even in the earliest regenerating period which co-expressed CD4 
and CD8. B cell regeneration is rapid after high dose chemotherapy as 
evidenced by the fact that CD20+ cells were among the earliest detected. Again 
there was no evidence that these cells had an immature phenotype, and no cells 
were found which were CD10+.
It may therefore be the case that the lymphocytes in the autologous setting are 
derived from an expansion of mature lymphocytes from the re-infused bone 
marrow. However, the fact that B cell regeneration may be more delayed after 
total body irradiation as evidenced by the slower regeneration of B cells in the 
small group of patients with ALL, may also be suggestive that there is a cellular 
fraction which is partly regenerated from cells which survived the high dose 
chemotherapy but did not survive the high dose irradiation therapy.
In vivo tests of T cell function showed a rapid recovery to normal despite 
continuing defects found in the peripheral blood phenotype and functional 
assays in vitro. Similarly, in vivo antibody production showed a remarkable 
resistance to the recent high dose therapy. This suggests that the antibody 
producing cells are derived from those re-infused with the cryopreserved 
marrow and are therefore not affected by the high dose chemotherapy. The fact 
that the patients who received TBI have a different response lends weight to the 
argument that antibody production is dependent on cells which are capable of 
functioning after very high dose therapy but not after radiotherapy. These 
cells may be not B cells, but either T cells or antigen presenting cells which
are necessary for in vivo cellular interactions with B cells. These interactions 
in vivo may not be apparent from investigation of peripheral blood 
lymphocytes.
In vitro tests of B cell function were markedly reduced after ABMT. These 
abnormalities were apparent at a time when the in vivo antibody responses 
were adequate. This was not due simply to a decreased number of B cells 
present since in vitro tests remained abnormally low at a time when the 
CD20+ cell numbers had returned to normal in those patients who had received 
chemotherapy alone and enrichment of the population with excess B cells did 
not increase the response. Similarly, the total number of T cells had no effect 
on antibody production post ABMT since altering the ratio of E+ to E- ceils had 
no effect on the response. In the post ABMT patients it is possible that the lack 
of response is due to the presence of excess of T suppressor cells in the system 
since there is an excess of CD8+ cells in the patients during this period of non­
responsiveness.
There are two possible explanations. Firstly, the peripheral blood 
lymphocytes may not be representative of the lymph node population which are 
responsible for in vivo antibody production, or the responses may be 
suppressed by the excess of suppressor function cells in vitro. This 
suppressor effect may perhaps be overcome in vivo by differences in cellular 
interactions which are possible within the lymph node microenviroment..The 
difference in response in patients who have received chemotherapy alone from 
the responses in the small number of patients who received TBI suggests that
these interactions would involve cells which have survived the chemotherapy 
but not the radiotherapy.
The patients with acute leukaemia were treated when in remission of disease. 
The patients with Hodgkin's disease all had active disease and one third had 
bulky disease. The differences in T cell function which occurred in the patients 
with Hodgkin's disease are largely explained by the immune suppressive effect 
of the disease
Defective cell mediated immunity with impaired responses to delayed 
hypersensitivity skin testing, impaired ability to reject allografts and 
depressed proliferative responses to T cell mitogens in vitro is a well 
recognized feature of patients with Hodgkin's disease. (Levy and Kaplan 1974). 
The reason for this remains unclear but intrinsic abnormalities of 
lymphocytes, the presence of immunosuppressive factors in serum or plasma 
and increased monocyte suppressor activity have all been implicated. Evidence 
for enhanced suppressor T cell activity in cancer patients has come from the 
demonstration of reduced lymphocyte proliferative responses to T cell 
mitogens. Severe impairment of lymphocyte function has been shown to 
correlate with poor outcome but this has been of limited clinical value. 
(Wedelin et al 1982)
In this study the immunological status of a total of fifty two patients with 
relapsed or refractory Hodgkin's disease was assessed prior to high dose 
chemotherapy and ABMT. Peripheral blood lymphocyte subset analysis of CD3,
CD4, CD8, CD14, CD20 and CD56 revealed no consistent abnormality although 
the CD4/CD8 ratio was reduced at 1.5 (±. 0.46). The T cell proliferative 
response to mitogens was reduced compared to normal controls and to patients 
with acute leukaemia and non Hodgkin's lymphoma prior to ABMT. The 
stimulation index was 13.7 + 4.2 in the patients with Hodgkin's disease 
compared to 30 ±  5 in the normal controls and similar data was obtained with 
Con A, anti CD3 and a combination of anti CD2 monoclonal; antibodies. T cell 
responses in vivo as measured by the skin response to recall antigens were 
measured in 32 individuals using a commercially available applicator and was 
found to be markedly suppressed - 8.5 ±  6.5 compared to 34 + 3.9 in normal 
controls.
Following ABMT there was a return to normal CD8, CD20 and CD56 lymphocyte 
numbers within three months but complete recovery of CD4 lymphocytes took 
up to one year. Proliferative responses to T cell mitogens recovered 
progressively to normality at one year in those patients who achieved 
remission after ABMT ( Stimulation index with PHA 28.2 + 5.7), whereas in 
those patients with failing to achieve a CR the response remained low 
(Stimulation index with PHA 10.5 ±  7). The skin responses to recall antigens 
returned to normal levels by two to three months after ABMT in those patients 
who achieved remission whereas responses remained weak in those patients 
with persistent disease. This rapid in vivo recovery of T cell function was 
mirrored clinically by a lack of late infectious complications in this group of 
patients.
These studies have shown that there are consistent abnormalities of immune 
phenotype and in vitro function following autologous bone marrow 
transplantation. These studies have failed to show the precise nature of this 
defect, although there are suggestions that these effects may be caused by 
suppression of normal effector cells by the excess supprressor function cells 
which are present after ABMT. These putative suppressor effects are 
currently under investigation.
The in vitro antibody response to influenza virus has been shown to be T cell 
dependent (Callard and Smith 1981). Irradiation of the T cells has revealed a 
differential sensitivity of helper and suppressor cells. One possible way to 
examine the suppressive function of these cells is to use the differential effect 
of irradiation on these functional assays. The effect of using differential 
dosages of irradiation on the T cell fraction on the response to influenza vaccine 
is currently under investigation. It has further been shown that there is an 
HLA compatibility requirement for T cell help in this system as the 
combination of E+ and E - fractions with HLA non compatablilty resulted in no 
antibody formation. This nonresponsiveness was shown also to be mediated by 
suppressor activity which could be eradicated by the use of low dose 
irradiation. This failure does not appear to be due to genetic restriction since 
DR identical combinations also fail to respond (Callard and Smith 1981). This 
may be due to allo-activation of suppressor cells which suppress the specific 
antibody responses to influenza virus, but not the polyclonal production of 
antibody by poke weed mitogen. Irradiation of cells to 10 Gy completely 
abrogates the suppressor capacity of allogeneic T cells. Irradiation of
autologous T cells may enhance antibody formation whereas non irradiated cells 
tend to slightly inhibit. This may be explained by the existence of 
radiosensitive autologous suppressor T cells. Following irradiation there is an 
apparent loss of restriction between T and B cells in antibody response to 
influenza. This may be complicated by the fact that influenza virus may fuse 
with cell membranes and overcome the need for normal antigen processing. It 
is possible that by utilizing this radiation sensitivity of suppressor cell 
functions that remixing experiments could be performed using cell fractions 
from normal donors and patients after ABMT to more definitively establish the 
cause of the nonresponsiveness in these patients. These experiments are 
currently being performed but have proven to be technically difficult.
These studies have, however, shown that humoral immune responses remain 
intact in patients receiving high dose therapy and that this may have 
implications for the use of recombinant proteins which may be recognized as 
foreign to the body. Furthermore, the defect in cell mediated immunity seen in 
all patients persisted for only three months after ABMT and rapidly thereafter 
returned to normal ABMT. The defect in cell mediated immunity associated with 
active Hodgkin's disease rapidly corrected when remission was obtained even in 
heavily pre-treated patients. This early recovery of in vivo T cell function 
correlated with the low incidence of late opportunistic infections with ABMT 
and indicates that the persistent abnormalities seen in vitro with peripheral 
blood lymphocytes may have little physiological relevance.
REFERENCES.
Acuto O, Reinherz EL. The human T-cell receptor: Structure and Function. N. 
Eng. J. Med. 1985;312:1100-1111.
Advisory Committee of the IBMTR. 1989. Report from the IBMTR. Bone 
Marrow Transplantation 4; 221-229.
Alcover A, Alberini C, Acuto 0, Clayton LK, Transy C, Spagnoli GC, Moingeon P, 
Lopez P and Reinherz EL 1988. Interdependence of CD3-Ti and CD2 activation 
in human T lymphocytes. EMBO J. 7:1973-1977.
Amiot M, Dastot H, Schmid M, Bernard A, Boumsell L 1987. Analysis of CD1 
molecules on thymic cells and leukaemic T lymphoblasts identifies discrete 
phenotypes and reveals that CD1 intermolecular complexes are observed only 
on normal cells. Blood 70:676-685.
Anderson KC, Park K, Bates M, Leonard RCF, Hardy R, Schlossman SF and 
Nadler LM. 1983. Antigens on human plasma cells identified by monoclonal 
antibodies. J. Immunol. 130:1132-1138.
Anderson P, Blue ML and Schlossman SF 1988. Comodulation of CD3 and CD4. J 
Immunol 140:1732-1737.
Antin JH, Ault KA, Rappaport JM and Smith BR 1987. B lymphocyte 
reconstitution after human bone marrow transplantation. J Clin Invest. 80: 
325.
Antin JH, Smith BR, Holmes W and Rosenthal DS 1988. Phase I/ll studies of 
recombinant human granulocyte macrophage colony stimulating factor in 
aplastic anaemia and myelodysplastic syndrome. N Eng J Med 319:1628-1634.
Antman KS, Griffin JG, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, 
Whitney M, Frei E and Schnipper LE 1988. Effect of recombinant granulocyte 
macrophage colony stimulating factor on chemotherapy induced 
myelosuppression. N Eng J Med ;319:593-598.
Appelbaum FR, Fefer A, Cheever MA, Strorb R, Buckner CD and Thomas ED 
1981. Treatment of non Hodgkin's lymphoma with marrow transplantation in 
identical twins Blood 58:509-513.
Appelbaum FR, Fisher LD, Thomas ED 1988. Chemotherapy versus marrow 
transplantation for adults with acute nonlymphoblastic leukaemia: a five year 
follow up. Blood 72: 179-184.
Armitage JO, Fyfe ME, Lewis J 1984. Long term remission durability and 
functional status of patients treated with the CHOP regimen. J Clin Oncol 2: 
898 - 902
Armitage RJ, Goldstone AH, Richards JDM, Cawley JC and Linch DC 1986. 
Lymphocyte function after autologous bone marrow transplantation. Br J 
Haematol 63:637-641
Ault KA, Antin JH, Ginsberg D, Orkin SH, Rappaport JM, Keohan ML, Martin P, 
Smith BR, 1985. Phenotype of recovering lymphoid populations after marrow 
transplantation. J Exp Med 161:1483-1488.
Barber EK, Dasgupta JD, Schlossman SF, Trevillyan JM, Rudd CE. 1989 The 
CD8 and CD8 antigens are coupled to a protein-tyrosine kinase (P58 Lck) that 
phosphorylates the CD3 complex Proc Natl Acad Sci 86:3277-3281.
Baumgartner C, Morelli A, Hirt A, Bucher U, Forster HK, Doran JE, Matter L, 
Brun del Re G and Wagner HP 1988. Humoral Immune function in Pediatric 
patients treated with autologous bone marrow transplantation for B cell non 
Hodgkin's lymphoma. Blood 71:1211-1217.
Bengtsson M, Smedmyr B, Simonsson B, Oberg G, Lonnerholm G and Totterman 
TH 1988. Repopulation of T, B and Natural killer like cells in the blood and 
bone marrow after purged autologous bone marrow transplantation. 
Transplantation Proceedings 20:506-509.
Bierer BE, Peterson A, Takai Y, Greenstein J, Herrman S, Seed B and Burakoff 
SJ 1987. Evidence that LFA-3 activates T cells via the CD2 receptor. Fed Proc 
46;1 498-1 505.
Bierer BE, Burakoff SJ and Smith BR 1989, A large proportion of T 
lymphocytes lack CD5 expression after bone marrow transplantation. Blood 
73:1359-1366.
Bockenstedt LK, Goldsmith MA, Dustin M, Olive D, Springer TA and Weiss A
1988. The CD2 ligand LFA-3 activates T cells but depends on the expression 
and function of the antigen receptor. J Immunol 141:1904-1911.
Bosly AE, Staquet P, Doyen C, Chatelain BJ, Humblet YP and Symmann ML
1987. Recombinant human interleukin 2 restores in vitro T cell colony 
formation by peripheral blood mononuclear cells after autologous bone marrow 
transplantation . Exp Haematol 15: 1048-1052.
Boyd AW, Anderson KC, Freedman AS, Fisher DC, Slaughenhoupt B, Schlossman 
SF and Nadler LM 1985a. Studies of in vitro activation and differentiation of 
human B lymphocytes. I. Phenotypic and functional characterization of the B 
cell population responding to anti-lg antibody. J. Immunol. 134:1516-1523.
Boyd AW, Fisher DC, Fox D, Schlossman SF, Nadler LM 1985b. Structural and 
functional characterization of II-2 receptors on activated B cells. J. Immunol. 
1985;134:2387-2392.
Brandt SJ, Peters WP, Ahoater SK et al. Effect of recombinant human 
granulocyte macrophage colony stimulating factor on haemopoietic
reconstitution after high dose chemotherapy and autologous bone marrow
transplantation. N Eng J Med 1988;318:869-875.
Brenner MB, McLean J, Dialynas DP, Strominger JL, Smith JA, Owen FL, 
Seidman JG, Ip S, Rosen F and Krangel MS. 1986. Identification of a putative 
second T cell receptor. Nature 322, 145-149.
Brouet JC, Preud'homme JL, Penit C, Valensi F, Rouget P, Seligmann M. 1979 
Acute lymphoblastic leukemia with pre-B cell characteristics. Blood 54:269- 
273.
Cabinillas F, Hagemeister FB, Bodevy GP and Freireich EJ, 1982. IMVP19: an 
effective regimen for patients with lymphoma who have relapsed after initial 
combination chemotherapy. Blood 60: 693 - 697
Cabinillas F, Hagemeister FB, McLaughlin P Salvador P, Velasquez WS, Riggs S, 
Freireich EJ,1987. Results of MIME salvage regimen for recurrent or 
refractory lymphoma. J Clin Oncol 5: 407 - 412.
Callard RE and Smith CM 1981. Histocompatibility requirements for T cell 
help in specific in vitro antibody responses to influenza virus by human blood 
lymphocytes. Eur J Immunol 11: 206-212.
Campana D, Sheridan B, Tidman N, Hoffbrand AV, Janossay G. 1986. Human 
Leukocyte fuction-associated antigens on lympho-hematopoetic precurser 
cells. Eur. J. Immunol. 1986;16:537-542.
Campana D, Thompson JS, Amlot P, Brown S, Janossy G. 1987. The 
cytoplasmic expression CD3 antigens in normal and malignant cells of T 
lymphoid lineage. J. Immunol. 138:648-655.
Canellos GP, Young RC, De Vita VT, 1972. Combination chemotherapy for 
advanced HD in relapse following extensive radiotherapy. Clin Pharmacol Ther 
13; 750.
Canellos GP, Skarin AT, Klatt MM 1987. The mBACOD combination 
chemotherapy regimen in the treatment of diffuse large cell lymphoma. Semin 
Hematol 24: 2-7.
Cantrell MA, Anderson D, Cerretti DP 1985. Cloning, sequence and expression 
of a human granulocyte macrophage colony stimulating factor. Proc Nat Acad 
Science 82:6250-6254.
Cayeux S, Meuer S, Pezzutto A, Korbling M, Haas R, Schultz R and Dorken B 
1989. T cell ontogeny after autologous bone marrow transplantation. Failure 
to synthesize Interleukin 2 and lack of CD2 and CD3 mediated proliferation by 
both CD4+ and CD8+ cells even in the presence of exogenous IL-2. Blood 
74 :2270-2277.
Cebon J, Dempsey P, Fox R, Kannourakis G, Bonnem E, Burgess AW, Morstyn G
1988. Pharmacokinetics of human granulocyte macrophage colony stimulating 
factor using a sensitive immunoassay. Blood 72:1340-1347.
Charbonneau H, Tonks NK, Walsh KA, Fischer EH. 1988. The leukocyte 
commmon antigen (CD45): A putative receptor-linked protein tyrosine
phosphatase. Proc. Natl. Acad. Sci. 85:7182-7186.
Clark EA and Ledbetter JA 1989. CD45 is a protein tyrosine phosphatase. 
Immunol Today 10; 225-228
Clift RA, Buckner CD, Thomas ED 1987. The treatment of acute 
nonlymphoblastic leukaemia by allogeneic transplantation. Bone Marrow 
Transplantation 2; 243-249.
Crist W, Pullen J, Boyet J, Falletta J, van Eys J, Borowitz M, Jackson J, 
Dowell B, Russell C, Quddas F, Ragab A and Vietti T 1988. Acute lymphoid 
leukaemia in adolescents: clinical and biologic features predict a poor 
prognosis. J Clin One 6; 34-43.
De Vita VT, Canellos, GP Chabner B 1975. Advanced histiocytic lymphoma: a 
potentially curable disease. Lancet i 248 - 250.
Denning SM, Kurtburg J, Leslie, DS and Haynes BF 1989. CD44 antibodies 
augment CD2 mediated peripheral blood T lymphocyte activation. In: Leukocyte 
Typing IV White cell differentiation antigens. Ed Knapp, Oxford University 
Press p 287- 289.
Devereaux, S, Linch DC. Gribben JG , Patterson K, McMillan AK and Goldstone 
AH 1989. GM-CSF accelerates neutrophil recovery after autologous bone 
marrow transplantation for Hodgkin's disease. Bone Marrow Transplantation 
4 :49-54 .
Dorken B, Moldenhauer G, Pezzutto A,.1986 HD39 (B3), a B lineage- 
restricted antigen whose cell surface expression is limited to resting and 
activated human B lynphocytes. J. Immunol.136:4470-4479.
Dorken B, Moller P. Pezzutto A, Scwarz Albiez R, Moldenhauer G. 1989. B cell 
antigens:CD39. In: Leukocyte Typing IV White cell differentiation antigens. Ed 
Knapp, Oxford University Press p89
Dorken B, Pezzutto A, Hunstein W. 1987. Expression of cyytoplasmic CD22 in 
B cell ontogeny. In: Leukocyte Typing III White cell differentiation antigens. Ed 
AJ McMichael, Oxford: Oxford Press, p 474-476.
Doyle C and Strominger JL. 1987 Interaction between CD4 and class II MHC 
molecules mediates cell adhesion. Nature 33;256-259.
Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. 1988. Molecular 
cloning of the human B cell CD20 receptor predicts a hydrophobic protein with 
multiple transmembrane domains. EMBO J. 7:711-717.
Emmrich F, Strittmetter U and Eichmann K 1986. Synergism in the activation 
of human CD8 T ceils by cross linking the T cell receptor complex with the CD8 
differentiation antigen. Proc Natl Acad Sci USA 83:8298-8303.
Erikstein BK, Asheim HC, Smeland EB, Beiske K, Funderud S 1989. 
Characterization of a new monoclonal antibody HH2 which recognizes a cell 
cycle regulated antigen specific for human B-lymphocytes. In: Leukocyte 
Typing IV White cell differentiation antigens. Ed Knapp, Oxford University 
Press 110-112
Fingerroth JD, Weis J, Tedder TF, Strominger JL, Biro PA, Fearon DT 1984. 
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. 
8 1 :451 0-451 4.
Fisher Rl, De Vita VT, Hubbard SM 1983. Diffuse aggressive lymphomas: 
increased survival after alternating flexible sequences of ProMACE and MOPP 
chemotherapy. Ann Intern Med 98: 304 - 309.
Fisher Rl, Miller TP, Dana BW 1987. Southwest oncology group clinical trials 
for intermediate and high grade non-Hodhkin's lymphomas. Semin Hematol 2 
(suppl 1) 21-25.
Frei E, Canellos GP, 1980. Dose: a critical factor in cancer chemoptherapy. 
Am J Med 69; 585-588.
Friedrich W, O'Rielly RJ, Kozinger B, Gebhard DR. 1982. T lymphocyte 
reconstitution in recipients of bone marrow transplants with and without 
GVHD. Blood 59: 696.
Funderdud S, Blomhoff HK, Asheim HC, Beiske K, Totterman T, Smeland EB
1989. Characterization of a new non-clustered B cell specific antigen (FN1) 
preferentially expressed on resting cells. Tissue Antigens 33:151.
Gale RP, Opelz G, Mickey MR, Graze PR, Saxon A 1978. Immunodeficiency 
following allogeneic bone marrow transplantation. Transplant Proc 10:223- 
229.
Gams RA, Rainey M, Danay M 1985. Phase III study of BCOP versus CHOP in 
unfavorable categories of malignant lymphoma. J Clin Oncol 3: 1188 - 1195.
Gillis S, Urdal D, Clevender W 1987. Production of recombinant human colony 
stimulating factors in yeast. Behring Inst Mitt 83: 1 - 7 .
Goldstone AH, Gribben JG. 1987 Autologous bone marrow transplantation in 
malignant disease.Blood Reviews 1: 193-200.
Goldstone AH, Gribben JG, McMillan AK and Taghipour G. 1989 The sixth 
report of the EBMTG autologous lymphoma registry. Bone Marrow
Transplantation. 4, (Suppl 2) 53.
Goldstone AH, Singer CRJ, Gribben JG and Jarret M 1989. European
experience of ABMT in non Hodgkin's lymphomas and Hodgkin's disease.ln: Bone 
Marrow Transplantation: Current conrtoversies. Ed. Gale and Champlin. Allan R 
Liss New York pp 256-278
Gorin NC, Aegerter P and Auvert B 1989. Autologous bone marrow
transplantation for acute leukaemia in remission. Bone Marrow 
Transplantation 4 (Suppl 1):206
Gratwohl A, Hermans J, Lyklema J 1989. Bone marrow transplantation for 
leukaemia in Europe. Bone Marrow Transplantation 4 (Suppl 1), 1-3.
Gribben JG, Linch DC, Watts M and Goldstone AH 1987a. Prolonged remission 
following autologous bone marrow transplantation with re-infusion of relapsed 
bone marrow in acute myeloid leukaemia. Bone Marrow Transplantation 2: 
SuppH ,66
Gribben JG, Linch DC, Anderson CC and Goldstone AH 1987b. Is irradiation of 
blood products necessary for patients receiving autologous bone marrow 
transplantation? Bone Marrow Transplantation 2: Suppl1,298.
Gribben JG, Goldstone AH, Linch DC and Richards JDM 1987c. Double 
autologous bone marrow transplantation and Autologous bone marrow 
transplantation in acute leukaemia. Bone Marow Tranplantation 2: SuppH, 
4 6 -48 .
Gribben JG, Vaughan Hudson B and Linch DC 1987d. The potential value of very 
intensive therapy with autologous bone marrow rescue in the treatment of the 
malignant lymphomas.Hematological Oncology 5: 281-293
Gribben JG, Goldstone AH and Ernst P. 1987e. Allogeneic versus autologous 
bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow 
Transplantation 2: SuppH, 204
Gribben JG, Goldstone AH, Linch DC and Richards JDM 1989a. Double 
autologous bone marrow transplantation for adult acute myeloid leukaemia in 
first remission. Bone Marrow Transplantation 4: Suppl 1, 209-212
Gribben JG, Linch DC, Singer CRJ, Jarret M, McMillan A and Goldstone AH 
1989b. Successful treatment of refractory Hodgkin's disease by high dose 
chemotherapy and autologous bone marrow transplantation. Blood 73: 340- 
344
Gribben JG, Goldstone AH, Linch DC, Taghipour G, McMillan AK, Souhami RL, 
Earl H and Richards JDM 1989c. Effectiveness of high dose combination 
chemotherapy and autologous bone marrow transplantation for patients with 
non Hodgkin's lymphoams who are still responsive to conventional dose 
therapy. J Clin Oncol 7:1621-1629.
Gribben JG, Devereaux S, Thomas NSB, Keim M, Jones HM, Goldstone AH, Linch 
DC 1990. Antibodies developing against recombinant human granulocyte 
macrophage colony stimulating factor. Lancet 335:434-437.
Groopman JE, Mitsuyaasu RT, DeLeo MJ 1987. Effect of recombinant human 
granulocyte macrophage colony stimulating factor on myelopoiesis in the 
acquired immunodeficiency syndrome. N Eng J Med 317:593-598.
Haynes BF, Denning SM, Singer KH and Kurtzberg J. 1989. Ontogeny of T cell 
precursors. Immunology Today 10, 87-91.
Hercend T, Nadler LM, Pesando JM, Reinherz EL, Schlossman SF, Ritz J 1981. 
Expression of a 26,000 dalton glycoprotein on activated human T cells. Cell. 
Immunol. 64:192-199.
Hoelzer D, Thiel E, Loeffler H, Buchner T, Ganser A, Heil G, Koch P, Freund M, 
Diedrich H, Ruhl H, Maschmeyer G, Lipp T, Nowrousian MR, Burkert M, 
Gerecke D, Pralle H, Muller U, Lunsken C, Fulle H, Ho AD, Kuchler R, Busch 
FW, Schneider W, Gorg C, Emmerich B, Brauman D, Vaupel HA, von Paleske A, 
Bartels H, Neiss A and Messerer D. 1988. Prognostic factors in a multicenter 
study for treatment of acute lymphoblastic leukemia in adults. Blood 71:123- 
131.
lida K, Nadler LM, Nussenzweig V. 1983. The identification of the membrane 
receptor for the complement fragment C3d by means of a monoclonal antibody. 
J. Exp. Med. 158:1021-1033.
Janeway CA 1989. The role of CD4 in T ceil activation Immunulogy Today 
10:234-238.
Keever CA, Small TN, Flomenberg N, Heller G, Pekle K, Black P, Pecora, Gillio 
A, Kernan NA, O'Reilly RJ 1989. Immune reconstitution following bone 
marrow transplantation. Blood 73:1340-1350.
Kehrl JH, Muraguchi A, Fauci AS 1984. Differential expression of cell 
activation markers after stimulation of resting human B Lymphocytes. J. 
Immunol. 132:2857-2861.
Kersey JH, LeBien TW, Abramson CS, Newman R, Sutherland R, Greaves M. A 
1981. Human hemopoietic progenitor and acute lymphoblastic leukemia- 
associated cell surface structure identified with a monoclonal antibody. 
153:726-731.
Kiesel S, Pezzuto A, Moldenhauer G, Haas R, Korbling M, Hunstein W and 
Dorken B 1988. B cell proliferative and differentiaitive responses after 
autologous peripheral blood stem cell or bone marrow autografting. 
Blood72:672-678.
Klimo P and Connors JM. 1985 MACOP-B chemotherapy for the treatment of 
difffuse large cell lymphomas. Ann Intern Med 102: 596 - 602.
Korsmeyer SJ, Greene WC, Cossman J 1983. Rearrangement and expression of 
immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. 
Proc. Natl. Acad. Sci. 80:4522-4526.
Korsmeyer SJ, Hieter PA, Ravetch JV, Poplack DG, Waldmann TA, Leder P 
1981. Development hierachy of immunoglobulin gene rearrengements in 
human leukemic pre-B cells. 78:301-313.
Laemmli U K 1970. Cleavage of structural proteins during the assembly of the 
head of the bacterial phage T4. Nature 227,680-685 .
Lanier LL, Le AM, Civin Cl, Loken MR and Phillips JH 1986. The relationship 
of CD16 and CD56 antigen expression on human peripheral blood NK cells and 
cytotoxic T lymphocytes. J Immunol 136: 4480-4483
Lanier LL, Testi R, Bindl J and Phillips JH 1989. Identity of CD56 leucocyte 
differentiation antigen and neural cell adhesion molecule. J Exp Med 169: 
2233-2238 .
Lawrence J, Coleman M and Allen SL. 1982. Combination chemotherapy 
regimen in the treatment of diffuse large cell lymphoma. Ann Intern Med 
97 :190-195 ,
Ledbetter JA, Tonks NK, Fischer EH and Clark EA 1988. CD45 regulates signal 
transduction and lymphocyte activation by specific association with receptor 
molecules on T or B cells. Proc Natl Acad Sci USA 85; 8628-8632
Levy R and Kaplan HS 1974. Impaired lymphocyte function in untreated 
Hodgkin's disease. N Engl J Med 290:181-184.
Linch DC, Knott LJ, Patterson KG, Harper P 1982 Bone marrow processing 
and cryopreservation J Clin Path 35; 186-190.
Linch DC and Burnett AK 1986. Autologous bone marrow transplantation in 
Acute Myeloid Leukaemia. In Clinics in Haematology, Autologous Bone Marrow 
Transplantation , Ed AH Goldstone, WB Saunders, London p 167-186.
Ling NR, MacLennan ICM, Mason DY 1987. B-cell antigens: new and previously 
defined cllusters, In: Leukocyte Typing 111 White cell differentiation antigens. 
Ed McMichael, Oxford University Press 302-335,
Longo DL, De Vita VT, Duffey P 1987. Randomized trial of Promace MOPP v 
Promace Cytabom in stage ll-IV aggressive non Hodgkin's lymphomas. Proc Am 
Soc Clin Oncol 6: 206, (abstr)
Lopez-Botet M, De Landrazuri M, Izquierdo M, Ramirez A, Figuera A, Camara 
R, Fernandez Ranada J 1987. Defective IL 2 receptor expression is associated 
with the T cell dysfunction subsequent to bone marrow transplantation. Eur J 
Immunol 17:1167-71.
Lum LG, Munn NA, Schanfield MS and Storb R 1986. The detection of specific 
antibody formation to recall antigens after human marrow transplantation. 
Blood 67:582-590.
Lum LG. 1987. The kinetics of immune reconstitution after human marrow 
transplantation. Blood 69: 369- 380.
Marcus RE, Catovsky D, Johnson SA 1986. A study of adult acute lymphoblastic 
leukaemia - progressive disease and response to treatment over a ten year 
period. Brit J Cancer, 53. 175-180.
Marlin SD, Pringer TA 1987. Purified intracellular adhesion molecule-1 
(ICAM-1) is a ligand for lymphocyte-functional antigen 1 (LFA-1). Cell 
51 :813-819 .
Matsue K, Lum LG, Witherspoon RP and Storb R. 1987. Proliferative and 
differentiative responses of B cells from human marrow graft recipients to T 
cell derived factors. Blood 69:308-315.
McMichael AJ, Gotch FM 1987. T-cell antigens: New andpreviously defined 
clusters. In: McMichael AJ ed. Leukocyte Typing III. Oxford: Oxford University 
Press, 31-62.
McMillan AK, Gribben JG, Tobias JS, Linch DC and Goldstone AH 1989. 
Radiotherapy for residual Hodgkin's disease after BEAM chemotherapy and 
autologous bone marrow transplantation .Bone Marrow Transplantation. 4, 
(Suppl 2) 52.
Meuer SC, Hussey RE, Fabbi M, Fox D, Acuto O, Fitzgerald KA, Hodgdon JC, 
Potentis JP, Schlossman SF and Reinhertz EL 1984. An alternative pathway of 
T cell activation: a functional role for the 50kD T11 sheep erythrocyte 
receptor protein. Cell 36; 897-905
Morimoto C, Letvin N, Boyd AW, Hagan M, Brown HM, Kornaki M and 
Schlossman SF 1985a. The Isolation and characterisation of the human helper 
inducer T cell subset. J Immunol 134:3762-3768
Morimoto C, Letvin N, Distaso J, Aldrich W, Schlossman S 1985b. The 
isolation and characterization of the human suppressor inducer T cell subset. J. 
Immunol. 134:1508-1515.
Morrisey PJ, Bressler L, Park LS , Alpert A and Gillis S.1987. Granulocyte 
macrophage colony stimulating factor augments the primary antibody response 
by enhancing the function of antigen presenting cells. J Immunol 139:1113- 
1119.
Muraguchi A, Kehrl JH, Butler JL and Fauci AS 1984. Sequential 
requirements for cell cycle progression of resting human B cells after 
activation by anti Ig. J Immunol 127:1307-1312.
Nadler LM, Stashenko P, Hardy R, van Agthoven A, Terhorst C, Schlossman SF 
1981. Characterization of a B cell specific (B2) distinct from B1. J. Immunol. 
126:1941-1947.
Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF and Schlossman 
SF 1983. B4, a human B cell associated antigen expressed on normal, mitogen 
activated, and malignant B lymphocytes. J. Immunol 131:244-250.
Nadler LM, Korsmeyer SJ, Anderson KC, Boyd AW, Slaughenhoupt B, Park E, 
Jensen J, Coral F, Mayer RJ, Sallan SE, Ritz J and Schlossman SF 1984. B cell 
origin of non-T cell acute lymphoblastic leukemia. J. Clin. Invest. 74:332- 
340.
Nemunaitis J, Singer JW, Buckner CD, Hill R, Storb R, Thomas ED and 
Appelbaum FR 1988. Use of recombinant human granulocyrte macrophage 
colonu stimulating factor in autologous marrow transplantation for lymphoid 
malignancies. Blood 72;834-836.
Noel DR, Witherspoon RP, Storb R et al. 1978. Does GVHD influence the tempo 
of immunologic recovery after allogeneic BMT? Blood 51:1087.
O'Connel MJ, Harrington DP, Earle JD, Johnson GJ, Glick JH, Carbonne PP, 
Creech RH, Neiman RS, Mann RS and Silverstein MN 1987. Prospectively 
randomized clinical trial of three intensive chemotherapy regimens for the 
treatment of advanced unfavorable histology non hodgkin's lymphoma. J Clin 
Oncol 5: 1329 - 1339.
O'Flynn K, Krensky AM, Beverley PCL, Burakoff SJ and Linch DC 1985. 
Phytohaemagglutinin activation of T cells through the sheep red blood 
receptors. Nature 313:686-9.
Olsen GE, Gockermen JP, Bast RC, Borowiitz M and Peters WP 1988. Altered 
immunologic reconstitution after standard dose chemotherapy or high dose 
chemotherapy with autologous bone marrow support. Transplantation 46: 57- 
60.
Pedrazzini A, Freedman AS, Andersen J, Heflin L, Anderson K, Takvorian T, 
Canellos GP, Whitman J, Coral F, Ritz J and NAdler LM 1989. Anti B cell 
monoclonal antibody purged autologous bone marrow transplantation for B cell 
non Hodgkin's lymphoma: phenotypic reconstitution and B cell function. Blood 
74: 2203-2211.
Pezzutto A, Dorken B, Moldenhauer G, Clark EA 1987. Amplification of human 
B cell activation by a monoclonal antibody to the B cell-specific antigen CD22, 
Bp 130/140. J. Immunol. 138:98-103.
Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JP, Maraninchi 
D, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K, 
Goldstone AH, Linch DC1987. High dose therapy and autologous bone marrow 
transplantation after failure of conventional chemotherapy in adults with 
intermediate and higyh grade non hodgkin's lymphoma. N Eng J Med 316:1493 
- 1498
Philip T, Biron P, Philip I Fvarot M., Souillet G, Frappaz D, Jaubert J, 
Bordigoni P, Bernard JL, Laporte JP, LeMevel F, Plouvier E, Marguarite G, 
Pinkerton R Brizard CP, Freycon F, Forster HK, Phillippe N, Brunat- 
mentigny M, 1986. Massive therapy and autologous bone marrow
transplantation in paediatric and young adult Burkitt's lymphoma with Eur J 
Cancer Clin Oncol 22: 1015-1027.
Philip T, Hartman O, Biron P, Cahn JY, Pein F, Bordigoni P, Souillet G, 
Gartner M, Lasset C, Chauvin F 1988 High dose therapy and autologous bone 
marrow transplantation in partial remission after first line induction therapy 
for diffuse non-Hodgkin's lymphoma. J Clin Oncol 6: 1118 - 1124.
Phillips GL, Herzig RH, Lazarus HM Fay FW, Wolff SN, Mill WB, Lin H, 
Thoams PRM, Glasgow GP, Shina DC and Herzig GP 1984. Treatment of 
resistant malignant lymphoma with cyclophosphamide, total body irradiation 
and cryopreserved autologous marrow. New Eng J Med 310: 1557-1561.
Preisler H, Davies RB, Kirshner J 1987. Comparison of three remission 
induction regimes and two post induction strategies for the treatment of acute 
nonlymphoblastic leukemia. Blood 69;1441-1448.
Procter SJ, Hamilton PJ, Taylor P 1988 A comparitive study of combination 
chemotherapy versus autologous bone marrow transplantation in adult acute 
lymphoblastic leukaemia. Brit J Haem 69, 35-39.
Radcliffe JA, Cowan RA, Flanagan M, Dunn G, Crowther D, Johnson RJ, 
Eddleston B 1988. The significance of residual mediastinal abnormality on the 
chesy radiograph following treatment for Hodgkin's disease. Jnl Ciin Oncol 6; 
940-946 .
Rees JHK, Gray RG, Swirsky D and Hayhoe FGJ 1986. Principal results of the 
Medical Research Council's Eighth Leukaemia trial. Lancet,8518, 1236-1240.
Reinherz EL, Schlossman SF 1980. The differentiation and function of human T 
lymphocytes: a review. Cell 19:821-827.
Reittie JE, Gottlieb D, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand 
AV, Prentice HG and Brenner MK 1989. Endogenously generated activated 
killer cells circulate after autologous and allogeneic marrow transplantation 
but not after chemotherapy. Blood 73:1351-1358.
Riehm H, Gardner H, Henze G 1980. The Berlin childhood acute lymphoblastic 
leukaemia therapy study, 1970-1976. Am J Pediatr Hematol Oncol, 2, 299- 
306.
Rosenstein Y, Ratnofsky S, Burakoff SJ and Herrman SH 1989. Direct evidence 
for binding of CD8 to HLA class I antigens. J Exp Med 169: 149-160.
Rudd CE, Trevillyan JM, Dasgupta JD, Wong LL, Schlossman SF. The CD4 
receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) 
from human T lymphocytes. Proc. Natl. Acad. Sci. 1988;85:5190-5194.
Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA and 
Shaw S. 1988. Human memory T lymphocytes express increased levels of 
three cell adhesion molecules (LFA-3, CD2 and LFA-1) and have three other 
molecules (UCHL1, CDw29 and Pgp-1) and have enhanced IFN-yproduction. 
Jnl Immunol 140;1401 -1407
Santoro A, Bonfante V Bonadonna G, 1982. Salvage chemotherapy with ABVD in 
MOPP resistant Hodgkin's disease. Ann Intern Med 96;139-143.
Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW and Saral R
1989. Herpes zoster infection after autologous bone marrow transplantation. 
Blood 74:1424-1427.
Selvaraj P, Plunkett ML, Dustin M, Sanders ME Shaw S and Springer TA 1987, 
The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature 
326, 400-403.
Skarin AT, Canellos GP, Rosenthal DS 1983. Improved prognosis of diffuse 
histiocytic and undifferentiated lymphoma by use of high dose methotrexate 
alternating with standard agents. J Clin Oncol 1: 91 - 98.
Small TN, Keever CA, Knowles RW, O'Reilly RJ, Flomenberg N 1989. CD1c 
expression during normal B cell ontogeny. Tissue Antigens 33:71.
Smith SH, Brown MH, Rowe D, Callard RE and Beverley PC 1986. Functional 
subsets of human helper-inducer cells defined by a new monoclonal antibody 
UCHL1. Immunulogy 58:63-68.
Stamenkovic I, Seed B 1988. Analysis of two cDNA clones encoding the B 
lymphocyte antigen CD20 (B1,Bp35), a type Hi integral membrane protein. J 
Exp Med 167:1975-1980.
Stamenkovic I, Seed B 1989. Molecular cloning of CD38. Tisssue Antigens 
33:139.
Stashenko P, Nadler LM, Hardy R, Schloosman SF 1980. Characterization of a 
new B lymphocyte specific antigen in man. J. Immunol. 125:1678-1685.
Stashenko P, Nadler LM, Hardy R, Schlossman SF 1981. Expression of cell 
surface markers following human B cell activation. Proc. Natl. Acad. Sci. USA 
1981;78:3848-3852.
Streuli M, Hall LR, Saga Y, Schlossman SF, Saito H 1987. Differential usage of 
three exons generates at least five different mRNAs encoding human leukocyte 
common antigens. J. Exp. Med. 166:1548-1566.
Surbonne A, Longo D, DeVita VT, Ihde DC, Duffey PL, Jaffe ES, Solomon D, 
Hubbard SM and Young RC. 1988. Residual abdominal mass in aggressive non 
hodgkin's lymphoma after combination chemotherapy: significance and 
management. J Clin Oncol 6: 1832-1837
Takvorian T, Canellos GP, Ritz J , Freedman AS, Anderson KC, Mauch P, Tarbell 
N, Coral F, Daley H, Yeap B, Schlossman SF and Nadler LM 1987. Prolonged 
disease free survival in patients with por prognosis non Hodgkin's lymphoma 
following autologous bone marrow transplantation. N Eng J Med 316: 1499 - 
1505
Tedder TF, Boyd AW, Freedman AS, Nadler LM 1985. The B cell surface 
molecule B1 is functionally linked with B cell activation and differentiation. J. 
Immunol. 135: 973-979.
Tedder TF, Streuli M, Schlossman SF, Saito H 1988. Isolation and structure of 
a cDNA encoding the B1 (CD20) cell surface antigen of human B lymphocytes. 
Proc. Natl. Acad. Sci. USA 85: 208-212.
Tedder TF and Isaacs CM 1989. Isolation of cDNAs encoding the CD19 antigen of 
human and mouse lymphocytes. J Immunol 143:712-717.
Terhorst C, van Agthoven A, LeClair K, Ledbetter JA, Moldenhauer G, Clark EA
1981. Biochemical studies in the human thymocyte antigens T6, T9, and T10. 
Cell 23:771-780.
Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, 
Glucksberg H, Buckner CD 1975. Bone marrow transplantation. N Engl J Med 
292: 832, 895.
Thomas ED 1985. Current status of bone marrow transplantation. 
Transplantation Proceedings 17; 428-431.
Thomas ML and Lefrancois L 1988. Differential expression of the leucocyte 
common antigen family. Immunol Today 9, 320-326.
Tsudo M, Uchiyama T, Uchino H 1984. Expression of TAC antigen on activated 
normal human B cells. J. Exp. Med. 160:612-617.
Tura S, Mazza P, Zinzani PL, Santoro A and Bonnadonna G 1986. Hodgkin's 
disease; a historical perspective. Eur J Cancer Clin Oncol 22:1315.
Uchiyama T, Broder S, Waldmann TA 1981. A monoclonal antibody (anti-TAC) 
reactive with activated and functionlly mature T cells I. Production of anti-TAC 
monoclonal antibody and distribution of Tac (+) cells. J. Immunol. 126:1393- 
1403.
Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo 
JM, Broxmeyer HE, Henney C, Gutterman JU. 1987. Effects of recombinant 
human granuiocyte-macrophage colony stimulating factor in patients with 
myelodysplastic syndrome. N Engl J Med. 317: 1545-1552.
Vaughan Hudson B, MacLennan KA, Easterling MJ, Jelliffe AM, Haybittle JL, 
Vaughan Hudson G 1983. The prognostic significance of age in Hodgkin's 
disease. Ciin Radiol 34:257-261.
Vaughan Hudson B, MacLennan KA, Bennet MH, Easterling MJ, Vaughan Hudson 
G, Jelliffe AM 1987. Systemic disturbances in Hodgkin's disease and its 
relationship to histopathology and prognosis. Clin Radiol 38:257-261.
Velardi A, Terenzi A, Cucciaioni S, Millo R, Grossi CE, Grignani F and Martelli 
MF 1988. Imbalances within the peripheral blood T helper and T suppressor 
cell populations in the reconstitution phase after human marrow 
transplantation. Blood 71: 1196-1200.
Velasquez WS, Cabinillas F, Salvador P,Salvador P, McLaughlin P, Fridrik M, 
Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F and Barlogie B
1988. Effective salvage therapy for lymphoam with cisplatin in combination 
with high dose Ara C and dexamethasone. Blood 71:117 -122.
Voller A, Bidwell DE and Bartlett A. Enzyme immunoassay in diagnostic 
medicine. Bull WHO 1976;53:55-65.
Wedelin C, Bjorkholm M, Hohn G, Ogenstad S, Johnanssen B, Mellstadt H
1982. Lymphocytes function in untreated Hodgkin's disease an important 
prodictor of prognosis. Br J Cancer 45: 70-74.
Weiss A, Wiskocil RL, Stobo JD 1984. The role of CD3 surface molecules in 
the activation of human T cells : a two stilulus requirement for IL-2 production 
reflects events occurring at a pretranslational level. J Immunol 133;123-28.
Wimperia JZ, Brenner MK, Prentice HG, Reittie JE, Karayianis P and Griffiths 
PD. 1986. Transfer of a functioning humoral immune system in 
transplantation of T lymphocyte depleted bone marrow. Lancet 1: 339-342.
Wimperis JZ, Gottlieb D, Duncombe AS, Heslop HE, PrenticeHG and Brenner 
MK 1990. Requirements for the adoptive transfer of antibody responses to a 
priming antigen in man. Jnl Immunol 144:541-547.
Witherspoon RP, Lum LG, Storb R and Thomas ED 1982. In vitro regulation of 
immunogobulin synthesis after human marrow transplantation. Blood 
59:844-849.
Witherspoon RP, Strorb R, Ochs HD, Flournay N, Kopecky KJ, Sullivan KM, 
Deeg HJ, Sosa R, Noel DR, Atkinson K, Thomas ED 1981. Recovery of antibody 
production in human post tranplant recipients. Blood 58:360-367.
Witherspoon RP, Matthews D, Storb R, Atkinson K, Cheever M, Deeg HJ, Doney 
K, Kalbfleisch J, Noel D, Prentice R, Sullivan K and Thomas ED 1984a. 
Recovery of in vivo immunity after human marrow grafting. Transplantation 
37:145-150.
Witherspoon RP, Lum LG and Storb R 1984b. Immunologic function after 
human marrow transplantation. Seminars in Hematology 21;2-14
Wong GC, Witeck JS, Temple PA 1985. Human GM-CSF: molecular cloning of 
the complementary DNA and purification of the natural and recombinant 
proteins. Science 1985;228:810-815.
Yeager AM, Kaizer H, Santos GW, Saraj R, Colvin M, Stuart R, Braine P, 
Ambinder R, Burns W, Fuller D, Davis J, Karp J, May W, Rowley S, 
Sensenbrenner L, Voselgang G, Wingard J 1986. Autologous BMT in patients 
with acute nonlymphocytic leukaemia using ex-vivo marrow purging with 4 
hydroperoxycyclophosphamide. N Eng J Med 315:141-146.
Zander AR, Keating M, Dicke K, Dixon D, Pierce S, Jagannath S, Peters L, 
Horwitz, L, Cockerill K, Spitzer G, Vellekoop L, Kantarjian H, Walters R, 
McCredie K and Freireich EJ 1988. A comparison of marrow transplantation 
with chemotherapy for adults with acute leukemia of poor prognosis in first 
complete remission. Jnl Clin Oncol 6:1548-1557.
Zanders ED, Smith CM and Callard RE 1981 A micromethod for the induction 
and assay of specific in vitro antibody responses by human lymphocytes. Jnl 
Immunol Methods 47:332-338.
cQ <dO 0)
cn o>
00 'si 'si "J 03 cn 03 'si 03 03 'si 03 03 03 03 'sicn
CO 00 cn ro 4^ -s| co to ' j ro 4^ 03 00 03 to ro ro
4»>
4^ 4* cn 4^ CO 4* CO 4»> 4>- co cn 4^to
cn CO ■sj —L ro L 00 ro 'si to CO ro cn 4»> 03 CO to
CO ro
03 ro ro ro ro CO CO CO ro ro ro ro ro ro ro COcn
03 CO 4^ cn CD ~1 CO ' j 'si cn ro CO 03 ro
o _ l ro ro _ L _ L __ l _ L _ L _ L _ x _ l _ L ro _ L ro _ L -i03
ro 03 b L l 03 cn ro ro cn 00 03 cn 00 b cn o cn r—►
"si to 4^ CO 00 00 CO -si ro —L CO 03 o o 'si 4^ CO o
ro
o
b
r o - * - r o r o - * - - ‘- i o r o r o - i- i o r o r o - ‘--*-
C O ' s J C n 4 * - * t O ' s l C n - J - ' s J - * - r O - > - ' s | C O
OO
co
OD
4^
OO
oo
O
00
OOro
o
“0
SJm
ro
ro
co
Lj
o
cn
ro
00
CO 03 , ,  (O 00 , ,  N „  00 (O . , .  ^  toco co 4^  ro —
oo to , to . ,—l -vj ^  —l o  oo to *v ic n
O
D
cn
CD
OO
03 ro _ L CO ro ro ro ro CO ro ro ro _ L _ L _ L _ L roro
CO 4 » to to 4v to cn 4l 4 » 03 ro ~L 03 to OO to cn
CO
ki
to -
'J CO ■sj 03 'si
10 13 17 15 16 00 CO to 00 *^ i
cn 03 03 cn cn 03 03 03 cn cn 03 03 03 03 'si cn 03
cn Lj “*• oo 00 CO 'si CO 4 ^ 03 43» “L 03 CO co ~L
o o o o o o o O o O O O o O o o o
b Ll L l ro L l ro L l L l ro 00 ro ro L l ro L l L l L l
'si oo — *■ ro ro 03 —L cn cn —1 CO cn CO o ro 4 ^ —*■
oo . 
4>. ro
co
coo  :
*vi to
. to to ^  
CD ^
' >s i -«-oocn- t^oo-^oi . (^coai^aioo
N j O O ^ N l M M O O ^ U O t D O l C O U
t0'vl__i r 0 t 0 0 0 t 0 o t 0 ^ 4;ktD_i t0'vJ
OO
CO
oD
4*.
oD
00
oW o
°  00 
o
O
ro
o
O
D
cn
CD
O
D
co
I
CD
<D
7s(/>
AML 
regeneration 
data
W  CDO 0) 3
00 CO
CO ro 4 s 4 s CO CO CO 4 s ro ro ro CO CO ro ro 4 s
ro ho CO O) “ 11 "si 00 "sj CO CO cn ~ L ~ L cn CO ro
CO ro
o ro ro ro ro
_L ro ro ro . ro
o > 4 s
"si L "4 cn 4 s cn cn "4 L CO cn 4 s cn CO —L
45s CO CO CO CO CO 4 s CO 4 s 4 s 4 s CO CO CO CO CO CO
CO
CO 00 "4 4 s
"J CO CO co 4 S 4 s cn 00 CO "si CO cn
o o O O o o o o o O o o o o o o o
Ll cn 45s CJ> 4 s 4 s cn b cn CO 4 s cn L j '" 4 4 S 4 s cn
ro 45s cn ro o> cn cn 4 S "4 CO "si o CO " J co 00
4 s 00 ro ro ro ro _L
ro ho "*4 00 cn 4 s cn - L 00 cn CO cn "si "4 cn cn
oo
co
Oo
4s
oD
oo
-i O 
ED O  
- -  -ts
°  00
O
Oroo
T3”T
CD
73
CDt
ro
CO
rocn 
cn ro
r °  5°
4s 00
cn -vi
Nl CD 03 CDro co V J C D C O ^ O ^ C O ^
C D O O O O .  . O ) C D ,  n s JC D  00ro cn co o  ro —*■
O
D
cn
cn
OO
cn ro 
b> !°
co cn
- ^ c o r o r o r o r o r o r o r o r o - j - - i - * - -^ r oc o o ) ^ r o o i N j ( D O > M - ^ c n o ) 0 ) o o - ^
O
D
co
CO
ro 
ro co
P s j -vj 00 CD S j^ c o  -s cnco4scn4s io
O
O
4s
co cn 
•-M P
CO "si
0 ) 0 1 0 > 0 ) 0 ) C D O > 0 1 0 ) 0 ) 0 ) 0 ) N | 0 > 0 )
- ‘• o o c o - » - c o " s j - ‘- c o c n 4 s c n o o c o c o 4 s
o o O O 0 0 0 0 0 0 0 O 0 0 0 0 0 ED
b
cn "sj ” *■
ho
10 - 00 m!
ho
4S
ho ho
4s
ho
CO
ho
ro ro 00 ro - "4
r*+*
0
4s
SsJ , , . ro _L , ro 10■sj
cn ro "si “ *• 00 cn 4s 00 cn 4s CO cn CO 4s *s|
CO
L j
4s
4s
Ol "4 cn 0
CO
1
7
1 
2 IO 00 CO cn 0 CO CO 00 cn
ro CO
CO
^4
CO
CO "4
- 10
CO 00 CO 0 CO "si 4s CO 4S 0 00
o
o
oo
O
00
O
D
ro
o
O
O
cn
cn
O
O
co
■
4s
€
CD
CD
7s</>
AML 
regeneration 
data
3.75 
3.23 
3.73 
0.1 
3.92 
3.35 
2.75 
3.93 
3.09 
5 
0.17 
2.34 
2.76 
3.04
CO O D  0) 
3
O
CO
^CO-^-^CO^COCO^-CO^^- I^CO-^-
M < o o o ^ r o c o M O ) c o r o s ^ c » o
O
o
co
co a i c o c o o o o c o - j - c o ^ i o i r o o o o j ^ c o
O
O
-r>.
■u
ro ^4^C0-^4^- t^- l ^4^4^CO4^-^-UaiCOr O I \ 3 ( D C O a O O « ^ C O I O ^ M - i N j
o
o
00
-uai
ro
co
ro
'•vi
o o o o o o o o o o o o o o o
c o c n a i ^ > c o ^ a i ^ c o b > b i ^ c o r o a i
o > a i c o i \ o c o o o c o ^ c o - t ^ r o ■&> "si
- ^ r o r o - ^ - ^ r o - ^ - ^ - ^ r o r o r o r o - ^ i N O
o a i c o c o c o ^ o o c o a i - t ^ a i - ^ r o c o a i
oo coC O O O D U s l O l  U oo co .O  -t*. CD
-I o
W D  
- .
°  Bo 
o
D
ro
o
O
O
a icr>
oo
£
CD
CD
PC
V)
ro
a i ro
CO—*■00 00 CO A  ^  CO (Jl o  o
O
O
ro
C 0 ^ ^ C 0 C 0 4 ^ 4 ^ C 0 C 0 C 0 ^ 4 ^ . ^ - ^ a i
o o - * - r o o o ' « j i o - i o o c o o > - * . o o ^ c o o
O
o
co
roco - ‘■ r o r o r o r o r o - ‘- r o r o r o r o r o r o r o r oo j i - i r o c o c o c o o j - A - ^ M N j o i o o i
CO
cd
ro
C O C O - ^ C O I O ^ C O C O C O C O C O C O ^ C O C O
'Nj 'Ni -^ooo>o)-L roco 's ia i co-* -co-^
oCJ
00
o  o o o o - * - o o o o o o o o o o
b> a i b > a i a i ^ b i b > b o a i a i k r b > b ) * N i b o■vi - ^ o i - ^ o o i o o - ^ - ^ ^ nj n j co - ^ co-j-
O S O O l - ^ O l O C O C O N j O O C O C O O l O i C D"si
ro
CD
o>
CO CO CO l O O l N j O l N l l O O l O l ^ CD
a> oo c o CDc j > r o c n t D - i- o r o
O
o
ro
o
O
O
a icr>
O
O
ro
00 _x
CD
S
CD
CD
7T
<0
AML 
regeneration 
data
w CD O 0) 
3
CO
05 ■c^ cn cn 4^ cn cn ■p* 4^ -Ps -P» 4^CO
00 Lj L IO L CO ■pv 00 05 00 L 05
4^ IO
■sj CO CO IO IO IO CO CO IO IO IO IO IO IO IO COCO
05 00
—L IO •'vl •Ps 'si 'si CO cn CO 00
cn CO
CO CO CO CO IO CO CO IO IO CO CO ro ro CO COCO
CO cn 05 IO 05 CO ~sl CO 05 "s| CO CD CD —L 'si
o o O o o O o O o o _L o o _L o o
b oo b b b b b b b o Lj b b b b b
05 05 cn CO 05 CO •p* CO IO o 05 -ps CO
CO IO co IO IO IO IO IO IOCO
CD CO cn 'si CO o 05 ~L cn ro —*■ CO 05 cn 05 o
ro -
CO COio
CO Lj CO
'si o CO IO cn ro CO IO 4^ o IO
CO
o
4^ b CO IO 'si IO
00 ■p* 05 - cn
'si IO CO CO 00 -
oo
co
O
O
4^
O
O
oo
O05 o
zr. ji. 
°  Ho
o
o
ro
o
0  
D
01 cn
OO
IO
COo
£
CD
CD
*■
(/>
cn cn
b  F>
05 's i
O l O l O l O l ' s l O l O l O l O l O l O l O l O l O l C n
- ^ - ‘■ c o c o o - ^ ' s i j ^ ro ro - t i . oo c o r oc o
O
O
co
Ol co 
L*. ^  
00
C O C O C O C O O lC O C O C O -I^ C O C O C O C O C O C O
o o - ^ o i o - ^ ^ M ^ o r o c o o i o o o o o i
o
o
4^
CO o> oo 
ro
C O ^ C O C O C O C O C O I O C O C O - ^ ^ O l ^ C O0 ) O - ^ 0 0 s | O - U ( 0 ( D 0 0 ^ 0 ) - i | O 0 0
o
o
00
o
CD
's i .
co co
CD .-*•
bo r-J
's i CO
r " ?  J ? r t rl r l - k rA rA ? ? ? 0 0b ' s i ’- * - b c o ^ - b ^ - ^ - b :s j k i :s j b b
C D O O C O O lO O C O C O 's lO O C O O lC D O lO r O
- ^ r o - t r o - ^ - j- r o r o r o - * - - ^ - j- r o - ^ - ^
' s l C 0 C O O > C O 'v J C O ^ . - * - C O O 5 O ) C O 0 0 's l
O  CO co ro cn co co ro o  ro cn co o
oo co co -*■ ro roc o i o o c o c o w o i c n c n N j ^ - ^ ^
-« O  05 ozr. .p*
o  ~  oo
O
D
io
o
O
O
cn
CD
O
O
co
o>
io
£
CD
CD7?
</>
AML 
regeneration 
data
5.26 
3.58 
4.05 
0.31 
5.1 
2.4 
5.69
r9 °O D) 3
CD
o CD Ol CD Ol CD Ol CD CD CD CD CD CD CD CD CD
b> 00 ■"si CO CO IO 4k 00 CO o 00 CD CO 4k CD
4k4k 4k 4k 4k 00 4k 00 4^ 4*. 4k 4k 4k 4k 4k 4k 4k
00 CD CD 4k CO 00 "4 co 4k •Nl 00 CD —L CD 4k o
roOl 00 IO IO IO ro IO ro IO ro ro ro IO ro ro 00
CO
_L 00 00 •Nl "vj IO ~L ro 4*. ro 4k CD oo 00 CD
_L _L ro _L _L _L _L IO ro _L ro _L _L _k _L ”1Oi
kl 4k b CD 4k Lj CD 00 o b Ll b b b b Ll
Ol 00 o 'vj 4k 00 00 00 o CD 00 ro 4k 4k •kj —*■ o’
CO
4*
ro
oo
ai
oo
corooocoNi (DO>sjco<D- ‘ ' « j ^ c o r o
oo ro cn oo ro ro _L 00 oo ro 4k oo o  oo o>
oo -*•o o o o o o o o - ^ o i N j r o o o N j r o oo
OO
oo
Oa
4k
oo
oo
oo
O
D
roo
OO
aiCD
o
o
cnio
€<D<DJ*T(/>
AML 
regeneration 
data
O  (D 0) 3 3o
o> o> CD cn CD 's i CD CD
CO o> -si CO CO "si ro 4k
b
4k 4k 4k 4k 4k 4k CO
© -k 4k OO ''I CO CO
CO Li
CO IO ro CO CO CO ro ro
© 00 CD -k -k 's i
00 b
. . .
o m m■ O l cn cn 00 CD■ A cn 00 ro cn ro — L COCO 00
cn IO ro _ L ro ro ro
L i 7 * 4k __l co " i cn -k
4k ro
ro _ jl. .
O) o CO 00 CO 4k ro 00
o> L i
CO _ x
COo ro 4k •vl 4k _ L o
Ooco
oo
4k
o
Doo
O
D4k
oo
O
Droo
O
Oaicn
O
O
UT
(D
io cn
4k
b
to
CD
29 25 ro
4k
CO
4k
ro
CD
ro
ro
*sl Li
CO
o ro 4k o CO cn 4k
O) ro
4k
b
CD
ro CD
6
3
6
7 CD
CO
54 66
CO b
o O o o o o o
o
CD
©
IO
io
CO
_L _L
cn
io io00 io
ro _L
b
ro cn 4k 4k -k o -k
■sj In
CO —L
CO
b CO 's i ro ro 00 4k
CO Li
b CO ro CO
00 CD —1.o CO
OO
CO
OO4k
oooo
O
D4k
00
o
Oroo
0  
D01 
CD
Oo
CO
€<D
CD7T(/>
oo cn
ALL 
regeneration 
data
g  £O  (D 0) 3
00 CO CO CO CO IO ro
00 -*■ v i 00 ->4 co CO
Ol io
_L
_JL o> cn v | cn cn o> CO
b> io
CO o> cn cn cnoo Ol CO ro ro —»■ o 00
b> ro
o o o o o o o o• 00 io io io COo 00 00 v l CO cn ro oo> IO
00 cn cn -Pw cn cn 00 a >Lj
-a. . . . .
IO oo co CO V I CO
00
CO _L
00 o 00 ro cn cn CO CO
ooco
oD-t*.
O
Doo
O
O
00
Oaroo
O
Ucno>
O
O
5
<DCD
77to
co cn
ro IO ro ro ro ro ro ro
L i cn ro cn v i CO cn ro
CO ro
IO _x _L _L ro
io V | cn CO cn oo o
CO io
CO O) cn cn cn cn cn cn
la . ro -*• CO v l —»■co 05
CO 00
o o o o o o o o
■ ■ io 00 io 00 io 00o IO cn o o 4^ oCO v l
ro _L _ L
4 * v i 00 —*■ cn 4^
00 00
CO
00
ro co v j ro ro 00 CO
"4 00
_a.
CO CO ro CO 00 CO o co
OOco
OO
OOoo
O
U
oo
O
Oroo
O
Ocncn
O
D
o>
$
CD
CD
77to
oo cn
ALL 
regeneration 
data
8  s  D  (DD>
4k CO 4k CO 4k CO CO 4k
Lj CO O ro 00 ro CD
Ol io
-L _JL _ L
o -v l 00 CD •vj 00 CO -vl
Ol cn
4k 4k ■tv 4k 4k 4kro 4k CO 00 4k ro CO 4k
-*■ 4k
o O o O o O O
O 4k CO CO 4k 4k COo
4k 4k ro CO CO CO 4k CO
ro _ Lro _ l CO co 4k 00 CO cn
b CO
CO mJL. 00
4k ro CO -vl cn CO CO
O l cn
CO _i. .
CO CO
CO _jl ro —*• CO 00
ODco
O
OOCD
O
D4k
oo
OOroo
O001cn
O
U
oo
S
CD
CD
?r0)
cn ro
CO CO CO 4^ 4k CO CO
b CO 00 -vl ro 00 CO
4^ io
_i. ro ro ro ro _L ro ro
CO ro ro CO CO ro -*•
00 b i
-vl CO CO ro 4k CO CO CO
o cn oo CD CD -*■ ro CO
CO CO
o o o o O o o o
• • cn 00 Ol CD CD b io> oo cn O _L CO 4kCO CO
CO ro ro
b 00 -*■ cn 05 CO CO -vl
00 b i
ro _i. _L
b i CO -A —A ro cn -vl cn
b i
CO _L
b o
CD oo CO CO Ol
Ouco
O
D4k
O
Doo
O
O4k
oo
O
Oro
o
O
001
CD
O
O
ro
€<D
CDPT</>
ro oi
ALL 
regeneration 
data
O  CD Q) 3
4k Ol 4k Ol 4k 4k CD
b>
v |
vl
bo
_L CO •vl 4k
CO IO ro ro CO IO IO ro
00
CO
4k
b i
IO 4k v| IO
a CO ro CO 4k CO 4k CO
b>
cn
o>
Li
CO CO v| 42k O
o o o O O O o
© vi CD CD V l Ol Lj
_jl o>00 CD IO CD CO CO
4k _L IO IO _L- _L IO
CO
4k
mX
CO
CO CD CD IO
IO _ L
CO
-J k
4k
mX
00
o CO IO CD ro
IO _L 00
CO IO ro 4k CD -*• CD
oDco
OO4k
oo
CXI
O
a4k
oo
O
Oro
o
O
Ocna>
OO
oo
€
<D
CDPT
(/)
4k -vl
CO CD CD CD CD CD CD CD
CO
v |
O
io
CO 4k v l 4k IO
4^ CO CO CO CO CO IO 4k
CO
ro
CD
b i
CD v l 4k v | OO
4k CO CO 4k CO CO IO CO
o
v |
CD
00
00 O CD 4k CD CO
o o O O O - O
• • CO b b o b boCD
CO
CO CD CO v l CO Vl CD
4k ro IO IO IO IO
00
4k
o
L i
CD CO v l CO 4k
-a. —1. CO
b
v |
ro
CO
CO ro CD CO ro
CD mX CO
4k Vl o CO 00 CO CD CD
OO
CO
OD4k
ODoo
O
O
4k
00
oOro
o
Oacn
CD
O
D
coo>
£
(D
CD
pc</)
cn
ALL 
regeneration 
data
g  2O (D fi) 3
o> Ol oi OI oi <31 Ol
coCO CO
CO IO -P^ CO CO
■U CO ■u CO ■u -f*.
co
00
4
4 CO 00 ^1 CO
IO NO IO IO IO IO IO IO
b> CO
00
^1 -si IO IO
-X ro IO -L
© bo L j b CO b bCO 00 00 CO o Ol
ro IO IO IO _L _L
cn 00
CO -s| CO 05 ■"4 CO
_x
00
00
-4
_x
Ol
CO ro IO CO
cn -X _L IO
_X
CO
cn
Lj
CO O) ~L Ol •Nl IO
ooco
Oa
oa
00
O
O
oo
ODroo
O
Daia>
O
D
oiro
3=<Da>7Tto
ALL 
regeneration 
data
O (D fi) 3 3<D
00 o>
b  !°
o  o>
v J O > 0 > O l O > > J O l O > O l O l O l J i ( J > 0 ) M O > 0 )
4 k C O v l O > - ‘> C O C O C D v l 4 k 4 k O > v j c O v | | \ 3 C O
o
D
00
O l 4k O l 4k 4k 4k 4k 4k 4k 4k CO CO 4k CO 4k CO 4k 4k 4k
b
o>
NO
L i
cn 0 0 IO __ L ro CO O CO v | CO ro CO ■vl co O l IO
NO _ L ro ro IO IO CO IO ro ro ro ro ro ro CO CO ro IO
4^
o>
NO
CO 4k CO co CO O ro V| CO O l 05 CO CO v l
ro r ° _ L _L _L _L _L -X _ L _ L _ L _ L - X - X _ L _ L ro
O b00
b b 4k 4k 4k 05 0 0 bi b CO b ro 4k L l cn b b
4k cn o cn ~L O l CO ro CO O) 0 0 ■vl L IO 0 0 v j o
4k NO IO ro ro IO IO ro ro ro ro ro
O l O 4k CO -* cn •vl 4k 4k Vj CO Vl O l 4k -*• co v l O l - 1-
CO 00
to -»■
io ?  vj to
4k -»■
■ to  00 . 
Ol 4k
- Vl ^ « O ° 0 , , C D 0 0 ^  . ^ o o4k —1L IO  O  IO  CO O  4k O
c n c o o i—*■ ro —*■ si -t^  - 1 o
O
D
-u
Oa
00
°  5D 5-fv m—.
00
I so o
O
0
cn01
Oa
to 
Ol o>
CO CO 
CO CO
b  b)
4k cn
o> o> ro
bi co
o  o  
o  Ll 
o> cn
co -*■
■ o> 00 .
■u CO
CO
• CO CO . O) Ol
O)
to to
CO ro ro IO CO ro IO ro _x CO IO IO CO ro CO ro _L
05 o cn CO — L ro v l 4 k CO v l 4 k CO CO 4 k 4 k 05 Vl
00 05 v l v l v l 4 k CO v l OlIO _L v l 4 k ro CO ro CO
V| v l Ol 05 Ol 05 05 05 05 Ol Ol 05 05 05 Ol Ol 05
00 CO 4 k CO v l CO CO CO “ *■ 00 CO ~ *■ 05 v l CO CD 05
O o O o o o O o o O O o O o o o O
Ll Ll io io Ll io Lx - X . Ll io Ll io b Ll io Ll b
Ol o Ol —L ro — *■ CO “ *■ IO ro o 05 CO Ol ro 00
- r
— L IO IO — L — L - X _ l ro — L — L — L ro — L — L — L —X — L 03
cn — >■ ro Ol Ol v | 4 k ro Vl — L 00 Ol 4 k Ol —*■ 00 05 r t *
CD 00 COa>cn~o co - ‘-cn 'Nio>o coGo-‘-'vi4^
CnOO^CO^COCOvlCDvl CO 00 00 CO
oa
CO
o
D
4k
o
D
00
O w 
a .4k 
00 *
8 ®  O <D
roo  W
o
D
cn
CD
o
D
NHL 
regeneration 
data
8  2  O  CD
D>
3
o> CO 
>4 4*
u c o c o r o c o r o c o r o ^ ^ i o c o c o ^ r o t o-sJ_L^.45k,ji.CO-^COO)-^<D^-*-COCOCO
O
o
CO
o> CO
CO ro ro —*■ ro -*■ ro ro io ro —*• roco ro • v i - ^ v io i - ^ r o o io o c n
O
O
P P
co b>
©  ©  
-»■ -ni
bi P
0 0  CO
CO -»>
co r1
CO 4 *
ro co
bi co oo oo
C0.^C0C0^-^C0C04k.C0C04>.C0.^-^.|^- ‘ CO0COOO-iCOM-‘ N jC O Q C O ^ ^ O l
o o o o o o o o o o o o o o o o
4 ^ 1 - L 4 ^ b ) ^ ^ b i 4 ^ b i 4 ^ o o ^ b i b i - ^ b i
O l O O C O N i i > - i ^ O ) - i O ) C O ( D O ) > J - A 0 )
ro ro -*■ -*• ro ro ro
io oi oi ^ . r o ^ - j - o o o i ^ c n - j - o o o )
CO
'vl ^ ro o  ro S  CO 00 CD CO —i. ' v l  CO
CO 00 CO Ol -Vl _  CO CD 03 k . O) COo  —l ro cn co
O
a
oo
O  o>
D  S 
"v CD 
00 CD
i g "O O
0a
01 
CD
O
O
4 * CO
' O) O) •
O) 00
^ C O C O ^ C O ^ C O U ^ C O C O ^ U I O ^-j.vv| ^ ^ v N| _ L _ x ( o o c o - ^ o c o c o r o
oa
CO
CO -L
bi p
CO CO
- ‘■ r o - i r o r o - ‘- - ‘- r o - ‘- - ‘- - ‘- - ‘- r o - * - r o
C D - ‘- U l - ‘- - ‘- C D U lC O C O 'v J C 0 C O 4 > - 'v I 'v l
O
D
4^
4*
• ro o> •
O) 00
4*
O
cn ro
• COo  .
CO -»■
ro
Li
cn
co
co - l
• CO 4* . 
4^  -»■
c o o o r o c o r o ' v i i 0 4 ^ c o c o o o i o o c o < D
o o o o o o o o o o o o o o o
0 34^004^014^000)4^^0 )4^0 )4^01
O ^ C n C D O C O C D O O C D O O O C n O O C O
- ‘■ r o - ^ r o r o r o - ^ r o r o - ^ - ' - r o r o r o - ^
0 O ) s I J i v J C O O > O l C O C D C O O O O O N i a i
ro _ L  0 0 ^CO^COOIOOCONOl-^CO CO
00 00 COsi cooooi M ^ r o w - ^ c j a i o D
oa
00
O  00 
°  s:
\  CD 00 CD
O WD3 O
o ' w  °  O
o
0
01 
CD
O
D
NHL 
regeneration 
data
C/> 2  a ro ro
Ol CO
*  ® cn cn
4^COC04^C04^CO-UCOCOC04^^COCO
- ‘■ a i ' N i o o c o o o o o - ' - c n c o v i r o t o - ' - c o
oD
CO
.U IO
b  5"a> 10
W W M M - H O M I O M - I I O I O I O M I V )00O>COv|vJ-»-CO.t».-*00CO-^00O>Vl
oD
cn 4^
_LOl . 
CO 0>
o  o
'-*■ o>o> IO
CO -»■CD IO . "J Vl
■>1 .00
C0-U-^C0aiC0C0C04^-I^C04^C0-^4^
C O ( O C O N j r O C O N jN l - iQ C O C 3 > - i IO C O
o o o o o o o o o o o o o o o
k i a i a r k i c o k i ^ b b i i ^ k i b i b b b i
r o c o c o c o c o c o o o o i - ^ r o j ^ r o o i o a i
- ‘• r o - « - r o r o i o - ‘' - j- - i i o r o - * - - ‘- r o r o
o o o a i o - ^ r o o o c n o i - ' - O ' N i c o c o ^
CD CDro -^ roco - j - - j -  co IO  U l IO  O l
~ L i O ”J , —L — l ~ l c d o > t c o i o r o i o - ^ — —•■co
Oa
00
o
o IO
■
00 _L
—1 O Oi
p+ D %
IO roO o ro
PC
O ro
oio>
O
D
io •** 
vi o
C O C O C O C O C O ^ - ^ C O C O - ^ C O ^ O l O l
s i c o ^ ^ - ^ c o - i ^ ^ ^ o i o o o ) - *
oD
CO
£» IO
io r 1vl o>
l o i o r o i o r o r o c o c o i o c o i o c o i o r o
N i ^ N j - i o i c o o o - ^ i o o r o - A O O N i
OD
■fc.
o> CO
: * «  CO £*
c o ^ - ^ c o c o c o c o c o r o c o - u c o i o i o
n| - a O ) ^ nICO^IOO)CD nI ^ 0 O >
o
D
00
o
o
oo bo
O) CD 
CD
IO -»■
CO . cn cd
CO -»■* 4*Oi mCO -±
0 0 0 0 0 0 ^ 0 0 0 0 0 0 - ^
’■ N i b i b i b b b ^ - b b o k i b i c o c o bc o c D r o r o o o o o M s i o i s i o i ^ s ^
c o - ‘- - ‘- - ‘ i o - ‘- - » - i o c o i o i o - * - - ‘- i o
O S ^ ^ O O l M C O O O J ^ O l M - i
CD v l  CDco ^ ^ - ^ - P ^ c o  o c o  rocnro
o o o > o > ^ 0 0 c o r o v i i o 0 0 .&>o>-‘-u i
D ■u
-P>> ■
00 CO
—t O o
ror+ O £
IO roo o ro
or
O  w
cno>
O
D
NHL 
regeneration 
data
8  2  O  (D0)
3
05 Ol 4k 4k Ol OI Ol Ol Ol 05 •vl OI Ol Ol Ol
o
05 CO CO 05 00 v i —X CO 05 o CO v l 4k V l
00 b
o > CO CO CO CO CO 4k CO ro 4 * . Ol 4k CO CO 4k
i o
00 05 ■vl 00 O CO CO -v l - X O 00 4k 05
b
Ol CO CO 4k CO CO CO 4k CO CO CO IO CO IO CO
b 4k 05 - X 05 v l o - X 00 -Vl Ol 4k CO -*■
00 O l
o
o O - X - L - L o o - L — L - L — L - L — L
• CD v | Ll o b CD CD r o GO b Ll Ll 4^>IO
CO O l ~ L
00 CO 05 00 00 4k 4k 00 o IO Vl 00
4 k —X ro ro ro ro IO ro IO
L a C O oo -vl ro -vl CO CO 05 CO V l CO 4k -*•
_ L b
_ L _ l _ L
CO r o CO 4k - X o CO - L CO ro Ol CO IO IO
00 CO
v l IO _ j . ro ro /vs _ L CO CO _ L _ L _ L _L _ L
v l _ l oo 00 05 -X CO ro o CO oo CO 05 -x
CD CO
oo
co
Oo
4k
oo
oo
O  W  
D ®4k i 
®  4k
S 8 s—■ ro <d o o  $
7T0  «
D
01 
05
O
O
05 05 Ol Ol 4k 05 Ol 05 Ol 05 Ol 05 05 V I
b o
-A
v l CO CO CO V l CD CO ro 4k _L CO 4k
00 4k 4k 4k CO 4k CO Ol IO Ol 4k 4k 4k Ol
io
CO b
v l CO 05 00 O CO IO 4k 05 00
Ol IO IO CO CO IO CO CO IO IO IO IO
b
05
4k
b
05 4k _ _ L 4k V I IO 4k Ol
o _L
ro ro -L -L -L -L —L -L -*■ ro -k ro
b
O l
b b b 4k Ol b v l b b L l b b
00
4k 4k o 00 00 “ *■ “A Ol ~~L o ro IO
4^ ro IO IO ro ro IO _4.
b4k
o o 00 CO co IO 00 CO V l CO 05 v l CO
_L
00
k j
00
_L
b
o CO CO IO Ol CO IO ro CO
v | —L
00
—1 . CO CO __k _ _ L -u. _ _ L IO _L _ _ L
b V l CO IO o CO 00 CO 05 -*• Ol V l IO
OD
CO
OD
4k
OO
oo
O <* 
O M
§  £ 00 (D
- o f tw D (/>
o 8
O
0
01 
05
O
O
00 CO
NHL 
regeneration 
data
HD regeneration data
lean
SD
PRE
CD 3 CD 4 CD 8 CD4/8 CD20 CD 56 CD 14 
rat io
67 45 36 1.25 25 13 15
62 35 29 1.21 19 12 17
54 30 29 1.03 23 17 19
69 41 27 1.52 22 16 9
74 45 30 1.50 18 1 1 18
67 41 29 1.41 22 9 1 1
53 37 21 1.76 21 8 10
62 45 27 1.67 25 12 1 1
77 49 31 1.58 27 14 14
69 37 33 1.12 19 10 17
47 20 29 0.69 1 1 8 14
46 31 26 1.19 24 9 9
54 42 25 1.68 25 13 1 1
54 39 21 1.86 1 7 8 9
57 37 23 1.61 23 9 8
63 43 27 1.59 1 7 7 7
59 40 22 1.82 14 12 12
73 46 30 1.53 24 10 9
61 39 29 1.34 1 7 12 1 1
56 41 29 1.41 26 1 1 26
67 42 29 1.45 21 7 19
63 48 24 2.00 19 14 15
74 56 19 2.95 24 1 1 8
51 38 26 1.46 24 13 25
57 37 36 1.03 14 8 17
46 30 39 0.77 25 7 1 1
45 29 44 0.66 21 8 1 1
47 37 30 1.23 19 9 12
72 51 21 2.43 21 1 1 14
62 41 1 9 2.16 23 13 7
69 46 27 1.70 19 14 14
56 39 24 1.63 21 1 1 7
43 27 29 0.93 18 12 14
49 39 27 1.44 19 13 20
57 38 26 1.46 21 14 14
59 41 24 1.71 19 9 18
63 40 27 1.48 18 19 9
68 43 22 1.95 21 27 12
74 55 29 1.90 23 1 1 10
79 52 24 2.17 22 13 1 1
47 28 41 0.68 17 8 14
48 29 28 1.04 19 1 1 19
61 39 27 1.44 17 12 12
60 40 28 1.5 20.6 11.5 13.3
9.8 7.5 5.4 0.46 3.48 3.65 4.55
3 - 4  weeks
CD 3 CD 4 CD 8 CD4/8 CD 20 CD 56CD 14
23 8 57
ratio
0.14 15 14 6
17 7 61 0.11 25 13 1 4
1 9 5 66 0.08 17 14 1 1
24 12 77 0.16 1 7 1 6 9
19 6 74 0.08 25 1 8 1 1
21 14 64 0.22 1 9 13 7
1 7 5 66 0.08 1 6 14 9
26 7 59 0.12 18 1 7 1 0
34 13 53 0.25 1 1 1 1 8
24 9 67 0.13 15 13 8
33 4 66 0.06 14 1 9 9
29 16 61 0.26 25 9 1 1
24 7 59 0.12 1 8 1 0 1 1
37 13 58 0.22 1 1 1 6 7
19 7 61 0.11 1 7 1 7 9
24 12 63 0.19 22 15 7
27 7 63 0.11 1 4 1 1 9
22 14 63 0.22 17 13 9
31 6 57 0.11 15 8 1 1
29 17 69 0.25 15 9 9
26 1 1 54 0.20 22 1 7 1 2
20 8 73 0.11 21 15 8
36 12 78 0.15 1 6 1 6 6
31 19 58 0.33 14 1 1 8
18 9 74 0.12 21 14 8
25 7 56 0.13 15 9 14
28 14 61 0.23 1 8 7 1 1
24 5 73 0.07 1 9 1 6 7
17 8 61 0.13 12 1 8 9
23 1 1 61 0.18 21 16 7
19 9 67 0.13 17 15 8
26 12 61 0.20 1 6 14 9
24 7 64 0.11 13 1 1 12
37 1 1 65 0.17 12 8 1 1
39 17 61 0.28 1 7 12 7
27 14 63 0.22 1 6 1 0 9
31 1 7 61 0.28 1 9 1 6 1 0
26 10 64 0.16 17.2 13.4 9.22
6.1 4 6.2 0.07 3.7 3.2 2
HD regeneration data
6 weeks 8 weeks
CD 3 CD 4 CD 8 CD4/8 CD20CD56CD14 CD 3 CD 4 CD 8 CD4/8 CD 20CD 56 CD14 
ratio ratio
39 14 39 0.36 15 14 8 39 17 37 0.46 26 1 1 12
19 19 39 0.49 25 13 1 1 31 12 51 0.24 1 7 13 1 1
24 11 37 0.30 17 14 9 42 14 47 0.30 25 8 15
33 12 31 0.39 17 16 7 42 15 44 0.34 28 9 13
31 19 30 0.63 25 8 12 39 19 42 0.45 25 8 16
24 19 33 0.58 19 13 10 37 25 39 0.64 35 1 1 14
23 25 45 0.56 16 19 13 42 17 44 0.39 15 9 9
29 16 44 0.36 18 17 9 29 17 43 0.40 27 13 18
43 25 44 0.57 21 1 1 6 33 21 40 0.53 28 1 1 15
31 25 39 0.64 15 13 15 40 19 40 0.48 28 15 13
34 23 43 0.53 14 9 12 31 15 48 0.31 19 17 1 1
29 15 33 0.45 25 8 8 33 1 7 43 0.40 1 9 13 1 2
41 17 37 0.46 18 9 8 40 19 39 0.49 29 1 8 1 2
46 21 32 0.66 1 1 7 9 39 13 34 0.38 25 16 1 1
23 17 37 0.46 17 12 1 1 31 15 42 0.36 1 6 13 1 7
31 21 39 0.54 22 10 10 41 16 37 0.43 28 14 8
29 17 41 0.41 14 12 1 1 37 21 42 0.50 27 13 15
34 21 48 0.44 7 11 7 44 21 43 0.49 24 1 4 1 8
24 22 33 0.67 15 7 5 34 15 42 0.36 17 8 13
34 19 39 0.49 15 14 9 37 21 48 0.44 26 1 1 8
31 9 49 0.18 22 1 1 8 41 16 53 0.30 1 9 12 17
37 14 31 0.45 21 13 9 36 15 58 0.26 25 10 12
19 13 45 0.29 16 8 17 42 17 54 0.31 16 1 1 15
28 20 44 0.45 24 17 10 38 20 51 0.39 28 13 17
41 21 47 0.45 21 9 12 34 19 43 0.44 17 9 1 1
40 22 39 0.56 15 8 10 43 18 39 0.46 26 12 13
24 19 43 0.44 18 1 1 8 30 17 39 0.44 19 14 1 8
27 14 33 0.42 19 13 8 34 19 36 0.53 24 13 9
20 13 32 0.41 12 14 14 37 19 41 0.46 1 6 13 1 6
31 20 38 0.53 21 1 1 1 1 31 22 45 0.49 16 1 1 14
28 15 36 0.42 17 12 12 30 23 38 0.61 13 1 0 1 0
26 22 35 0.63 16 13 14 42 21 39 0.54 25 1 1 13
24 16 41 0.39 13 12 12 37 19 41 0.46 26 12 12
34 27 31 0.87 12 15 1 1 35 24 47 0.51 28 10 14
45 1 6 38 0.42 17 13 9 43 21 40 0.53 24 1 1 8
29 1 9 45 0.42 21 14 9 29 1 9 43 0.44 1 9 8 13
38 25 36 0.69 17 12 8
/lean 31 18 39 0.49 17.5 12 10.1 37 18 43 0.43 22.9 11.8 13.1
SD 7.2 4.4 5.3 0.13 4.13 2.89 2.55 4.6 3 5.4 0.09 5.26 2.48 2.91
HD regeneration data
1 2 - 1 6  weeks 24 - 30 weeks
CD 3 CD 4 CD 8 CD4/8 CD 20CD 56 CD ,14 
ratio
34 27 34 0.79 25 14 8
37 16 39 0.41 15 13 10
40 19 41 0.46 16 17 1 1
43 24 39 0.62 18 14 9
41 25 38 0.66 19 13 5
36 19 43 0.44 18 17 8
39 21 49 0.43 24 15 6
31 26 42 0.62 23 12 9
29 19 31 0.61 19 15 13
42 18 46 0.39 17 12 1 1
37 29 39 0.74 20 1 1 8
39 18 43 0.42 21 1 1 6
35 21 41 0.51 15 13 17
41 24 37 0.65 16 9 1 1
38 19 37 0.51 1 8 9 14
41 1 9 39 0.49 22 1 1 12
33 17 41 0.41 21 1 1 12
48 18 37 0.49 20 13 22
37 1 8 43 0.42 15 12 13
35 26 49 0.53 26 1 1 1 1
41 1 7 39 0.44 18 12 1 7
30 13 37 0.35 21 14 6
35 1 6 37 0.43 22 14 9
43 22 39 0.56 1 7 14 8
32 1 9 56 0.34 25 14 10
47 17 34 0.50 21 12 1 0
41 1 9 39 0.49 15 13 12
37 1 6 37 0.43 16 1 1 13
39 22 42 0.52 13 13 6
36 19 41 0.46 18 13 5
42 21 47 0.45 19 9 14
58 17 37 0.46 16 15 17
36 19 44 0.43 15 14 12
40 22 42 0.52 16 15 13
CD 3 CD 4 CD 8 CD4/8 CD 20CD 56CD 14 
ratio
43 27 37 0.73 20 12 1 1
32 24 31 0.77 21 1 0 8
40 25 26 0.96 16 9 9
39 29 29 1.00 15 14 9
38 27 39 0.69 26 1 2 1 2
35 21 37 0.57 1 9 13 7
51 27 26 1.04 21 1 2 15
34 24 29 0.83 12 15 1 1
48 31 34 0.91 15 12 1 6
35 22 47 0.47 21 9 14
41 21 39 0.54 26 13 8
34 22 26 0.85 30 10 1 2
37 31 32 0.97 23 7 17
41 38 34 1.12 17 13 1 2
43 29 33 0.88 15 14 13
31 17 37 0.46 26 1 1 8
34 21 34 0.62 14 14 21
34 27 46 0.59 1 1 14 1 6
38 24 41 0.59 1 7 9 1 6
37 27 37 0.73 30 13 1 8
42 26 31 0.84 20 13 14
43 21 30 0.70 1 7 1 2 9
35 31 46 0.67 23 13 1 6
36 32 37 0.86 13 1 2 8
42 29 36 0.81 21 14 12
38 32 37 0.86 25 1 2 11
43 28 44 0.64 15 1 2 1 2
41 32 31 1.03 21 8 1 1
59 26 29 0.90 19 9 9
54 29 37 0.78 22 1 1 9
47 27 37 0.73 26 12 14
42 30 53 0.57 17 9 8
51 29 44 0.66 15 15 21
37 26 38 0.68 20 9 9
49 30 38 0.79 15 13 13
/lean 39 20 41 0.5 18.8 12.8 10.8
SD 5.56 3.62 4.86 0.10 3.35 1.99 3.85
41 27 36 0.77 19.5 11.7 12.3
6.5 4.2 6.4 0.17 4.92 2.08 3.72
HD regeneration data
36 - 42 weeks
CD3 CD 4 CD 8 CD4/8 CD20 CD 56 CD 14 
ratio
57 33 39 0.85 24 12 14
50 36 44 0.82 28 14 23
59 32 51 0.63 23 14 9
56 21 46 0.46 12 13 12
45 29 44 0.66 20 8 17
41 41 29 1.41 20 11 25
57 46 31 1.48 21 12 1 1
54 34 29 1.17 24 12 16
57 27 34 0.79 23 13 13
53 40 25 1.60 17 15 18
70 51 37 1.38 13 12 13
66 47 38 1.24 26 13 30
59 29 31 0.94 13 1 1 32
51 29 40 0.73 23 13 13
57 40 37 1.08 17 10 8
49 29 36 0.81 21 11 21
56 37 31 1.19 22 14 26
49 26 36 0.72 17 1 1 18
49 31 34 0.91 18 13 28
64 44 29 1.52 16 12 24
71 51 27 1.89 19 14 9
47 25 35 0.71 20 8 16
51 26 38 0.68 23 1 1 8
39 25 34 0.74 19 14 12
40 26 37 0.70 21 12 19
52 38 29 1.31 19 13 18
61 41 37 1.11 14 1 1 12
39 31 34 0.91 17 15 14
49 29 32 0.91 20 1 1 15
54 37 29 1.28 23 8 14
53 33 30 1.10 17 12 9
52 weeks
CD 3 CD 4 CD 8 CD4/8 CD 20CD56CD14 
ratio
51 37 39 0.95 15 15 9
60 41 33 1.24 23 8 16
55 34 40 0.85 12 9 8
54 31 34 0.91 27 12 12
57 44 31 1.42 21 14 1 7
49 40 27 1.48 1 9 1 2 9
74 56 25 2.24 1 9 13 12
63 46 24 1.92 17 8 1 7
61 44 21 2.10 26 1 1 25
54 37 22 1.68 29 12 1 1
62 51 31 1.65 17 12 16
59 29 17 1.71 23 13 13
69 50 38 1.32 18 15 18
57 34 29 1.17 12 12 13
63 46 31 1.48 19 13 30
49 31 31 1.00 23 1 1 32
53 49 24 2.04 1 8 13 13
57 47 16 2.94 20 1 0 8
56 39 24 1.63 22 1 1 21
69 49 28 1.75 1 7 14 26
57 41 34 1.21 23 1 1 18
61 43 27 1.59 26 13 28
54 37 30 1.23 23 12 24
57 34 34 1.00 21 14 9
61 46 33 1.39 20 8 1 6
48 36 22 1.64 21 1 1 8
54 35 34 1.03 20 14 12
58 35 39 0.90 27 1 0 19
63 29 33 0.88 30 13 1 8
57 31 28 1.11 24 1 1 12
63 43 37 1.16 18 15 14
49 46 21 2.19 23 13 15
67 45 27 1.67 19 8 14
65 38 26 1.46 1 7 1 0 9
53 42 22 1.91 20 14 12
‘an 53 34 35 1.02 19.7 12 16.7 
D 8.2 8 5.9 0.34 3.86 1.85 6.61
58 40 29 1.48 20.8 11.9 # # #
6.2 6.9 6.3 0.47 4.23 2.06 6.46
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